Conditions: Advanced Solid Tumor
Keywords: Topotecan Ataxia telangiectasia mutated and Rad3-related (ATR) protein ATR inhibitor M6620 Berzosertib Mass balance
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 6
Healthy volunteers: no

Brief summary:
The study was conducted in two periods, Period 1 (mass balance) and Period 2 (extension). The purpose of Period 1 of this study was to provide a quantitative characterization of the mass balance, rates and routes of elimination, and metabolic pathways after a single intravenous administration of \[14C\]berzosertib. The purpose of Period 2 was to assess safety and efficacy of berzosertib in combination with topotecan.

Detailed description:

Arms:
arm 1: Participants received single intravenous infusion of\[14C\]Berzosertib at a dose of 210 milligrams per square meter (mg/m\^2) on Day 1 in Period 1 and stay in clinical research unit (CRU) is required until the discharge criteria are met with a maximum confinement period of 15 days. arm 2: Participants received single intravenous infusion of Berzosertib at a dose of 210 mg/m\^2 on Day 2 and Day 5 in combination with topotecan at a dose of 1.25 mg/m\^2 intravenously on Days 1 through 5 of each 21-day cycle in period 2 until disease progression or other criteria for study intervention discontinuation were met.

Interventions: intervention 1: [14C]Berzosertib intervention 2: Berzosertib intervention 3: Topotecan
Intervention descriptions: intervention 1: Participants received single intravenous infusion of \[14C\]Berzosertib at a dose of 210 milligrams per square meter (mg/m\^2) on Day 1 in Period 1 and stay in clinical research unit (CRU) is required until the discharge criteria are met with a maximum confinement period of 15 days. intervention 2: Participants received single intravenous infusion of Berzosertib at a dose of 210 mg/m\^2 on Day 2 and Day 5 in period 2 until disease progression or other criteria for study intervention discontinuation were met. intervention 3: Participants received topotecan at a dose of 1.25 mg/m\^2 intravenously on Days 1 through 5 of each 21-day cycle in period 2 until disease progression or other criteria for study intervention discontinuation were met.

Protocol document:
Prot_000.pdf: 
Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
1/85
Clinical Study Protocol
Title Page
Clinical Study Protocol Title:
Phase I study to evaluate the mass balance, 
pharmacokinetics (PK), metabolism and excretion 
of berzosertib (intravenous) containing microtracer 
[14C]berzosertib in participants with advanced solid 
tumors
Study Number:
MS201923_0008
Protocol Version:
15 June 2021/Version 1.0
Merck Compound:
Berzosertib
Merck Registered Compound Name in 
Japan:
Not Applicable
Study Phase:
Phase I
Short Title:
Berzosertib Human Mass Balance Study
Acronym:
DDRiver Solid Tumors 208
Principal Investigator:
, MD, PhD
 
 
 
 
 
 
 
 
 
Sponsor Name and Legal Registered 
Address:
Sponsor:
Affiliates of Merck KGaA, Darmstadt, Germany
For all countries, except the US and Canada:
Merck Healthcare KGaA, Darmstadt, Germany 
an affiliate of Merck KGaA, Darmstadt, Germany
Frankfurter Str. 250
64293, Darmstadt, Germany
Regulatory Agency Identifying 
Number:
EudraCT: 2021-002226-24
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'
PPD
PPD
CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
2/85
Keywords
Unique terms not already on the Title Page:
!
Topotecan
!
Ataxia telangiectasia mutated and Rad3-related 
(ATR) protein
!
ATR inhibitor 
!
M6620
- Confidential –
This document is the property of Merck KGaA, Darmstadt, Germany, or one of its subsidiaries. It is intended for 
restricted use only and may not – in full or part – be passed on, reproduced, published or used without express 
permission of Merck KGaA, Darmstadt, Germany, or its subsidiary. Copyright © 2021 by Merck KGaA, Darmstadt, 
Germany, or its subsidiary. All rights reserved.
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
3/85
Table of Contents
Title Page
..............................................................................................................1
Table of Contents
..............................................................................................................3
1
Protocol Summary ................................................................................7
1.1
Synopsis................................................................................................7
1.2
Schema..................................................................................................9
1.3
Schedule of Activities...........................................................................9
2
Introduction.........................................................................................18
2.1
Study Rationale...................................................................................18
2.2
Background.........................................................................................19
2.3
Benefit/Risk Assessment ....................................................................20
2.3.1
Risk Assessment.................................................................................21
2.3.2
Benefit Assessment.............................................................................24
2.3.3
Overall Benefit: Risk Conclusion.......................................................24
3
Objectives and Estimands...................................................................24
4
Study Design.......................................................................................26
4.1
Overall Design....................................................................................26
4.1.1
Period 1: Berzosertib Mass Balance Study.........................................27
4.1.1.1
Period 1: Clinical Research Unit Discharge Criteria..........................27
4.1.2
Period 2: Extension with Berzosertib in Combination with 
Topotecan ...........................................................................................28
4.2
Scientific Rationale for Study Design ................................................28
4.3
Justification for Dose..........................................................................28
4.4
End of Study Definition......................................................................29
5
Study Population.................................................................................29
5.1
Inclusion Criteria ................................................................................30
5.2
Exclusion Criteria...............................................................................32
5.3
Lifestyle Considerations .....................................................................36
5.3.1
Meals and Dietary Restrictions...........................................................36
5.3.2
Caffeine, Alcohol, Tobacco, and Cannabinoid...................................36
5.3.3
Activity ...............................................................................................36
5.4
Screen Failures....................................................................................37
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
4/85
5.5
Criteria for Temporarily Delaying the Administration of Study 
Intervention.........................................................................................37
6
Study Intervention(s) and Concomitant Therapies.............................37
6.1
Study Intervention(s) Administration.................................................37
6.1.1
Period 1: Study Intervention Administration......................................38
6.1.2
Period 2: Study Intervention Administration......................................38
6.2
Study Intervention(s) Preparation, Handling, Storage, and 
Accountability.....................................................................................39
6.3
Measures to Minimize Bias: Study Intervention Assignment and 
Blinding ..............................................................................................40
6.3.1
Study Intervention Assignment ..........................................................40
6.3.2
Blinding ..............................................................................................41
6.4
Study Intervention Compliance..........................................................41
6.5
Dose Modification ..............................................................................41
6.5.1
Berzosertib Dose Modifications (Period 2 Only) ...............................41
6.5.2
Topotecan Dose Modifications...........................................................42
6.6
Continued Access to Study Intervention after the End of the Study..44
6.7
Treatment of Overdose .......................................................................44
6.8
Concomitant Therapy .........................................................................44
6.8.1
Rescue Medicine.................................................................................44
6.8.2
Permitted Medicines...........................................................................44
6.8.3
Prohibited Medicines..........................................................................44
6.8.4
Other Interventions.............................................................................46
7
Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal...............................................................46
7.1
Discontinuation of Study Intervention................................................46
7.2
Participant Discontinuation/Withdrawal from the Study ...................47
7.3
Lost to Follow-Up...............................................................................47
8
Study Assessments and Procedures....................................................48
8.1
Efficacy Assessments and Procedures................................................48
8.2
Safety Assessments and Procedures ...................................................49
8.2.1
Physical Examinations........................................................................49
8.2.2
Vital Signs ..........................................................................................49
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
5/85
8.2.3
Electrocardiograms.............................................................................49
8.2.4
Clinical Safety Laboratory Assessments ............................................50
8.3
Adverse Events, Serious Adverse Events, and Other Safety 
Reporting ............................................................................................50
8.3.1
Method of Detecting Adverse Events and Serious Adverse Events...51
8.3.2
Follow-up of Adverse Events and Serious Adverse Events ...............51
8.3.3
Regulatory Reporting Requirements for Serious Adverse Events .....51
8.3.4
Pregnancy ...........................................................................................52
8.3.5
Cardiovascular and Death Events.......................................................52
8.3.6
Disease-Related Events and/or Disease-Related Outcomes Not 
Qualifying as AEs or SAEs ................................................................53
8.3.7
Adverse Events of Special Interest.....................................................53
8.4
Pharmacokinetics................................................................................53
..55
56
8.7
Immunogenicity Assessments ............................................................56
8.8
Medical Resource Utilization and Health Economics........................56
9
Statistical Considerations....................................................................56
9.1
Statistical Hypotheses.........................................................................56
9.2
Sample Size Determination ................................................................56
9.3
Analyses Sets......................................................................................57
9.4
Statistical Analyses.............................................................................57
9.4.1
Efficacy Analyses ...............................................................................57
9.4.2
Safety Analyses ..................................................................................58
9.4.3
Other Analyses....................................................................................59
9.4.4
Sequence of Analyses.........................................................................60
10
References...........................................................................................61
11
Appendices .........................................................................................62
Appendix 1
Abbreviations......................................................................................63
Appendix 2
Study Governance...............................................................................66
Appendix 3
Contraception and Barrier Requirements ...........................................71
Appendix 4
Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow-up, and Reporting................................................73
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
6/85
Appendix 5
Eastern Cooperative Oncology Group Performance Status................80
Appendix 6
Clinical Laboratory Tests ...................................................................81
82
Appendix 8
Protocol Amendment History.............................................................83
Appendix 9
Sponsor Signature Page......................................................................84
Appendix 10
Principal Investigator Signature Page.................................................85
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
7/85
1
Protocol Summary
1.1
Synopsis
Protocol Title: Phase I study to evaluate the mass balance, pharmacokinetics (PK), metabolism 
and excretion of berzosertib (intravenous) containing microtracer [14C]berzosertib in participants 
with advanced solid tumors
Short Title: Berzosertib Human Mass Balance Study
Rationale: The mass balance study will determine drug-related entities present in circulation and 
provide a comprehensive understanding of biotransformation pathways and clearance mechanisms 
in humans. The mass balance study may identify potential contributors to interparticipant 
variability. In this respect, the performance of a mass balance study is recommended by guidance 
documents such as the European Medicines Agency (EMA) drug interaction guideline on the 
investigation of drug interactions, the International Council for Harmonisation (ICH) M3 and the 
Food and Drug Administration (FDA) Metabolites in Safety Testing (MIST) guidance.
Objectives and Estimands:
Objectives
Estimand Attributes
Primary
To determine the rates and routes of 
excretion and mass balance of 
berzosertib following single 
intravenous administration of 
210 mg/m2 of [14C]berzosertib to 
participants with advanced solid 
tumors (Period 1).
Endpoint: Percent urinary recovery (feurine), percent fecal recovery 
(fefeces), percent total recovery in urine and feces (fetotal) of total 
radioactivity over the entire period of collection.
Population: Participants with advanced solid tumors.
Treatment: Single dose berzosertib.
To characterize the PK of berzosertib 
in plasma and urine; and of 
drug-related material (total 
radioactivity) in plasma and whole 
blood (Period 1).
Endpoint: PK parameters: Cmax, AUC0-tlast, AUC0-∀#t1/2, CL, Vz, and Vss
of berzosertib and Cmax, AUC0-tlast, AUC0-∀# t1/2 of total radioactivity in 
plasma; PK parameters (Cmax, AUC0-tlast, AUC0-∀# t1/2) of total 
radioactivity in blood.
PK parameters of berzosertib in urine: cumulative amount excreted in 
urine (Ae and feurine (%)), renal clearance (CLR).
Population: Participants with advanced solid tumors.
Treatment: Single dose berzosertib.
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
8/85
Objectives
Estimand Attributes
Secondary
To evaluate the safety and tolerability 
of berzosertib (Period 1) and 
berzosertib + topotecan (Period 2).
Endpoint: Occurrence of treatment-emergent adverse events (TEAEs)
and treatment-related adverse events (AEs) and occurrence of clinically 
significant changes in vital signs, laboratory parameters and 12-lead
electrocardiogram (ECG) findings.
Population: Participants with advanced solid tumors.
Treatment: Single dose berzosertib and berzosertib in combination with 
topotecan.
Overall Design: This is a single group, sequential period, unblinded study with treatment of 
berzosertib single dose (Period 1 Mass Balance), followed by berzosertib in combination with 
topotecan (Period 2 Extension) in participants with advanced solid tumors.
Brief Summary:
The purpose of Period 1 of this study is to provide a definitive quantitative characterization of 
the mass balance, rates and routes of elimination, and metabolic pathways after a single 
intravenous administration of [14C]berzosertib. The purpose of Period 2 is to assess safety and 
efficacy of berzosertib in combination with topotecan.
Number of Participants: A total of approximately 6 participants (or more) will be treated with 
study intervention such that approximately 4 to 6 PK evaluable participants are anticipated to be 
obtained. If the initial group of 6 leads to fewer than 4 evaluable participants, the cohort will be 
increased up to a maximum of 12 participants, until 4 participants have completed all study 
procedures for Period 1 and are evaluable.
Study Intervention Groups and Duration: Period 1 represents the period for assessment of the 
mass balance, PK, metabolism, and elimination of berzosertib. During Period 1, admission to the 
CRU is required until the discharge criteria are met, with a maximum confinement period of 
15 days (Day -1 plus 14 days).
After completing Period 1, within 7 days of discharge from the clinical research unit (CRU), if no 
study withdrawal criteria are met, participants may enter Period 2 Extension of the study and will 
continue with 21-day cycles of berzosertib in combination with topotecan until disease progression 
or other criteria for study intervention discontinuation are met, an End-of-Treatment Visit, and a 
Safety Follow-up Period of 30 days (± 7 days) after last study intervention dose. Berzosertib will 
be administered at a dose of 210 mg/m2 intravenous (IV) on Day 2 and Day 5 and topotecan by IV 
administration at a dose of 1.25 mg/m2 on Days 1 through 5 of each 21-day cycle.
Involvement of Special Committee(s): No
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
9/85
1.2
Schema
The study will consist of 2 periods (1 and 2; see Figure 1):
!
Period 1: Mass balance inpatient period, with single dose [14C]berzosertib in 4 to 6 PK 
evaluable participants with advanced solid tumors
!
Period 2: Extension period. After completion of Period 1, participants from Period 1 will 
continue with berzosertib in combination with topotecan.
Figure 1
Schema
Note: for details, see the Section 1.3, Section 4.1, Section 4.1.1.1, and Sections 6.1.1 and 6.1.2.
1.3
Schedule of Activities
The schedule of activities (SoA) for Period 1 for the mass balance study is presented in Table 1. 
The Period 1 schedule of blood and plasma samples is provided in Table 2. The Period 1 schedule 
of urine and fecal samples is provided in Table 3. 
The SoA for Period 2 for the berzosertib and topotecan combination is presented in Table 4. 
8  to 14
Confinement
1
2
4
5
6
7
-28 to -2
-1
Check-in
Screening
[14C]Berzosertib
PERIOD 1
Mass Balance/Pharmacokinetics
PERIOD 2
3
Discharge
Berzosertib (210 mg/m2, D2, D5)
+ Topotecan (1.25 mg/m2, D1-D5) every 21 days 
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
10/85
Table 1
Period 1 Schedule of Activities: Mass Balance Study
Activity
Screening
Period 1
Notes
D-28 to -2
D-1 
D1 
Predose
D1 D2 D3 D4 D5
D6
D7
Discharge 
D8 to D14
Safety Follow-up 
(only if not 
continuing to 
Period 2; 30 days 
after single dose)
Informed 
Consent
X
Confinement 
to CRU
X
X
X
X
X
X
X
X
X
X
Note: D8 to D14 assessments are 
obtained once, prior to discharge from 
the CRU
-Discharge occurs once criteria are met 
(see details in Section 4.1.1.1)
-Maximum stay up to 15 days (D-1 plus 
14 days)
Inclusion and 
Exclusion 
Criteria; 
Medical 
History
X
X
-Should be checked during Screening 
and either at D-1 or D1 Predose
-Medical history includes collection of 
prior therapy
Demographics
X
Physical 
Examination
X
X
X
X
Symptom-directed physical 
examinations performed as clinically 
indicated per Investigator’s judgment.
Height
X
Weight
X
X
X
X
X
Obtain weight either at D-1 or D1 
Predose.
Vital Signs
X
X
X
X
X
X
X
X
X
X
X
X
Obtain vital signs either at D-1 or D1 
Predose.
Standard 
12-lead ECG
X
X
X
X
X
Obtain ECG either at D-1 or D1 
Predose
Urine Cotinine
X
X
At Screening and D-1
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'
CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
11/85
Activity
Screening
Period 1
Notes
D-28 to -2
D-1 
D1 
Predose
D1 D2 D3 D4 D5
D6
D7
Discharge 
D8 to D14
Safety Follow-up 
(only if not 
continuing to 
Period 2; 30 days 
after single dose)
Covid 19 PCR 
Testing
X
If test is positive, discussion with 
Medical Monitor is required.
Hematology
X
X
X
X
Serum 
Chemistry
X
X
X
X
Coagulation
X
X
X
Plasma for 
Radioactivity
X
Screening for 14C levels by AMS
FSH and 
Estradiol
X
Serum test at Screening, as needed if 
not a WOCBP only
β-HCG, 
Serum/Urine 
(WOCBP only)
X
X
X
Serum test at Screening and D8 to 
D14, urine test on D-1
Imaging 
Disease 
Assessment
X
ECOG PS
X
X
X
X
Single Dose 
14C-
berzosertib IV 
X
Dose: berzosertib 210 mg/m2 IV 
solution containing ~3 μCi of 
[14C]berzosertib over 60 minutes
Oral Laxative 
Administration
X
If not medically contra-indicated, oral 
laxative(s) of osmotic properties with 
short onset of action, such as 
magnesium hydroxide and lactulose 
may be administered to ensure fecal 
output is complete for mass balance 
assessment
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'
CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
12/85
Activity
Screening
Period 1
Notes
D-28 to -2
D-1 
D1 
Predose
D1 D2 D3 D4 D5
D6
D7
Discharge 
D8 to D14
Safety Follow-up 
(only if not 
continuing to 
Period 2; 30 days 
after single dose)
Concomitant 
Medications, 
Therapies and 
Procedures
X
X
AEs and SAEs
Blood Sample 
Collection 
See Table 2, Period 1 for Blood Sampling Collection 
Schedule
 
Urine Sample 
Collection 
See Table 3, Period 1 for Urine Collection Sample Schedule
For TR, berzosertib PK and metabolite 
profiling
Fecal Sample 
Collection 
See Table 3 Period 1 for Fecal Collection Sample Schedule
For TR and metabolite profiling
Vomitus
X
Collect vomitus if event occurs any 
time after dosing on Day 1 and/or 
Day 2
AE = adverse event; AMS = accelerator mass spectrometry; β-HCG = β-human chorionic gonadotropin; CRU = Clinical Research Unit; D = Day(s); 
ECG = electrocardiogram; ECOG PS= Eastern Cooperative Oncology Group Performance Status; FSH = follicle-stimulating hormone; IV = intravenous; PCR = 
polymerase chain reaction; PK = pharmacokinetic; SAEs = serious adverse events; TR = total radioactivity; WOCBP = woman of childbearing potential.
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'
CCI
CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
13/85
Table 2
Period 1 Blood and Plasma Samples
Timepoint (min / hour)
Blood 
Samplesa
Plasma 
Samplesb
Plasma 
Samples for 
Metabolite 
Profiling
Plasma 
Samples for 
ex vivo 
Plasma 
Protein 
Binding
D1 Predose (60 min before BOI) 
X
X
X
0.5 hours post BOI (∃5 min)
X
X
EOIc (% 5 min before EOI to & 1 min after EOI) 
X
X
X
X
0.5 hours post EOId (∃5 min)
X
X
1 hours post EOId (∃15 min)d
X
X
X
2 hours post EOId(∃15 min)d
X
X
3 hours post EOId (∃30 min)d
X
X
4 hours post EOId (∃45 min)d
X
X
X
8 hours post EOId (∃1 hour)d
X
X
X
12 hours post EOId (∃1 hour)d
X
X
X
X
24 hours after BOI (∃1 hour)e
X
X
X
X
48 hours after BOI (∃2 hours)e
X
X
X
72 hours after BOI (∃3 hours)e
X
X
X
X
96 hours after BOI (∃4 hours)e
X
X
X
120 hours after BOI (∃4 hours)e
X
X
X
144 hours after BOI  (∃4 hours)e
X
X
168 hours after BOI  (∃4 hours)e,f
X
X
X
BOI = beginning of infusion; EOI = end of infusion; IV = intravenous; PK = pharmacokinetics; TR = total radioactivity.
a
For determination of TR.
b
For determination of TR and berzosertib PK.
c
The window for collection of the EOI time point is between 5 minutes before completion of infusion to 1 minute 
after completion of infusion. In the event that the IV infusion is interrupted, 2 additional PK samples (1 sample 
drawn when the infusion is stopped, and 1 sample drawn when the infusion is restarted) should be collected so 
that the participant may be considered evaluable.
d
      Samples are to be collected after completion of berzosertib IV infusion on Day 1.
e
      Samples are to be collected after beginning of berzosertib IV infusion on Day 1.
f
Samples will continue to be collected in 24-hour intervals until discharge criteria are met, for metabolite profiling 
samples in 48-hour intervals.
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'
CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
14/85
Table 3
Period 1 Urine and Fecal Samples
Time Interval (hour)
Urine Collectiona
Feces Collectionb
Predose (-24 to 0 hours) (before BOI)
X
X
0 (BOI)-4 hours post EOIc
X
X (0-24 hours after BOI)
4-12 hours post EOI 
X
12 post EOI-24 hours after BOI
X
24-48 hours after BOI
X
X
48-72 hours after BOI
X
X
72-96 hours after BOI
X
X
96-120 hours after BOI
X
X
120-144 hours after BOI
X
X
144-168 hoursd after BOI
X
X
BOI = beginning of infusion; EOI = end of infusion; PK = pharmacokinetics; TR = total radioactivity
a
For determination of TR, berzosertib PK, and metabolite profiling
b
For determination of TR and metabolite profiling.
c
Collection of urine should start from BOI and until 4 hours post EOI for this collection interval. 
d
Samples will continue to be collected in 24-hour intervals until discharge criteria are met.
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'
CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
15/85
Table 4
Period 2 Schedule of Activities: Treatment, End of Treatment, and Follow-up Period
Assessments and 
Procedures
Cycle Duration = 21 Days
EOT
(within 7 days
after last 
dose)
Follow-up
30 days after 
last dose 
(± 7 days)
Notes
D1 
(± 3)
D2
D3
D4
D5
D8
(± 3)
D15
(± 3)
C1D1 up to 7 days after 
discharge in Period 1
Cycle start may be 
delayed up to 7 days to 
accommodate scheduling 
conflicts
Review Inclusion 
and Exclusion 
Criteria; Medical 
History
X
Physical 
Examination
X
X
X
Weight
X
X
X
Vital Signs
X
X
X
X
X
X
X
Predose on all visits
Standard 12-lead 
ECG
X
X
Hematology
X
X
X
X
X
Recommended at D8 and 
D15 at Cycle 1 only, 
optional at subsequent 
cycles.
Baseline neutrophils 
should be ≥ 1,500/μL and 
platelets ≥100,000/μL
prior to C1; for 
subsequent cycles, 
neutrophils should be 
> 1,000/μL, 
platelets > 100,000/μL, 
and hemoglobin ≥ 9 g/dL
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'
CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
16/85
Assessments and 
Procedures
Cycle Duration = 21 Days
EOT
(within 7 days
after last 
dose)
Follow-up
30 days after 
last dose 
(± 7 days)
Notes
D1 
(± 3)
D2
D3
D4
D5
D8
(± 3)
D15
(± 3)
C1D1 up to 7 days after 
discharge in Period 1
Cycle start may be 
delayed up to 7 days to 
accommodate scheduling 
conflicts
Serum Chemistry
X
X
X
Coagulation
X
X
β-HCG, Urine 
(WOCBP only)
X
X
X
Imaging Disease 
Assessment
At the end of every 6 weeks (± 1 week) after first dose (C1D1) until Week 24, then every 9 weeks 
(± 2 weeks) until disease progression, start of new anticancer therapy, death, withdrawal of consent, lost to 
follow-up, or End-of-Study, whichever comes first, regardless of study intervention 
modifications/discontinuation
ECOG PS
X
X
X
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'
CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
17/85
Assessments and 
Procedures
Cycle Duration = 21 Days
EOT
(within 7 days
after last 
dose)
Follow-up
30 days after 
last dose 
(± 7 days)
Notes
D1 
(± 3)
D2
D3
D4
D5
D8
(± 3)
D15
(± 3)
C1D1 up to 7 days after 
discharge in Period 1
Cycle start may be 
delayed up to 7 days to 
accommodate scheduling 
conflicts
Concomitant 
Medications and 
Procedures
X
AEs and SAEs
Berzosertib
X
X
Dosing: 210 mg/m2 IV on 
D2 and D5 every 21 days
Topotecan
X
X
X
X
X
Dosing: 1.25 mg/m2 IV on 
Days 1 through 5 every 
21 days
AEs = adverse events; β-HCG = β-human chorionic gonadotropin; C = Cycle; D = Day(s); ECG = electrocardiogram; ECOG PS= Eastern Cooperative Oncology 
Group Performance Status; EOT = end of treatment; IV = intravenous; SAEs = serious adverse events; WOCBP = woman of childbearing potential.
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'
CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
18/85
2
Introduction
Berzosertib (formerly known as M6620) is a free base drug substance that acts as a potent 
inhibitor of the ataxia telangiectasia mutated and Rad3-related (ATR) protein that is being 
developed for the treatment of malignancies as a single agent or in combination with 
chemotherapy and/or ionizing radiation or other anticancer agents.
Detailed information on the chemistry, pharmacology, efficacy, and safety of berzosertib is in 
the Investigator’s Brochure (IB) and details regarding topotecan are in the topotecan product 
information.
2.1
Study Rationale
Mass balance study in humans is part of a standard clinical development program and its results 
will be included in the submission package for the marketing authorization applications. The 
mass balance study will determine drug-related entities present in circulation and provide a 
comprehensive understanding of biotransformation pathways and clearance mechanisms in 
humans. The mass balance study may identify potential contributors to inter-participant 
variability. In this respect, the performance of a mass balance study is recommended by guidance 
documents such as the European Medicines Agency (EMA) drug interaction guideline on the 
investigation of drug interactions, the International Council for Harmonization (ICH) M3 and 
the Food and Drug Administration (FDA) Metabolites in Safety Testing (MIST) guidance.
The berzosertib human mass balance study will consist of 2 periods (Periods 1 and 2). Period 1 
will evaluate mass balance and metabolism after a single intravenous administration of 
[14C]berzosertib. Period 2 consists of an extension of the study where participants will receive 
berzosertib in combination with topotecan until disease progression or other criteria for study 
intervention discontinuation are met.  
The purpose of Period 1 of this study is to provide a definitive quantitative characterization of 
the mass balance, rates and routes of elimination, and metabolic pathways after a single 
intravenous administration of [14C]berzosertib. Such definitive characterization will help guide 
understanding of the potential for patient-specific (e.g., renal function, hepatic function) or 
extrinsic (e.g., concomitant medications with potential to affect drug metabolism) factors to 
affect berzosertib pharmacokinetics (PK) and thereby, is important to inform the need for future 
clinical pharmacology studies (e.g., special population studies in patients with organ impairment, 
drug-drug interaction [DDI] as a victim, etc.).
The purpose of Period 2 is to assess safety and efficacy of berzosertib in combination with 
topotecan. The results from a Phase I/II study of berzosertib + topotecan demonstrated clinical 
activity across different tumor types, particularly in participants with platinum-resistant small 
cell lung cancer (SCLC), high grade neuroendocrine tumors, or tumor with DNA damage 
response (DDR) deficiencies. In addition, topotecan has clinical activity in several other 
malignancies such as gynecological, soft tissue, and brain tumors (topotecan product 
information), which can be potentialized with the combination with berzosertib. In terms of 
safety, comparison with historical data of single agent topotecan, the berzosertib and topotecan 
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'
CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
19/85
combination has a toxicity profile that largely mirrored that of topotecan as single agent (Thomas 
2018; Thomas 2021). Thus, the berzosertib and topotecan combination has the potential of 
providing clinical benefit in advanced solid tumor patients with poor outcomes and high unmet 
medical need.
2.2
Background
Chemotherapeutic agents that induce DNA damage are an effective and common treatment 
option for patients with many types of solid tumors; however, many cancers, despite displaying 
initial sensitivity and clinical response to these agents, ultimately progress. One mechanism that 
has been proposed to protect tumor cells from DNA damage is the DDR pathway regulated by 
the ATM and ATR kinases. Theoretically, small molecule-mediated inhibition of ATR should 
enhance the effect of DNA damaging chemotherapy on cancer cells.
Berzosertib is a potent inhibitor of ATR that blocks ATR activity in cells, with a concentration 
resulting in 50% maximal inhibition of 20 nM. Based on nonclinical and clinical data (refer to 
the latest IB), berzosertib has the potential to have a substantial therapeutic impact on a number 
of malignancies, particularly in combination with chemotherapeutic agents such as gemcitabine, 
platinum agents, and topotecan (Konstantinopoulos 2020; Thomas 2018, Thomas 2021). 
Following intravenous (IV) dosing of 14C-labeled berzosertib to rats, means of 10.4% and 81.1% 
of the administered radioactivity were excreted in urine and feces, respectively, by 96 hours 
postdose. The high percentage of radioactivity eliminated in feces after IV dosing indicates 
biliary excretion was the major route of elimination of 14C-berzosertib-derived radioactivity. The 
overall mean recovery of radioactivity after IV dosing to rats was 94.3% (Study 8302826 Final 
Report 2015). After IV administration to bile duct-cannulated dogs (Vertex Study I135 
Nonclinical Study Report 2012), little unchanged berzosertib was detected in dog urine and bile 
(3.59% and 6.46%, respectively). These data indicated that berzosertib was eliminated primarily 
through metabolism in nonclinical species.
In a subsequent study in human hepatocytes and liver microsomes, biotransformation of 
14C-berzosertib revealed multiple metabolites. Exploratory metabolite profiling performed on 
pooled plasma samples from 6 participants revealed 3 circulating metabolites i.e. a carboxylic 
acid metabolite (M11) and 2 glucuronides, the likely acyl glucuronide of M11 (M17) and the 
direct glucuronide of parent (M14). In humans, the mean percentage of berzosertib excreted 
unchanged in the urine was approximately 5% to 6%, indicating minimal renal clearance of the 
unchanged drug. Overall, human in vitro and in vivo data indicated metabolism is the primary 
clearance mechanism of berzosertib. 
The plasma PK of berzosertib are characterized by a moderate to high clearance (approximately 
60 L/h), high distribution volume (approximately 1250 L) and a mean terminal elimination 
half-life of approximately 17 hours across all dose groups (18 to 480 mg/m2). Systemic 
exposures of berzosertib (Cmax and AUC0-∞) tended to increase proportionally with increasing 
dose after IV administration of the drug as monotherapy. Mean berzosertib plasma exposures, 
when berzosertib was given 1 day after administration of gemcitabine, cisplatin, carboplatin, 
carboplatin plus avelumab, or in combination with irinotecan were largely comparable to the 
corresponding values of berzosertib when administered alone at equivalent doses. In Parts A and 
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'
CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
20/85
B of Study MS201923-0001, the mean percentage of berzosertib excreted unchanged in the urine 
was approximately 5% to 6%, indicating minimal renal clearance of the unchanged drug. 
Exploratory metabolite profiling was performed on pooled plasma samples from 6 participants 
administered berzosertib at a dose of 72 mg/m2 (Study MS201923-0001). Three circulating 
metabolites were detected: M11 (MSC2699092A), a de-alkylation product (major), M14, a direct 
glucuronide (minor), and M17, a glucuronide of M11 (minor). No clinical DDI studies to assess 
the victim or perpetrator potential of berzosertib have been conducted.
Berzosertib was extensively metabolized via oxidative metabolism pathways, cytochrome P450 
(CYP)3A4 as the principal isozyme based on preliminary in vitro assessment. Berzosertib is a 
P-glycoprotein (P-gp) substrate but not a Breast Cancer Resistance Protein (BCRP) substrate. 
Using both basic and static mechanistic modeling prediction, berzosertib is in general not 
expected to elicit clinically meaningful DDI as a perpetrator based on in vitro assessment 
(potential for CYP induction, inhibition of CYPs, uridine diphosphate glucuronosyltransferases 
(UGTs), P-gp, organic anion transporting polypeptide (OATP)1B1, and OCT1 inhibition) at 
maximum unbound berzosertib concentrations observed in humans. A weak DDI risk is 
predicted for inhibition of CYP3A4 and according to EMA criteria, a possible DDI risk is 
predicted for BCRP and OATP1B3. As berzosertib is primarily metabolized by CYP3A4, strong 
inhibitors and inducers of CYP3A4 are expected to impact berzosertib exposure.
The berzosertib + topotecan combination has shown promising clinical activity and a favorable 
safety profile in participants with solid tumors. A Phase I/II study with the berzosertib + 
topotecan combination established the recommended Phase II dose, with topotecan at 
1.25 mg/m2 administered from Day 1 to Day 5, and berzosertib at 210 mg/m2 administered on 
Day 2 and Day 5, in cycles of 21 days. The toxicity profile of this regimen largely mirrored that 
of topotecan as single agent. The most common Grade 3 and 4 toxicities were hematological, 
such as anemia, leukopenia, and neutropenia (40% to 50% each) and thrombocytopenia (25%); 
however, with most participants having received granulocyte colony-stimulating factor (G-CSF)
prophylactically, complications such as febrile neutropenia were uncommon, and no 
treatment-related deaths occurred (Thomas 2018; Thomas 2021). In the Phase I portion, in terms 
of efficacy, there were 2 partial responses (PRs) of ≥18 months, and ≥7 months, and 7 stable 
disease (SD) responses lasting ≥3 months (median: 9 months; range, 3 to 12 months). Three of 
5 participants with SCLC, all of whom had platinum-resistant disease, had a PR or prolonged 
SD of ≥6 months (Thomas 2018). In the subsequent Phase II portion of the study of berzosertib 
in combination with topotecan in participants with relapsed SCLC, there was an overall response 
rate of 36%: 30% in participants with platinum-resistant disease (n = 20) and 60% in participants 
with platinum-sensitive disease (n = 5) (Thomas 2021). These results suggest a potential benefit 
of the combination in patients with platinum-resistant SCLC, defined by disease recurrence 
within 90 days from the last dose of platinum given in prior lines; thus, the berzosertib and 
topotecan combination is being further investigated in this patient population with poor outcomes 
(NCT04768296).
2.3
Benefit/Risk Assessment
More detailed information about the known and expected benefits and risks and reasonably 
expected AEs of berzosertib (and topotecan) may be found in the respective IBs.
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
21/85
Based on the available nonclinical and clinical data to date, the conduct of the study, as specified 
in this protocol, is considered justifiable.
2.3.1
Risk Assessment
The planned intravenous infusion of 210 mg/m2 of berzosertib will contain approximately 
∋0.111 MBq (∋3 μCi) of radioactivity (14C) per participant. The radioactive burden due to low 
amounts of radioactivity (approximately ∋( μCi) planned to be administered per participant is 
considered to pose negligible risk above the background cosmic radiation. The estimated 
radiation burden is far below the recommended dose limit for public of 1 mSv per year (Study 
No. MSI2047A-2047AX, M6620 – Radiation Burden Calculation Report 2020). The safety 
profile of berzosertib from clinical studies performed to date suggests that berzosertib is well 
tolerated when administered as single agent.
In the Phase I (Thomas 2018) and Phase II (Thomas 2021) berzosertib and topotecan 
combination studies, the toxicity profile of berzosertib + topotecan was similar to that of 
topotecan when given as a single agent. The combination of berzosertib with topotecan will be 
further assessed and evaluated for exacerbated toxicities or unforeseen adverse events (AEs), as 
compared with historical data from berzosertib and topotecan as single agents, and from 
berzosertib in combination with topotecan. 
Identified and potential risks of the study intervention and procedures are presented in Table 5.
Table 5
Berzosertib and Topotecan – Identified and Potential Risks with 
Mitigation Strategies
Identified and Potential Risks of 
Clinical Significance
Summary of Data/Rationale for 
Risk
Mitigation Strategy
Study Intervention: Berzosertib
Identified risks for berzosertib in combination with chemotherapy
Gastrointestinal disorders such as 
nausea and vomiting 
Refer to the berzosertib IB.
Continuous safety monitoring is 
performed during the study per the 
SoA (Sections 1.3 and 8.3).
Hypersensitivity, including 
infusion-related reactionsa
Refer to the berzosertib IB
Exclusion criteria are in place to 
prohibit enrollment of participants 
with known hypersensitivity to the 
study interventions, a similar 
structural compound, or to 1 or 
more excipients used.
Continuous safety monitoring is 
performed during the study.
Premedication is permitted for 
participants who have experienced 
an infusion-related reaction 
(Section 6.1).
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
22/85
Identified and Potential Risks of 
Clinical Significance
Summary of Data/Rationale for 
Risk
Mitigation Strategy
Potential risks for berzosertib in combination with chemotherapy
Risks associated with DDIs
No formal drug interaction studies 
have been conducted with 
berzosertib in humans; however, in a 
Phase I/II study of berzosertib in 
combination with topotecan, no drug 
interactions were reported with 
authorized concomitant medications 
and/or with topotecan. The toxicity 
profile of the study drugs 
combination largely mirrored that of 
topotecan as single agent.
Refer to the berzosertib IB.
Concomitant administration with 
potent inhibitors or inducers of 
CYP3A4 is prohibited in this study.
In Period 1, moderate inhibitors 
and inducers of CYP3A4 and 
inhibitors of P-gp are also 
prohibited. 
Clinical protocol-specific 
instructions should be closely 
followed (see Section 6.8.3). 
Pregnancy, fertility, and lactation
There is a potential risk, based on its 
mechanism of action, that 
administration of berzosertib during 
pregnancy could cause fetal harm.
Refer to the berzosertib IB.
A negative serum pregnancy test 
is required for inclusion. 
Participants who get pregnant 
during the study must discontinue 
the study intervention (see 
Section 7.1).
Refer to the berzosertib IB for 
guidance regarding pregnancy, 
lactation, contraception and fertility 
and see protocol Section 5.1 and 
Appendix 3 for contraception and 
barrier requirements. 
Further, strict use of contraception 
is required; participants should be 
informed that fertility might be 
impaired long term and may opt to 
cryopreserve sperm or ova prior to 
treatment. Male participants must 
also use a condom with pregnant 
female partners during the study, 
since exposure to the study 
intervention through the ejaculate 
could harm an existing fetus.
Increased toxicity in patients with 
Li Fraumeni Syndrome or ataxia 
telangiectasia
Based on non-clinical findings, 
increased toxicity in patients with 
Li-Fraumeni Syndrome or ataxia 
telangiectasia was classified as an 
important potential risk.
Exclusion of patients with 
Li_Fraumeni Syndrome or ataxia 
telangiectasia
Study Intervention: Topotecan (SmPC 2019)
Anemia
Moderate to severe (Hb ≤8.0 g/dL) 
in 37% of patients (14% of courses). 
AEs are continually monitored 
during the study (see Section 8.3) 
and managed clinically, as 
indicated, including by study 
intervention interruption, dose 
modification or discontinuation.
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
23/85
Identified and Potential Risks of 
Clinical Significance
Summary of Data/Rationale for 
Risk
Mitigation Strategy
Leukopenia (including 
neutropenia)
Abnormally low white blood cell 
count (leukopenia, neutropenia) that 
may be accompanied with fever and 
signs of infections (febrile 
neutropenia). Severe neutropenia 
(neutrophil count < 0.5 × 109/L) 
during Course 1 in 55% of patients, 
with duration ≥7 days in 20% and 
overall, in 77% of patients (39% of 
courses). In association with severe 
neutropenia, fever or infection 
occurred in 16% of patients during 
Course 1 and overall, in 23% of 
patients (6% of courses). Median 
time to onset of severe neutropenia 
was 9 days and the median duration 
was 7 days.
AEs are continually monitored 
during the study (see Section 8.3) 
and managed clinically, as 
indicated, including by study 
intervention interruption, dose 
modification or discontinuation.
Thrombocytopenia
Severe (platelets < 25 × 109/L) in 
25% of patients (8% of courses); 
moderate (platelets between 25.0 
and 50.0 × 109/L) in 25% of patients 
(15% of courses). Median time to 
onset of severe thrombocytopenia 
was Day 15 and the median duration 
was 5 days.
AEs are continually monitored 
during the study (see Section 8.3) 
and managed clinically, as 
indicated, including by study 
intervention interruption, dose 
modification or discontinuation.
Study Procedures
Blood sampling
Blood sampling is required for 
participants as detailed in the SoA 
and is considered essential for the 
study’s scientific objectives. Blood 
sampling carries a risk of AEs 
including pain, bruising, bleeding, 
redness and swelling of the site/vein, 
and infection.
Minimization of blood sampling 
was thoughtfully considered during 
protocol development weighing 
risk to participants versus 
achievement of the study’s 
scientific objectives. 
Blood samples will be taken by 
qualified professional and every 
effort will be made to minimize any 
discomfort.
Imaging procedures
Imaging disease assessments are 
required for all participants as 
detailed in the SoA to monitor 
disease progression. These are 
associated with a risk of allergic 
reactions to contrast agents, 
exposure to ionizing radiation for 
some types of imaging (e.g. CT 
scans, bone scintigraphy), 
nephrogenic systemic fibrosis, and 
intracranial gadolinium deposition for 
gadolinium and contrast-induced 
renal damage for iodinated contrast.
Imaging procedures in this study 
will be conducted at a similar 
frequency to that in routine clinical 
practice.
Participants will be monitored for 
allergic reactions, as per routine 
clinical practice.
Selection of imaging modality will 
be guided by any identified risk 
factors, as described in the 
Imaging Manual.
AEs = adverse events; CT = computed tomography; CYP3A4 = cytochrome P450 3A4; DDI = drug-drug interaction; 
Hb = hemoglobin; IB = Investigator’s Brochure; SoA = Schedule of Activities.
a
Infusion-related reactions have been reported using a variety of terms to describe the same biologic event, 
including erythema, eyelid edema, face edema, flushing, hypersensitivity, infusion-related reaction, pruritus, pruritus 
allergic, rash, rash erythematous, rash macular, rash pruritic, and rhinitis allergic.
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
24/85
2.3.2
Benefit Assessment
!
All participants in the current study will receive [14C]berzosertib in Period 1 and berzosertib 
in combination with topotecan in Period 2, which has the potential to improve their treatment 
outcome (see Section 2.2).
!
Participants in this study will be contributing to the process of developing new therapies in 
areas of unmet needs.
!
The medical evaluations and assessments in the current study protocol, with regular physical 
examinations, monitoring of AEs, imaging disease assessments, and laboratory assessments, 
in many instances go beyond the local standard of care.
2.3.3
Overall Benefit: Risk Conclusion
Considering the measures taken to minimize risk to participants in this study, as outlined in 
Table 5, the risks (potential and identified) associated with berzosertib (and in combination with 
topotecan) are justified by the anticipated benefits that may be afforded to participants with 
advanced solid tumors.
3
Objectives and Estimands
Table 6
Periods 1 and 2: Objectives and Estimand Attributes
Objectives
Estimand Attributes
Primary
To determine the rates and routes of 
excretion and mass balance of 
berzosertib following single 
intravenous administration of 
210 mg/m2 of [14C]berzosertib to 
participants with advanced solid 
tumors (Period 1).
Endpoint: Percent urinary recovery (feurine), percent fecal recovery 
(fefeces), percent total recovery in urine and feces (fetotal) of total 
radioactivity over the entire period of collection.
Population: Patients with advanced solid tumors.
Treatment: Single dose berzosertib.
To characterize the PK of berzosertib 
in plasma and urine; and of 
drug-related material (total 
radioactivity) in plasma and whole 
blood (Period 1).
Endpoint: PK parameters: Cmax, AUC0-tlast, AUC0-∀#t1/2, CL, Vz, and Vss
of berzosertib and Cmax, AUC0-tlast, AUC0-∀# t1/2 of total radioactivity in 
plasma; PK parameters (Cmax, AUC0-tlast, AUC0-∀# t1/2) of total 
radioactivity in blood.
PK parameters of berzosertib in urine: cumulative amount excreted in 
urine (Ae and feurine (%)), renal clearance (CLR).
Population: Patients with advanced solid tumors.
Treatment: Single dose berzosertib.
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
25/85
Objectives
Estimand Attributes
Secondary
To evaluate the safety and tolerability 
of berzosertib (Period 1) and
berzosertib + topotecan (Period 2.)
Endpoint: Occurrence of TEAEs and treatment-related AEs and 
occurrence of clinically significant changes in vital signs, laboratory 
parameters and 12-lead ECG findings.
Population: Patients with advanced solid tumors.
Treatment: Single dose berzosertib and berzosertib in combination with 
topotecan.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
.
To assess efficacy of intervention in 
terms of objective response of 
berzosertib + topotecan therapy 
(Period 2).
Endpoint: Objective response according to RECIST 1.1 as assessed 
by the Investigator.
Population: Patients with advanced solid tumors.
Treatment: Berzosertib + topotecan.
Intercurrent Event Strategy:
• Discontinuation of treatment: treatment-policy strategy, i.e.,
regardless of the intercurrent event.
• Start of subsequent anticancer treatment: while not treated with 
subsequent anticancer therapy strategy, i.e., ignoring tumor 
assessments after the intercurrent event.
• Progression according to RECIST 1.1: while not progressed strategy, 
i.e., assessments up to the intercurrent event.
AE = adverse event; DME = drug-metabolizing enzyme; ECG = electrocardiogram; PK = pharmacokinetic(s); 
RECIST 1.1 = Response Evaluation Criteria in Solid Tumors Version 1.1; TEAE = treatment-emergent adverse 
event
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
26/85
4
Study Design
4.1
Overall Design
Study Design
Single group; see Section 1.2 for Study Schema
Control Method
None (i.e., uncontrolled)
Single or Multicenter
Multicenter
Control Group
Not applicable
Study Population Type
Patients with advanced solid tumors
Level and Method of 
Blinding
Open-label study
Bias Minimalization 
Method(s)
See Section 6.3
Study Intervention 
Assignment Method
Not applicable, open-label study
Involvement of Special 
Committee(s):
No
Total Duration of Study 
Participation per 
Participant
Screening: 27 days (from D-28 to D-2)
Period 1 ([14C]berzosertib single dose): confinement maximum 
up to 15 days (D-1 plus 14 days)
Safety Follow-up (if not entering Period 2): 30 days after single 
dose administered
Period 2 (berzosertib in combination with topotecan):
Study Intervention consisting of 21-day cycles until disease 
progression or other criteria for study intervention 
discontinuation are met.
Safety Follow-up (at the end of Period 2): 30 days (± 7 days) 
after last dose of study intervention
Participants who discontinue study intervention for reasons 
other than disease progression or death will continue with 
regular imaging assessments until disease progression, addition 
of subsequent anticancer therapy, death, withdrawal of consent, 
lost to follow-up, or Endof-Study.
Provisions for Study 
Extension or Entry into 
Roll-Over Studies
See Section 6.6
Adaptive Aspects of 
Study Design
Not applicable
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
27/85
This is a single group, sequential period, unblinded study with treatment of berzosertib single 
dose (Period 1 Mass Balance), followed by berzosertib in combination with topotecan (Period 2 
Extension) in participants with advanced solid tumors.
4.1.1
Period 1: Berzosertib Mass Balance Study
Period 1 represents the period for assessment of the mass balance, PK, metabolism, and 
elimination of berzosertib. 
During Period 1, admission to the clinical research unit (CRU) is required until the discharge 
criteria are met (see Section 4.1.1.1), with a maximum confinement period of 15 days (Day -1 
plus 14 days). Patients who meet all inclusion criteria and none of the exclusion criteria will be 
admitted to the clinical facility on the morning of Day -1 for predose samples collection. 
Following the collection of Day 1 predose assessments and samples (if any), participants will 
receive a single dose of 210 mg/m2 of [14C]berzosertib IV solution (containing approximately 
∋3 μCi of [14C]berzosertib) via an intravenous infusion for 1 hour. The actual amount of 
administered radioactivity will be documented for each participant. 
Participants will be closely monitored for AEs throughout the period. Safety will be assessed by 
monitoring vital signs, physical examinations, electrocardiogram (ECGs), and clinical laboratory 
tests.
Blood will be collected at prespecified time points for analyses of berzosertib and drug-related 
material, and metabolite profiling over the confinement period. The mean terminal elimination 
half-life (t1/2) of berzosertib as parent drug is approximately 17 hours (range 14.2 to 17.6 h) in 
adults with advanced solid tumors. The human t1/2 of metabolites of berzosertib is not known; 
therefore, the t1/2 of total drug-related material (parent drug + metabolites) cannot be accurately 
estimated. The estimated confinement period of 7 days (approximately 5 t1/2) takes into account 
potential metabolites that may have t1/2 that are up to 2 times that of parent drug for characterizing 
the PK of total radioactivity (TR) and excretion of drug-related material in urine and feces. 
Complete urinary and fecal output will be collected until discharge from the clinical unit and 
analyzed for total drug-related material and products of berzosertib biotransformation. To ensure 
defecation prior to release from the clinical facility, oral laxatives of osmotic properties 
(e.g., magnesium hydroxide, lactulose) may be administered as needed. 
For those not participating in Period 2, a Safety Follow-up Visit should be performed 30 days 
after the single dose of berzosertib in Period 1.
4.1.1.1
Period 1: Clinical Research Unit Discharge Criteria
Admission to the CRU is required, with a maximum confinement period of 15 days (Day -1 plus 
14 days), until the following discharge criteria are met: 
!
At least 85% of the total dose of radioactivity has been collected 
OR
!
The excretion of radioactivity in the urine and feces combined has declined to ≤ 1% of the 
total administered radioactivity for at least 2 consecutive days
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
28/85
4.1.2
Period 2: Extension with Berzosertib in Combination with 
Topotecan
After completing Period 1, within 7 days of discharge from the CRU, if no study withdrawal 
criteria are met, participants may enter Period 2 Extension of the study and will continue with 
21-day cycles of berzosertib in combination with topotecan until disease progression or other 
criteria for study intervention discontinuation are met, an End-of-Treatment Visit, and a Safety 
Follow-up Period of 30 days (± 7 days) after last study intervention dose. Berzosertib will be 
administered at a dose of 210 mg/m2 IV on Day 2 and Day 5 and topotecan by IV administration 
at a dose of 1.25 mg/m2 on Days 1 through 5 of each 21-day cycle.
4.2
Scientific Rationale for Study Design
The study design is based on the regulatory guidance (FDA and EMA) to characterize rates and 
routes of elimination, mass balance and clearance pathways. The PK and disposition of any drug 
is governed by several processes, including organ distribution, and elimination by metabolism 
and/or transport processes, and ultimately excretion. Period 1 of this study is designed to 
elucidate these processes, a [14C]-radiotracer of berzosertib will be used, which allows the 
detection, tracking, and quantification of parent drug and metabolites in biological samples.  
Since a berzosertib mass balance study can only be performed in patients with cancer, and only 
a single-dose administration of berzosertib is required, the Period 2 Extension will consist of a 
combination of berzosertib with topotecan, which is a regimen potentially active in several solid 
tumors, particularly SCLC, high grade neuroendocrine tumors, or tumor with DDR deficiencies.
4.3
Justification for Dose
Berzosertib will be administered in Period 1, the mass balance portion of this study, as a single 
1-hour IV infusion of 210 mg/m2 containing approximately ∋3 μCi of [14C]berzosertib as the 
radioactive tracer to allow mass balance evaluation and quantitative metabolite profiling in 
plasma, urine, and feces. Since radioactivity used in this study is approximately ∋3 μCi, 
accelerator mass spectrometry (AMS) analysis, a highly sensitive method for the detection of 
radioactive 14C, will be used to assess the recovery and PK of TR, and perform metabolite 
profiling. Depending on the excretion profile of [14C]berzosertib, traditional radioactivity 
detection methods such as liquid scintillation counting will also be explored for recovery of TR 
and mass balance determination.
The radioactive burden due to low amounts of radioactivity (approximately ∋3 μCi) planned to 
be administered per participant is considered to pose negligible risk above the background 
cosmic radiation. The estimated radiation burden is far below the recommended dose limit for 
public of 1 mSv per year (Study No. MSI2047A-2047AX, M6620 – Radiation Burden 
Calculation Report 2020). 
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
29/85
The selected 210 mg/m2 of berzosertib is based on the reported Phase I study, which determined 
the combination of berzosertib and topotecan to be safe and tolerable (Thomas 2018). The 
starting study intervention doses for the combination in the Period 2 are as follows:
!
Berzosertib by IV administration at a dose of 210 mg/m2 on Day 2 and Day 5 of each 21-day 
cycle
!
Topotecan by IV administration at a dose of 1.25 mg/m2 on Days 1 through 5 of each 21-day 
cycle.
Section 6.5 provides the dose selection and modification information for this study.
4.4
End of Study Definition
A participant has completed the study if he/she has completed all study periods, including the 
Safety Follow-up Visit, as shown in Section 1.3 (SoAs for Periods 1 and 2) and fulfilled at least 
1 of the following criteria: 
!
Withdrawal of consent from the study
!
Lost to Follow-up
!
Died.
The end of the study is defined as the date of last contact (related to this study) with the last 
participant who participates in this study (Safety Follow-up Visit).
The Sponsor may terminate the study at any time once access to berzosertib or topotecan for 
participants still benefiting is provisioned via a rollover study, expanded access, marketed 
product or another mechanism of access as appropriate.
5
Study Population
The criteria in Sections 5.1 and 5.2 are designed to enroll only participants, who are appropriate 
for the study; thereby, ensuring the study fulfills its objectives. All relevant medical and 
nonmedical conditions are considered when deciding whether a participant is suitable for this 
study.
Prospective approval of protocol deviations to inclusion and exclusion criteria, also known as 
protocol waivers or exemptions, is not permitted.
Before performing any study assessments that are not part of the participant’s routine medical 
care, the Investigator will confirm that the participant or the participant’s legal representative 
(where allowed by local laws and regulations) has provided written informed consent, as 
indicated in Appendix 2.
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
30/85
5.1
Inclusion Criteria
Participants are eligible to be included in the study only if all the following criteria apply:
Category
Criterion
Age
1.
Are ≥ 18 years of age at the time of signing the informed 
consent.
Type of Participant 
and Disease 
Characteristics
2.
Histologically proven advanced
solid tumors that are 
considered appropriate for treatment in Period 2 of this study, 
for which no effective standard therapy exists, or standard 
therapy has failed or cannot be tolerated
3.
Eastern Cooperative Oncology Group Performance Status 
(ECOG PS) ≤ 1 (see Appendix 5)
4.
Evaluable disease according to Response Evaluation Criteria in 
Solid Tumors Version 1.1 (RECIST 1.1) at Screening. 
5.
Have adequate hematologic function as indicated by:
!
Platelet count ≥100,000/mm3
!
Hemoglobin ≥9.0 g/dL. Prior red blood cell transfusions are 
allowed
!
Absolute neutrophil count ≥ 1,500/μL with no growth factor 
treatment within 14 days of obtaining the Screening blood 
sample
!
Total bilirubin level ≤1.5 × upper limit of normal (ULN), an 
aspartate 
aminotransferase 
(AST)
and 
an 
alanine 
aminotransferase (ALT) level ≤3.0 × ULN or ≤5 × ULN in 
presence of liver metastases
!
Adequate renal function defined as creatinine clearance 
≥60 mL/min by calculation using the Cockcroft-Gault 
formula or measured by 24-hour urine collection. The 
Cockcroft-Gault formula is: 
(l40 – age) × weight [kg]) / (72 × serum creatinine [mg/dL]) 
× 0.85 (if female)
!
Suitable venous access for the study-required blood 
sampling (including PK sampling)
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
31/85
Sex and 
Contraception/Barrier 
Requirements
6.
All sexes allowed
The Investigator confirms that each participant agrees to use 
appropriate contraception and barriers, if applicable. The 
contraception, barrier, and pregnancy testing requirements are 
below. 
7.
Contraceptive use by males or females will be consistent with 
local regulations on contraception methods for those 
participating in clinical studies
Male participants:
Agree to the following during the Study Intervention Period and for 
at least 6 months after the last study intervention dose:
!
Refrain from donating sperm
!
PLUS, either: 
o
Abstain from any activity that allows for exposure to 
ejaculate
OR 
o
Use a male condom: When having sexual intercourse 
with a woman of childbearing potential (WOCBP), who 
is not currently pregnant, and advise her to use a highly 
effective contraceptive method with a failure rate of < 1% 
per year, as described in Appendix 3, since a condom may 
break or leak. 
Male participants must use a condom with pregnant 
female partners
Female participants:
Are not pregnant or breastfeeding, and at least 1 of the following 
conditions applies:
!
Not a WOCBP 
OR
!
If a WOCBP, use a highly effective contraceptive method (i.e., 
with a failure rate of < 1% per year), preferably with low user 
dependency, as described in Appendix 3 for the following time 
periods:
o
Before the first dose of the study intervention, if using 
hormonal contraception:
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
32/85
Category
Criterion

Has completed at least one 4-week cycle of an oral 
contraception pill and either had or has begun her 
menses
OR 

Has used a depot contraceptive or extended-cycle oral 
contraceptive for least 28 days and has a documented 
negative pregnancy test using a highly sensitive assay
AND 
A barrier method, as described in Appendix 3.
o
During the Study Intervention Period
o
After the Study Intervention Period (i.e., after the last 
study intervention dose is administered) for at least 
6 months after the last study intervention dose and agree 
not to donate eggs (ova, oocytes) for reproduction during 
this period
The Investigator evaluates the effectiveness of the
contraceptive method in relationship to the first dose of study 
intervention.
o
Have a negative serum pregnancy test, as required by 
local regulations, within 24 hours before the first study 
intervention dose.
Additional requirements for pregnancy testing during and after study 
intervention are in Appendix 3.
Informed Consent
8.
Capable of giving signed informed consent, as indicated in
Appendix 2, which includes compliance with the requirements 
and restrictions listed in the informed consent form (ICF) and 
this protocol.
5.2
Exclusion Criteria
Participants are excluded from the study if any of the following criteria apply:
Category
Criterion
Medical Conditions
1.
Clinically relevant (i.e., active), uncontrolled intercurrent illness 
including, but not limited to, severe active infection including, 
acute respiratory syndrome coronavirus-2 infection/coronavirus 
disease 2019 (Covid 19), immune deficiencies, uncontrolled 
diabetes, uncontrolled arterial hypertension, symptomatic 
congestive heart failure (New York Heart Association 
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
33/85
Category
Criterion
Classification ≥ Class III), unstable angina pectoris, myocardial 
infarction, uncontrolled cardiac arrhythmia, and cerebral 
vascular accident/stroke. Calculated QTc average (using the 
Fridericia correction calculation) of > 450 msec for males and 
> 470 msec for females. Any psychiatric illness/social situations 
that would limit compliance with study requirements, including 
required inpatient confinement. Known hepatic cirrhosis or 
severe pre-existing hepatic impairment.
The following exceptions apply:
a.
Participants with human immunodeficiency virus infection 
are eligible if they are on effective antiretroviral therapy with 
undetectable viral load within 6 months, provided there is no 
expected DDI. Human immunodeficiency virus testing is not 
mandated for study inclusion. If performed, the participant 
must be consented for testing as per local standard guidance.
b. Participants with evidence of chronic hepatitis B virus (HBV)
infection are eligible if the HBV viral load is undetectable on 
suppressive therapy (if indicated), and if they have ALT, 
AST, and total bilirubin levels < ULN, and provided there is 
no expected
DDI with berzosertib due to treatment 
medication (see Table 11). 
c.
Participants with a history of hepatitis C virus (HCV)
infection are eligible if they have been treated and cured. For 
participants with HCV infection who are currently on 
treatment, they are eligible if they have an undetectable HCV 
viral load, and if they have ALT, AST, and total bilirubin 
levels < ULN, and provided there is no expected DDI with 
berzosertib due to treatment medication (see Table 11).
2.
Unstable brain metastases; however, participants with known 
brain metastases may be enrolled in this clinical study if they are 
clinically stable (without evidence of progression by imaging for 
at least 2 weeks prior to the first study intervention 
administration and any neurologic symptoms have returned to 
baseline), have no evidence of new brain metastases, and are on 
a stable or decreasing dose of steroids for at least 14 days prior 
to study intervention. Participants with carcinomatous 
meningitis are excluded regardless of clinical stability. 
Screening central nervous system imaging is not mandatory.
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
34/85
Category
Criterion
3.
Participants not recovered from AEs Grade > 1 from prior 
anticancer therapies, including surgeries. Exception: Grade 2 
AEs not constituting a safety risk (e.g., alopecia), based on the 
Investigator’s judgment; must consult with the Medical Monitor 
prior to enrollment.
4.
Participants with known history of Li-Fraumeni Syndrome and 
ataxia telangiectasia.
5.
Irregular defecation patterns (< 1 defecation/2 days or excessive 
diarrhea).
6.
Persistent diarrhea (≥ Grade 2) lasting > 3 days within 2 weeks 
before the first dose of study intervention.
7.
History of urinary and/or fecal incontinence.
8.
Major surgery within 14 days before the first dose of study 
intervention or scheduled surgery during Period 1 of the study.
9.
Participation in a trial involving administration of 14C labeled 
compound(s) within last 6 months prior to start of study 
intervention.
10. Total 14C radioactivity measured by AMS in plasma (during 
screening) exceeding 14C/12C ratio 1.1E-12
11. Radiotherapy within 14 days before the first dose of study 
intervention
12. Prior treatment with an ATR inhibitor
13. Prior 
or 
concurrent 
treatment 
with 
a 
nonpermitted 
drug/intervention from the first dose of study intervention 
administration:
!
Participants who may have received any of the following 
anticancer therapy(ies) within the following time windows 
from the first day of study interventions administration:
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
35/85
Category
Criterion
a. Small 
molecule 
inhibitor 
therapy 
(including 
investigational) within 2 weeks or 5 half-lives, whichever 
is longer
b. Any type of anticancer antibody or antibody drug 
conjugates within 3 weeks 
c. Systemic chemotherapy within 4 weeks (within 6 weeks 
for nitrosoureas/ mitomycin C)
d. Prior curative-intent high-dose radiotherapy within 
4 weeks. Prior palliative radiotherapy to metastatic 
lesion(s) is permitted provided it was completed at least 
1 week prior to first day of study interventions 
administration and toxicities recovered to Grade ≤1. 
e. Any other type of anticancer therapy, not listed above, 
within 4 weeks.
!
Concomitant use of medication or supplements that are 
known strong and moderate inhibitors (Period 1 only) of 
CYP3A4 enzymes that cannot be discontinued within 
5 times the inhibitor half-life (if a reasonable half-life 
estimate is known) or 7 days prior to administration of study 
intervention and for the duration of study intervention.
!
Concomitant use of medication or supplements that are 
known strong and moderate CYP3A4 inducers that cannot 
be discontinued 4 weeks prior to administration of study 
intervention and for the duration of study intervention.
!
Concomitant use of medication or supplements that are 
known inhibitor of P-gp that cannot be discontinued within 
5 times the inhibitor half-life (if a reasonable half-life 
estimate is known) or for 7 days prior to administration of 
study intervention and for the duration of study intervention 
(Period 1 only).
!
Food and beverage containing grapefruit within 7 days 
before the first dose of study interventions. Note that food 
and beverages containing grapefruit, Seville orange, and 
star fruit are not permitted during the study (Period 1 only).
!
No history of amiodarone use in the 6 months before the 
first dose of berzosertib.
!
Admission or evidence of illicit drug use, drug abuse, or 
alcohol abuse.
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
36/85
Category
Criterion
!
Other prohibited concomitant medications as listed in 
Section 6.8.3
Prior/Concurrent 
Clinical Study 
Experience
14. Concurrent participation in another interventional clinical study 
is not permitted. There are no restrictions on prior clinical study 
participation provided the above washout periods are followed.
Other Exclusions
15. Known hypersensitivity to the study interventions, a similar 
structural compound, or to one or more excipients used.
16. Smokers (use of tobacco products or nicotine-containing 
smoking cessation agents in the previous 1 month). Urine 
cotinine levels will be measured during screening and admission 
on Day -1 for all participants (Period 1 only). Smokers will be 
defined as any participant who reports tobacco use and/or who 
has a urine cotinine ≥ 500 ng/mL.
17. Donation or loss of more than 450 mL of blood in the 60 days 
prior to screening. 
18. Is not willing to comply with dietary and fluid restrictions.
5.3
Lifestyle Considerations
5.3.1
Meals and Dietary Restrictions
During Period 1 only, abstain from consumption of the following from 7 days before the start of 
study intervention: Seville oranges, grapefruit or grapefruit juice, and star fruit.
There are no dietary restrictions for Period 2.
5.3.2
Caffeine, Alcohol, Tobacco, and Cannabinoid
! No restrictions on caffeine or modest alcohol use apply during this study.
! Use of tobacco products will not be allowed from 1 month prior to screening until after the 
final follow-up visit.
5.3.3
Activity
Participants will abstain from strenuous exercise for 2 hours before each blood collection for 
clinical laboratory tests. Participants may participate in light recreational activities (e.g., 
watching television or reading). 
Based on in vitro and in vivo assays, berzosertib has a phototoxic potential as it absorbs in the 
UV-visible radiation spectrum, and is widely distributed in tissues, including skin. Therefore, 
participants should be cautioned to minimize exposure to the sun and other sources of visible 
and UV radiation, and to take protective measures when necessary.
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
37/85
5.4
Screen Failures
Individuals who do not meet the criteria for participation in this study (screen failure) may be 
rescreened once within 7 days, after the reason for the screening failure has been addressed. 
Rescreened participants will be assigned a new participant number and will undergo Screening 
procedures as planned in the protocol. Any previous screening tests can be used for rescreening, 
provided they are within the new screening window of -28 days.
5.5
Criteria for Temporarily Delaying the Administration of 
Study Intervention 
See Section 6.5 in this protocol.
6
Study Intervention(s) and Concomitant Therapies
Study intervention is any investigational interventions, marketed product(s), placebo, or medical 
device(s) intended to be administered to a study participant per the study protocol. Study 
intervention is used instead of “study drug, Investigational Medicinal Product, or study 
treatment”.
6.1
Study Intervention(s) Administration
Participants are planned to continue with study intervention until documented disease 
progression, discontinuation due to AEs, death, or withdrawal from the study, whichever occurs 
earlier.
Additional details of sourcing, packaging, including quantity per container, anticipated length of 
supply per container, and labeling of the study interventions will be defined in a separate 
Pharmacy Manual.
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
38/85
Table 7
Study Interventions
Intervention Name
Berzosertib 
Topotecan
Type 
Drug
Drug
Dose Formulation
Solution for infusion
Concentrate for solution for infusion
Unit Dose Strength
20 mg/mL
1 mg/mL topotecan free base
Dose Amount
Periods 1 and 2: 210 mg/m2
Containing ~3 μCi of [14C]berzosertib in 
Period 1
Period 2 only: 1.25 mg/m2
Premedication
Suggested premedication regimen: 
hydrocortisone (200 mg IV) and a locally 
available antihistamine approximately 
60 minutes before study intervention 
infusions. The regimen may be modified 
based on local treatment standards and 
guidelines, as appropriate, as long as not 
prohibited by the protocol (see 
Section 6.8.3)
Prophylactic or therapeutic use of 
antiemetic medication according to the 
topotecan product information is 
recommended, unless the specific 
medication is prohibited for other 
reasons, e.g., the antiemetic is also a 
strong CYP3A4 inhibitor (see Table 11)
Frequency
Period 1: Single dose on Day 1
Period 2: On Day 2 and Day 5 of each 
21-day cycle
Period 2: Days 1 through 5 of each 
21-day cycle
Route of Administration
IV infusion
IV infusion
Use
Experimental
Experimental 
IMP and NIMP
IMP
SoC/IMP depending on local law (in 
Hungary)
Sourcing
Provided centrally by the Sponsor
Provided centrally by the Sponsor or 
locally by the study site, subsidiary, or 
designee
Packaging and Labeling
Study Intervention will be provided in 
vials. Each vial will be labeled per country 
requirements.
Depending on the local regulations (in 
Hungary), topotecan may be either 
sourced from a local hospital pharmacy 
or supplied by the Sponsor (or 
designated service provider) and will be 
packaged/labeled according to local 
requirements.
Current/Former Name(s) 
or Alias(es)
Substance code MSC2527093A, M6620, 
VX-970
CYP = Cytochrome P450; IMP = Investigational Medicinal Product; IV = intravenous; NIMP = non-investigational 
medicinal product; SoC = standard of care.
6.1.1
Period 1: Study Intervention Administration
Berzosertib will be administered after predose samples and assessments are performed in 
Period 1, the mass balance portion of this study, as a single 1-hour IV infusion of 210 mg/m2
containing ∋3 μCi of [14C]berzosertib as the radioactive tracer to allow mass balance evaluation 
and quantitative metabolite profiling in plasma, urine, and feces.
6.1.2
Period 2: Study Intervention Administration
In Period 2, berzosertib at a dose of 210 mg/m2 will be administered via IV over 60 minutes 
(± 10 minutes) and start approximately 15 minutes after completion of topotecan administration 
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
39/85
on Day 2 and Day 5, of each 21-day cycle. Topotecan at a dose of 1.25 mg/m2 will be 
administered via IV over 30 minutes on Days 1 through 5 of each 21-day cycle. Study 
intervention details are provided in Table 7.
Prior to study intervention administration, baseline neutrophils should be ≥ 1,500/mm3 and 
platelets ≥ 100,000/mm3 prior to Cycle 1. For subsequent cycles, neutrophils should be 
> 1,000/mm3, platelets > 100,000/mm3, and hemoglobin ≥ 9 g/dL.
Investigators should prophylactically premedicate participants with corticosteroid and 
antihistamine before the first 2 berzosertib infusions. Premedication should be administered for 
subsequent berzosertib infusions based upon clinical judgment and presence/severity of prior 
infusion-related reactions to berzosertib. See Table 7 for suggested premedication regimen with 
corticosteroids and antihistamine.
Prophylactic G-CSF will be administered according to local practice and topotecan label. Its 
administration as primary or secondary prophylaxis is highly recommended and can be adjusted 
according to institutional guidelines and clinical judgment. G-CSF may be used from Day 6, at 
least 24 hours after the last dose of topotecan.
6.2
Study Intervention(s) Preparation, Handling, Storage, and 
Accountability
The Investigator, institution, or the head of the medical institution (where applicable) is 
responsible for study intervention accountability, reconciliation, and record maintenance (i.e., 
receipt, reconciliation, and final disposition records).
! Upon receipt of the study intervention(s), the Investigator or designee will confirm 
appropriate temperature conditions have been maintained during transit and any discrepancies 
are reported and resolved before use. Also, the responsible person will check for accurate 
delivery. Further guidance and information for study intervention accountability are provided 
in the Pharmacy Manual.
! Only participants enrolled in the study may receive study intervention(s) and only authorized 
site staff may supply it. All study intervention(s) will be stored in a secure, environmentally 
controlled, and monitored (manual or automated) area, per the labeled storage conditions, and 
with access limited to the Investigator and authorized site staff.
! Dispensing will be recorded on the appropriate accountability forms so that accurate records 
will be available for verification at each monitoring visit.
! Study intervention(s) accountability records at the study site will include the following:
! Confirmation of receipt, in good condition and in the defined temperature range.
! The inventory provided for the clinical study and prepared at the site.
! The dose(s) each participant used during the study.
! The disposition (including return, if applicable) of any unused study intervention(s).
! Dates, quantities, batch numbers, container numbers, expiry dates, formulations, and the 
participant numbers.
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
40/85
! The Investigator site will maintain records, which adequately documents that participants 
were provided the doses specified in this protocol, and all study intervention(s) provided were 
fully reconciled.
! Unused study intervention(s) will not be discarded or used for any purpose other than the 
present study. No study intervention that is dispensed to a participant may be re-dispensed to 
a different participant.
! A Study Monitor will periodically collect the study intervention(s) accountability forms.
! Further guidance and information for the final disposition of unused study intervention(s) are 
provided in the Pharmacy Manual.
6.3
Measures to Minimize Bias: Study Intervention Assignment 
and Blinding
6.3.1
Study Intervention Assignment
After obtaining informed consent, participants will receive a subject number. This number will 
ensure identification throughout the study. Only subjects that pass screening according inclusion 
and exclusion criteria will be enrolled in the treatment part of the study.
This is a single-arm study, all participants will receive the same study interventions. 
Administration will be supervised by the Principal Investigator and clinical site staff. The date 
and time of administration, the volume of the IMP will be documented in the electronic Case 
Report Form (eCRF).
Trial medication will be prepared and distributed by Good Manufacturing Practice (GMP) 
pharmacies specialized for that service in compliance with ICH Good Clinical Practice (GCP)
and GMP guidance.
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
41/85
6.3.2
Blinding
Not applicable as this is an open-label study.
6.4
Study Intervention Compliance
When participants are dosed at the site, they will receive study intervention directly from the 
Investigator or designee, under medical supervision. The date and time of each dose administered 
in the clinic will be recorded in the source documents and recorded in the eCRF. The dose of 
study intervention and study participant identification will be confirmed at the time of dosing by 
a member of the study site staff other than the person administering the study intervention. 
6.5
Dose Modification
There will be no dose modification for the single dose of [14C]berzosertib in Period 1 of this 
study. If during Period 1 there is a need to interrupt or slow the IV infusion, contact the project 
clinician or designee as soon as possible for consideration of participant replacement as 
appropriate.
In Period 2, participants will receive berzosertib in combination with topotecan as per Table 7
until the criteria are met as outlined in Section 4.4 (End of Study Definition) and/or Section 7.1
(Discontinuation of Study Intervention). Berzosertib and topotecan should be administered in 
combination, including during dose modifications and interruptions, unless one agent is 
permanently discontinued. 
In case a dose reduction is necessary, berzosertib and topotecan will be administered as outlined 
in Sections 6.5.1 and 6.5.2, respectively. See Section 7 for information regarding discontinuation 
of study intervention and participant discontinuation/withdrawal.
The justification for study intervention dose is presented in Section 4.3.
6.5.1
Berzosertib Dose Modifications (Period 2 Only)
In Period 2, the dose of berzosertib may be reduced for the occurrence of drug-related toxicity 
using the following toxicity-dependent guidelines:
!
For Grade 4 hematologic toxicity: The dose of berzosertib will be reduced by 1 dose level 
(first dose reduction).
!
For Grade 3 nonhematologic toxicity: The dose of berzosertib will be reduced by 1 dose 
level (first dose reduction).
!
For Grade 4 nonhematologic toxicity: The dose of berzosertib will be reduced by 2 dose 
levels (equivalent to second dose reduction).
For liver function toxicity, please also see Section 7.1 as it may indicate potential severe liver 
injury (possible Hy’s Law) and study intervention discontinuation.
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
42/85
Based on the criteria above, a maximum of 2 dose reductions will be permitted. Once the 
berzosertib dose has been reduced, it should not be re-escalated to the starting dose. If a second 
Grade 4 nonhematologic toxicity were to recur, treatment will be discontinued. Dose reduction 
levels are provided in Table 8.
Table 8
Berzosertib Dose Modifications
Dose modifications for Grade 4 hematologic and Grade 3 nonhematologic drug-related AEs
Starting dose
210 mg/m2 
First dose reduction (1 dose level)
160 mg/m2 
Second dose reduction (2 dose levels)
105 mg/m2
Dose modifications for Grade 4 nonhematologic drug-related AEs
Starting dose
210 mg/m2
First dose reduction (2 dose levels)
105 mg/m2
AE = adverse event.
In case of hematological toxicity during any cycle, treatment may be interrupted. Prior to 
initiation of the next cycle, neutrophils should be > 1,000/mm3, platelets > 100,000/mm3, and 
hemoglobin ≥ 9 g/dL.
In addition, in case of non-hematologic Grade 3 or higher toxicity during any cycle, treatment 
should be interrupted and may be resumed when all toxicities have returned to Grade ≤ 2; 
resumption may be at the discretion of the Investigator. 
Treatment interruptions due to a study intervention-related AE may occur for a maximum of 
21 days.
Participants who develop intolerance to berzosertib may continue on single agent topotecan at 
the discretion of the Investigator, administered every 3 weeks (on Days 1 to 5) at the same dose 
administered in combination therapy, until disease progression or other criteria for 
discontinuation are met (Section 7.1).
6.5.2
Topotecan Dose Modifications
The dose of topotecan may be reduced for drug-related toxicity using the toxicity-dependent 
guidelines in Table 9 and Table 10. Topotecan dose reductions will be accomplished by 
decreasing the dose of topotecan for each of the 5 days.
Based on the below criteria, a maximum of 2 dose reductions will be permitted. Once the 
topotecan dose has been reduced, it should not be re-escalated to the starting dose.
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
43/85
Table 9
Topotecan Dose Modifications for Hematologic and Nonhematologic 
Toxicities
Topotecan 1st Dose 
Reduction (mg/m2)
Topotecan 2nd Dose 
Reduction (mg/m2)
Dose Modifications for Hematologic Toxicities
Toxicity
Grades 1 and 2
No adjustment
Not applicable
Grades 3 neutropenia persisting after Day 21 
1
0.75
Grade 4 thrombocytopenia or Grade 4 neutropenia 
with fever or infection or of duration ≥7 days
1
0.75
Dose Modifications for Nonhematologic Toxicities
Toxicity
Grades 1 and 2
No adjustment
Not applicable
Grades 3 and 4 (except Grade 3 nausea)
1
0.75
Table 10
Topotecan Dose Modifications for Renal Function (Regardless of Drug 
Relationship)
Creatinine Clearance (Cockcroft-Gault Formula)
Topotecan 1st Dose Reduction (mg/m2)
≥60 mL/min
No adjustment
40-59 mL/min
1
20-39 mL/min
0.75
< 20 mL/min
Discontinue
For liver function toxicity, please also see Section 7.1 as it may indicate potential severe liver 
injury (possible Hy’s Law) and study intervention discontinuation.
In case of hematological toxicity during any cycle, treatment may be interrupted. Prior to 
initiation of the next cycle, neutrophils should be > 1,000/mm3, platelets > 100,000/mm3, and 
hemoglobin ≥ 9 g/dL.
In addition, in case of non-hematologic Grade 3 or higher toxicity during any cycle, treatment 
should be interrupted and may be resumed when all toxicities have returned to Grade ≤ 2; 
resumption may be at the discretion of the Investigator. 
Treatment interruptions due to a drug-related AE may occur for a maximum of 21 days.
Participants who develop intolerance to topotecan may continue single agent berzosertib at the 
discretion of the Investigator, administered weekly (on Days 2 and 5 of 21-day cycles) at the 
same dose administered in combination therapy, until disease progression or other criteria for 
discontinuation are met (Section 7.1).
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
44/85
6.6
Continued Access to Study Intervention after the End of the Study
The Sponsor will not provide any additional care to participants after they leave the study 
(outside of potential continued treatment as described in Section 4.4) because such care would 
not differ from what is normally expected for patients with advanced solid tumors.
6.7
Treatment of Overdose
For this study, any dose of berzosertib or topotecan greater than 10% over the planned daily dose
included in this study protocol or planned for an individual participant enrolled in the study will 
be considered an overdose.
The Sponsor has no specific recommendation for treating an overdose. The Investigator will use 
his/her clinical judgment to manage any overdose, considering the symptoms and any site 
procedures or standards.
Even if not associated with an AE or a serious adverse events (SAE), any overdose is recorded 
in the eCRF and reported to global patient safety in an expedited manner. Overdoses are reported 
on a SAE and Overdose Report Form, following the procedure in Appendix 4.
6.8
Concomitant Therapy
Record in the eCRF all concomitant therapies (e.g., medicines or nondrug interventions) used 
from the time the participant signs the informed consent until completion of the study, including 
any changes. For prescription and over-the-counter medicines, vaccines, vitamins, and herbal 
supplements, record the name, reason for use, dates administered, and dosing information.
Contact the Medical Monitor for any questions on concomitant or prior therapy.
6.8.1
Rescue Medicine
There is no specific treatment or medicine available to counteract the inhibition of ATR intended 
by berzosertib or topotecan. For any unwanted events during treatment with berzosertib and/or 
topotecan, the oncological standards in supportive care should be applied.
6.8.2
Permitted Medicines
Any medicines that are considered necessary to protect the participant’s welfare in emergencies 
may be given at the Investigator’s discretion, regardless if it results in a protocol deviation.
Permitted premedications are described in Section 6.1. 
6.8.3
Prohibited Medicines
Prohibited concomitant medications during berzosertib treatment are listed in Table 11. 
Any inadvertent use of prohibited medications during the Study Intervention Period will be 
reported as protocol deviations. These will be reviewed by the Sponsor and proportionate action 
taken. In cases where prohibited medication use is judged to significantly affect the participant’s 
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
45/85
safety or compromise the study’s scientific objectives, study participants will be permanently 
discontinued from the study. 
Participants must not receive concurrent anticancer therapy. 
Because berzosertib is primarily metabolized by CYP3A4, inhibitors of CYP3A4 might be 
expected to decrease berzosertib’s clearance and inducers of CYP3A4 might be expected to 
increase its clearance.
Berzosertib is a substrate of P-gp. 
The Investigator should refer to the topotecan summary of product characteristics (SmPC) or 
Package Insert for guidance on prohibited mediations during treatment. 
Table 11
Prohibited Concomitant Medications During Berzosertib Treatment
Restricted Medication/Food
Screening and Treatment Period
Medication:
Strong CYP3A4 inhibitors (Periods 1 & 2)
!
Examples of strong CYP3A4 inhibitors include 
clarithromycin, diltiazem, idelalisib, cobicistat, 
HIV/HBV/HCV protease inhibitors, itraconazole, 
ketoconazole, posaconazole, voriconazole and 
nefazodone.
Moderate CYP3A4 inhibitors (Period 1 only)
!
Examples of moderate CYP3A4 inhibitors 
include Aprepitant, cimetidine, ciprofloxacin, 
clotrimazole, crizotinib, cyclosporine, 
dronedarone, erythromycin, fluconazole, 
fluvoxamine, imatinib, isavuconazole (or 
isavuconazonium), tofisopam, verapamil
P-gp inhibitors (Period 1 only)
!
Examples of P-gp inhibitors azithromycin 
(Zithromax), captopril, carvedilol, felodipine, 
quercetin, quinidine, ranolazine, ticagrelor
Food (Period 1 only)
!
Grapefruit, Seville orange, exotic citrus fruits 
and star fruit or beverages containing these 
fruits
None allowed within 7 days before the first dose of study 
intervention and until the permanent discontinuation of 
berzosertib
Strong CYP3A4 inducers (Periods 1 & 2)
!
Examples of strong CYP3A4 inducers include 
apalutamide, carbamazepine, enzalutamide, 
mitotane, phenytoin, rifampin and St. John's 
wort.
Moderate CYP3A4 inducer (Period 1 only)
•
Examples 
of 
moderate 
CYP3A4 
inducers 
Bosentan, 
Efavirenz, 
Modafinil, 
Nafcillin, 
Rifabutin
None allowed within 4 weeks prior to the first dose of 
study intervention and until the permanent 
discontinuation of berzosertib
CYP3A4 = cytochrome P450 3A4; HBV = hepatitis B virus; HCV = hepatitis C virus; HIV = human immunodeficiency 
virus; P-gp = P-glycoprotein.
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
46/85
6.8.4
Other Interventions
Radiation therapy is allowed on this study for palliative treatment e.g., for lesions that cause 
symptoms that cannot be adequately controlled by other means e.g., analgesics; however, the use 
of radiation therapy during the Study Intervention Period should be discussed with the Medical 
Monitor on a case by case basis considering the influence on imaging assessments of 
target/nontarget lesions. 
In addition, the Investigator should ensure that tumor assessments are recently obtained and 
reported as per RECIST 1.1, before initiation of radiation therapy. Berzosertib and topotecan 
should be withheld at least 1 day before the administration of radiation therapy; both 
interventions can be resumed after radiation therapy is completed, provided the participant has 
recovered from potential radiation therapy toxicities (Grade < 2 or back to baseline) and will 
derive benefit from resuming study treatment, as assessed by the Investigator. In case whole 
brain radiation therapy is administered, a wash-out period of ≥ 14 days is required before 
resuming study treatment.
7
Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal
7.1
Discontinuation of Study Intervention
If study intervention is permanently discontinued, the participant will remain in the study to be 
evaluated for safety, 30 days after the last dose of study intervention. The SoA indicates data to 
be collected at the time of discontinuation of study intervention and follow-up and for any further 
evaluations that need to be completed.
Participants will be withdrawn from study intervention for any of the following reasons:
!
A participant may withdraw from the study intervention at any time at his/her own request, 
and without giving a reason. The participant will continue follow-up, unless consent to study 
was withdrawn as well
!
Upon documentation of disease progression per RECIST 1.1
!
General or specific changes in the participant’s condition that render the participant 
unacceptable for further treatment in the judgment of the Investigator
!
Unequivocal clinical progression
!
A participant may be withdrawn at any time at the discretion of the Investigator for safety, 
behavioral, compliance, or administrative reasons
!
Pregnancy
!
Liver injury: 
The Investigator will consider discontinuation of study intervention for abnormal liver 
function when a participant meets 1 of the conditions outlined in the algorithm or if the 
Investigator believes that it is in best interest of the participant.
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
47/85
!
All events of ALT or AST > 8 × ULN 
!
All events of ALT or AST > 5 × ULN for more than 2 weeks
!
All events of ALT ≥3 × ULN and bilirubin ≥2 × ULN (> 35% direct bilirubin) or 
ALT > 3 × ULN and international normalized ratio (INR) > 1.5, if INR measured 
!
ALT or AST > 3 × ULN with the appearance of fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, fever, rash, and/or eosinophilia (> 5%)
These may indicate potential severe liver injury (possible Hy’s Law) and will be reported as a 
SAE.
7.2
Participant Discontinuation/Withdrawal from the Study
! A participant may discontinue from the study at any time, at his/her own request or at the 
discretion of the Investigator for safety, behavioral, compliance, or administrative reasons.
! At the time of study discontinuation, if possible, a discontinuation visit will be conducted, as 
listed in the SoA. The SoA specifies the data to collect at study discontinuation and follow-
up, and any additional evaluations that need to be completed.
! If the participant revokes consent for the study, any data collected up to that point may still 
be used, but no future data can be generated, and any biological samples collected will be 
destroyed.
! A participant has the right at any time to request destruction of any biological samples taken. 
The investigator will document this in the site study records and the eCRF and inform the 
Sponsor. The samples will be destroyed.
! Additional participants must be enrolled for each participant who withdraws from the study 
after signing consent and successfully meeting entry criteria but did not receive study 
intervention. 
7.3
Lost to Follow-Up
A participant will be considered lost to follow-up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contacted by the study site.
The following actions will be taken if a participant fails to return to the clinic for a required study 
visit:
! The site will attempt to contact the participant and reschedule the missed visit as soon as 
possible, counsel the participant on the importance of maintaining the assigned visit schedule 
and ascertain if the participant wants to or should continue in the study.
! Before a participant is deemed “lost to follow-up”, the Investigator or designee will make 
every effort to regain contact with the participant: 1) where possible, make 3 telephone calls; 
2) if necessary, send a certified letter (or an equivalent local method) to the participant’s last 
known mailing address, and 3) if a participant has given the appropriate consent, contact the 
participant’s general practitioner or caretaker (where allowed by local regulations) for 
information. These contact attempts will be documented in the participant’s medical record.
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
48/85
! If the participant continues to be unreachable, he/she will be deemed as “lost to follow-up”.
8
Study Assessments and Procedures
! Study assessments and procedures and their timing are summarized in the SoA.
! No protocol waivers or exemptions are allowed.
! Immediate safety concerns are discussed with the Sponsor immediately upon occurrence or 
awareness to determine if the participant should continue or discontinue study intervention.
! Adherence to the study design requirements, including those specified in the SoA, is essential 
and required for study conduct.
! All screening evaluations will be completed and reviewed to confirm that potential 
participants meet all eligibility criteria. The Investigator will maintain a screening log to 
record details of all participants screened, to confirm eligibility, and if applicable, record 
reasons for screening failure.
! Prior to performing any study assessments that are not part of the participant’s routine medical 
care, the Investigator will obtain written informed consent as specified in Appendix 2.
! Procedures conducted as part of the participant’s routine medical care (e.g., blood count) and 
obtained before signing of the ICF may be used for screening or baseline purposes provided 
the procedures met the protocol-specified criteria and were performed within the time frame 
defined in the SoA.
! No more than 400 mL of blood may be drawn in a 2-week period.
Where allowed by local law/regulations, samples collected during this clinical study may be 
transferred to a biobank and used for future research outside the clinical protocol when 
additional consent for this purpose is given. Transfer to the biobank will be documented and 
any testing of coded biobank samples will not be reported in the Clinical Study Report (CSR).
The long-term storage of samples after study completion for future research may be 
performed with all sample types collected in the study (e.g., PK or pharmacogenomics) if the 
participant consents to optional future medical research.
8.1
Efficacy Assessments and Procedures
Radiographic images and clinical findings (such as physical assessments and biopsies) will be 
used by the Investigators for the local determination of disease progression and participant 
treatment decisions.
Participants will have a chest/abdomen/pelvis imaging scan (e.g., computed tomography [CT], 
magnetic resonance imaging [MRI]) and, if clinically indicated, imaging scans of other body 
areas (e.g., neck) or other modalities (e.g., bone scan, positron emission tomography-CT 
[PET-CT]). A brain scan with contrast (MRI [preferred] or CT, with contrast) should be 
performed as clinically indicated. Participants should have a repeat imaging scan as described in 
the SoA in Section 1.3. All imaging scans to assess disease progression should be performed 
using similar CT/MRI platforms and imaging techniques, including the use or absence of 
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
49/85
contrast, and should be of consistent anatomic locations with prior imaging scans, whenever 
possible. 
Imaging scans will be locally read, and the Investigator should continue treatment administration 
until progressive disease (PD). The applicable overall response category for each visit that 
includes disease assessment, based on evaluation of imaging scan, will be recorded in the eCRF. 
Determination of participant study disposition (i.e., discontinuation or extension of therapy) will 
be based on disease progression as interpreted from the local evaluation of the imaging scan. 
Tumor assessments per protocol will be performed until PD or start of subsequent anticancer 
treatment, whichever comes first, regardless of study intervention discontinuation. 
8.2
Safety Assessments and Procedures
The safety profile of the study intervention will be assessed through the recording, reporting and 
analysis of baseline medical conditions, AEs, physical examination findings, vital signs, 
electrocardiograms, and laboratory tests.
Comprehensive assessment of any potential toxicity experienced by each participant will be 
conducted starting when the participants give informed consent and throughout the study. The 
Investigator will report any AEs, whether observed by the Investigator or reported by the 
participant; the reporting period is specified in Section 8.3.
8.2.1
Physical Examinations
Physical examinations will be performed and the ECOG PS should be recorded according to the 
SoA (Table 1 and Table 4). Symptom-directed physical examinations may be performed as 
clinically indicated per Investigator’s judgment.
! A complete physical examination will include, at a minimum, assessments of the 
cardiovascular, respiratory, gastrointestinal and neurological systems.
! A brief physical examination will include, at a minimum, assessments of the skin, lungs, 
cardiovascular system, and abdomen (liver and spleen).
! Investigators will pay special attention to clinical signs related to previous serious illnesses.
8.2.2
Vital Signs
! Blood pressure and participant’s position; pulse; respiratory rate; temperature and location of 
measurement, weight, and height (at Screening only) will be measured and recorded.
! Blood pressure and pulse measurements will be preceded by at least 5 minutes of rest for the 
participant in a quiet setting without distractions (e.g., television, cell phones) and measured 
with an automated device. Manual techniques will be used only if an automated device is not 
available.
8.2.3
Electrocardiograms
! Single 12-lead ECG will be obtained as outlined in the SoA using an ECG machine that 
automatically measures heart rate, PR, RR, QRS, QT, and QTcB or QTcF. 
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
50/85
! ECGs will be recorded after 5 minutes of rest.
8.2.4
Clinical Safety Laboratory Assessments
! Blood and urine samples will be collected for the clinical laboratory tests listed in Appendix 6
at the time points listed in the SoA. All samples will be clearly identified. 
! Additional tests may be performed at any time during the study, as determined necessary by 
the Investigator or required by local regulations.
! The tests will be performed by the local laboratory.
! The Sponsor must receive a list of the local laboratory normal ranges before shipment of study 
intervention(s). Any changes to the ranges during the study must be forwarded to the Sponsor.
! The Investigator will review each laboratory report, document this review, and record any 
clinically significant changes occurring during the study as an AE, unless it does not meet the 
AE definition, as specified in Appendix 4. The laboratory reports will be filed with the source 
documents.
! Pregnancy testing (serum or highly sensitive urine, as required by local regulations) will be 
conducted at monthly intervals during study intervention administration.
! Pregnancy testing (serum or highly sensitive urine, as required by local regulations) will be 
conducted at the end of the relevant systemic exposure of the study intervention plus an 
additional 30 days and correspond with the time frame for female participant contraception 
in Section 5.1 (Inclusion Criteria).
! Additional serum or highly sensitive urine pregnancy tests may be conducted, as determined 
necessary by the Investigator or required by local regulation, to establish the absence of 
pregnancy at any time during the study.
8.3
Adverse Events, Serious Adverse Events, and Other Safety 
Reporting
! The definitions of an AE and a SAE are in Appendix 4.
! The Investigator and any qualified designees (e.g., Sub-Investigators) are responsible for 
detecting, documenting, and recording events that meet the definition of an AE or SAE. The 
Investigator remains responsible for following up AEs that are serious or that caused the 
participant to discontinue the study intervention or study, as specified in Section 8.3.2.
! Requests for follow-up will usually be made via the Sponsor or Clinical Research 
Organization (CRO)-designated study team member, although in exceptional circumstances 
the global patient safety department may contact the Investigator directly to obtain further 
information or to discuss the event.
! The method of recording, evaluating, and assessing causality of AEs and SAEs and the 
procedures for completing and transmitting SAE reports are in Appendix 4.
! All AEs and SAEs will be collected from the signing of the ICF until the follow-up visit at 
the time points specified in the SoA (Section 1.3). Beyond this reporting period, any new 
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
51/85
unsolicited SAEs that the Investigator spontaneously reports to the Sponsor will be collected 
and processed.
! All SAEs will be recorded and reported to the Sponsor or designee immediately and under no 
circumstance will this exceed 24 hours, as indicated in Appendix 4. The Investigator will 
submit any updated SAE data to the Sponsor within 24 hours of it being available using the 
same procedure that was used for the initial report.
! Investigators are not obligated to actively solicit information on AEs or SAEs after the end of 
study participation. However, if the Investigator learns of any SAE, including a death, at any 
time after a participant has been discharged from the study, and he/she considers the event to 
be reasonably related to the study intervention or study participation, the Investigator will
promptly notify the Sponsor.
8.3.1
Method of Detecting Adverse Events and Serious Adverse 
Events
At each study visit, the participant will be queried on changes in his or her condition. 
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open-ended and non-
leading verbal questioning of the participant is the preferred method to inquire about AE 
occurrences.
The method of recording, evaluating, and assessing causality of AEs and SAEs and the 
procedures for completing and transmitting SAE reports are in Appendix 4.
8.3.2
Follow-up of Adverse Events and Serious Adverse Events
After the initial AE/SAE report, the Investigator is required to proactively follow each participant 
at subsequent visits/contacts. All SAEs will be followed until resolution, stabilization, the event 
is otherwise explained, or the participant is lost to follow-up (as defined in Section 7.3). 
Reasonable attempts to obtain this information will be made and documented. It is also the 
Investigator’s responsibility to ensure that any necessary additional therapeutic measures and 
follow-up procedures are performed. Further information on follow-up procedures is in 
Appendix 4.
8.3.3
Regulatory Reporting Requirements for Serious Adverse 
Events
Prompt notification by the Investigator to the Sponsor of an SAE (particularly life-threatening 
and deaths) is essential so that legal obligations and ethical responsibilities towards the safety of 
participants and the safety of a study intervention under clinical investigation are met.
The Sponsor has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a study intervention under clinical investigation. The 
Sponsor will comply with country-specific regulatory requirements relating to safety reporting 
to the regulatory authority, Institutional Review Board (IRB)/ Independent Ethics Committee 
(IEC), and Investigators.
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
52/85
Individual Case Safety Reports will be prepared for suspected unexpected serious adverse 
reactions (SUSARs) according to local regulatory requirements and Sponsor policy and 
forwarded to Investigators, as necessary.
An Investigator who receives an Individual Case Safety Report describing a SUSAR or other 
specific safety information (e.g., Emerging Safety Issue Report, summary or listing of 
SAEs/SUSARs) from the Sponsor will review and file it in the Investigator’s Site File and will 
notify the IRB/IEC, if appropriate according to local requirements.
8.3.4
Pregnancy
! Details of all pregnancies in female participants and, if indicated, female partners of male 
participants will be collected after the start of study intervention and until 6 months after the 
last study intervention dose.
! If a pregnancy is reported, the Investigator will record the pregnancy information on the 
appropriate form and submit it to the Sponsor within 24 hours of female participant or female 
partner of male participant (after obtaining the necessary signed informed consent from the 
female partner) pregnancy.
! While pregnancy itself is not considered to be an AE or SAE, any pregnancy complication or 
elective termination of a pregnancy will be reported as an AE or SAE. Adverse pregnancy 
outcomes (e.g., spontaneous abortion, fetal death, stillbirth, congenital anomalies, ectopic 
pregnancy) are considered and reported as SAEs. A spontaneous abortion (occurring at 
<22 weeks gestational age) or stillbirth (occurring at >22 weeks gestational age) is always 
considered to be an SAE and will be reported as such.
! The participant/pregnant female partner will be followed to determine the outcome of the 
pregnancy. The Investigator will collect follow-up information on the participant/pregnant 
female partner and the neonate, and the information will be forwarded to the Sponsor.
Generally, follow-up will not be required for longer than 6 to 8 weeks beyond the estimated 
delivery date for a healthy newborn. In case of a congenital anomaly or other illness of the 
newborn, follow-up will continue until the illness has resolved or there is a definite outcome 
of the event.
! Any post-study pregnancy related SAE considered reasonably related to the study 
intervention by the Investigator will be reported to the Sponsor as specified in Section 8.3.3. 
While the Investigator is not obligated to actively seek this information in former study 
participants/pregnant female partner, he or she may learn of an SAE through spontaneous 
reporting.
! Any female participant who becomes pregnant while participating in the study will 
discontinue study intervention or be withdrawn from the study.
8.3.5
Cardiovascular and Death Events
Not applicable for cardiovascular events.
For death events refer to Appendix 4 for more information.
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
53/85
8.3.6
Disease-Related Events and/or Disease-Related Outcomes 
Not Qualifying as AEs or SAEs
The following disease-related events (DREs) are common in participants with advanced solid 
tumors and can be serious/life threatening:
!
Progressive disease
Because PD is typically associated with the disease under study, it will not be reported according 
to the standard process for expedited reporting of SAEs even though the event may meet the 
definition of a SAE. These events will be recorded on the applicable eCRF page.
However, if either of the following conditions applies, then the event will be recorded and 
reported as an AE/SAE (instead of a DRE):
!
The event is, in the Investigator’s opinion, of greater intensity, frequency, or duration than 
expected for the individual participant.
OR
!
The Investigator considers that there is a reasonable possibility that the event was related to 
study intervention.
8.3.7
Adverse Events of Special Interest
No AEs of special interest have been identified.
8.4
Pharmacokinetics
Whole blood samples of approximately 12 to 24 mL will be collected at each time point for 
measurement of whole blood (total radioactivity) and plasma concentrations of total 
radioactivity, and berzosertib and metabolite profiling and identification (MetID). Collection 
times are specified in the SoA and Table 2. Details of timepoints and required blood volumes 
will be captured in the laboratory manual. The actual date and time (24-hour clock time) of each 
sample will be recorded to calculate actual time elapsed since the prior dose administration. The 
sampling timing may be altered during the study based on newly available data (e.g., to obtain 
data closer to the time of peak plasma concentrations) to ensure appropriate monitoring.
Urine and feces samples for measurements of concentrations of total radioactivity, berzosertib 
(urine only) and for metabolic profiling will be collected as specified in the SoA (Table 3). The 
actual start and end date and time (24-hour clock time) of each urine and feces fraction as well 
as the volume (urine) and the weight (feces) of each collection fraction will be recorded. The 
accepted time deviations from planned whole blood and plasma sampling times that will not be 
considered a protocol deviation are listed in Table 2.
The quantification of berzosertib in plasma and urine, will be performed using validated assay 
methods. In addition, known berzosertib metabolites may be measured and samples will be used 
for metabolic profiling. Concentrations will be used to evaluate the PK of study intervention and 
TR (and metabolites, if applicable).
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
54/85
Remaining samples collected for analyses of berzosertib, metabolite profiling and TR 
concentration may also be used to evaluate safety or efficacy aspects related to concerns arising 
during or after the study.
Details on processes for collection and handling of these samples are in the Laboratory Manual. 
Retention time and possible analyses of samples after the end of study are specified in the 
respective ICF, according to local regulations.
The following PK parameters will be calculated for berzosertib and total radioactivity in plasma 
and whole blood when appropriate:
Symbol
Definition
AUC0-tlast
The area under the concentration-time curve (AUC) from time zero 
(= dosing time) to the last sampling time (tlast) at which the concentration 
is at or above the lower limit of quantification. Calculated using the mixed 
log-linear trapezoidal rule (linear up, log down).
AUC0-∀
The AUC from time zero (dosing time) extrapolated to infinity, based on
the predicted value for the concentration at tlast, as estimated using the 
linear regression from λz determination. AUC0-∞= AUC0-tlast + Clast pred/ λz
AUC0-t
The partial area under the concentration-time curve (AUC) from time 
zero (= dosing time) to a defined time ‘t’. Calculated using the mixed 
log-linear trapezoidal rule (linear up, log down). Timepoint ‘t’ will be 
defined upon receipt of the metabolite profiling data.
Cmax
Maximum observed concentration.
Ceoi
The observed concentration at the end of the infusion period.
CL 
(berzosertib 
only)
The total body clearance of study intervention following intravenous
administration, CL = Dose /AUC0-∞.
tmax
The time to reach the maximum observed concentration collected during 
a dosing interval.
t1/2
Terminal half-life. t1/2 = ln (2)/λz
tlast
The last sampling time at which the concentration is at or above the lower 
limit of quantification.
VZ 
(berzosertib 
only)
The volume of distribution during the terminal phase following 
intravenous administration. VZ = Dose/(AUC0-∞*λz).
Vss 
(berzosertib 
only)
An estimate of the volume of distribution at steady-state based on the last 
predicted concentration, calculated as CL * MRTiv.
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
55/85
Symbol
Definition
MRTiv (berzosertib 
only)
The mean residence time extrapolated to infinity, calculated as 
(AUMC0-∞/AUC0-∞ )-T/2, where T is the infusion duration.
The following PK parameters will be calculated for berzosertib (urine only) and total 
radioactivity in urine and feces, when appropriate:
Symbol
Definition
Aet1-t2, urine
Amount excreted in urine between times t1 (= start) and t2 (= end), 
calculated per collection interval and cumulative.
Aet1-t2, feces
Amount excreted in feces between times t1 (= start) and t2 (= end), 
calculated per collection interval and cumulative.
Aetotal
Total (cumulative) amount radioactivity recovered in urine and feces over 
the entire collection period.
CLR 
(berzosertib 
only)
The renal clearance of study intervention. CLR= Ae0-t_urine/AUC0-t
fe (%)
(berzosertib 
only)
Percent of dose excreted as an unchanged berzosertib in urine.
fet1-t2, urine %
Fraction of administered drug that is excreted in urine between times t1 
(= start) and t2 (= end), calculated per collection interval and cumulative.
fet1-t2, feces %
Fraction of administered radioactivity that is excreted in feces between times 
t1 (= start) and t2 (= end), calculated per collection interval and cumulative.
fetotal %
Total (cumulative) fraction of administered radioactivity recovered in 
urine and feces over the entire collection period.
Free fraction (%unbound) of berzosertib in plasma may be summarized by time points and pool 
of time points as permitted by the data. In case vomitus is collected, total radioactivity will be 
assayed and results listed. Details will be provided in the Integrated Analysis Plan (IAP).
Additional PK parameters may be calculated, if appropriate. Methodology for the calculation of 
PK parameters will be detailed in the IAP.
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
56/85
 
 
 
 
8.6
Biomarkers
Not applicable.
8.7
Immunogenicity Assessments
Not applicable.
8.8
Medical Resource Utilization and Health Economics
Not applicable.
9
Statistical Considerations
This section outlines the statistical analysis strategy and procedures for the study. Full details of 
all planned analyses will be described in the study IAP. 
9.1
Statistical Hypotheses
The statistical analysis of study data will be purely descriptive; no hypothesis tests will be 
performed.
9.2
Sample Size Determination
A total of approximately 6 participants (or more) will be treated with study intervention such 
that approximately 4 to 6 PK evaluable participants are anticipated to be obtained. If the initial 
group of 6 leads to fewer than 4 evaluable participants, the cohort will be increased up to a 
maximum of 12 participants, until 4 participants have completed all study procedures for 
Period 1 and are evaluable.
The decision to enroll additional participants will be taken on a case-by-case basis, in agreement 
between the Sponsor and the Investigator. 
For participants who experience emesis during the first 48 hours after the end of [14C]berzosertib 
administration, the vomitus should be collected as much as possible and assayed for total 
radioactivity. 
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
57/85
A participant who has any missing urine or feces samples that impact assessment of mass balance 
or does not have sufficient PK sampling to derive the primary PK parameters, is not considered 
evaluable.
9.3
Analyses Sets
The analysis sets are specified below.
Analysis Set
Description
SCR 
All participants, who provided informed consent, regardless of the participant’s study 
intervention status in the study.
FAS / SAF
All participants, who were administered any dose of any study intervention. 
PKAS
The PKAS is a subset of the SAF and will consist of all participants, who receive the 
single dose of study intervention in Period 1 and provide at least one measurable 
post-dose concentration. A measurement BLQ is considered a valid measurement. 
All PK analyses will be based on this analysis set.
BLQ = below lower limit of quantification; FAS = Full Analysis Set; PK = pharmacokinetic; PKAS = Pharmacokinetics 
Analysis Set; SAF = Safety (Analysis Set); SCR = Screening (Analysis Set) 
9.4
Statistical Analyses
Statistical analysis will be performed using the computer program package SAS® System 
(release 9.2 or later version; SAS Institute, Cary NC, US), or R (R Core Team, 2020. R: A 
Language 
and 
Environment 
for 
Statistical 
Computing, 
Vienna, 
Austria. 
https://www.R-project.org/). More details on the statistical analyses will be presented in the IAP 
prior to database lock. This document will provide further details regarding the definition of 
analysis variables and analysis methodology to address all study objectives.
The statistical analysis will not be started until all data have been cleaned and checked for 
plausibility, and until all necessary coding and assessments have been completed. 
All data recorded during the study will be presented in individual data listings. 
All data will be evaluated as observed, no imputation method for missing values. The handling 
of concentration values below the limit of quantification will be described in the IAP.
9.4.1
Efficacy Analyses
All analyses on efficacy estimands will be conducted on the Full Analysis Set (FAS). The 
estimands framework is used in Table 12.
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
58/85
Table 12
Efficacy Analyses and Estimands (Period 2)
Endpoint
Statistical Analysis Methods/Further Estimand Attributes
Objective Response 
Endpoint: Objective Response according to RECIST 1.1 as assessed by the Investigator
Population: Patients with advanced solid tumors
Treatment: Berzosertib + topotecan
Intercurrent Event Strategy:
•
Discontinuation of treatment: treatment-policy strategy, i.e., regardless of the 
intercurrent event
•
Start of subsequent anticancer treatment: while not treated with subsequent anticancer 
therapy strategy, i.e., ignoring tumor assessments after the intercurrent event
•
Progression according to RECIST 1.1: while not progressed strategy, i.e., 
assessments up to the intercurrent event
9.4.2
Safety Analyses
All safety analyses will be performed on the Safety Analysis Set (SAF).
Medical history and AE terms will be coded with the latest version of the Medical Dictionary 
for Regulatory Activities (MedDRA) (Version 23.0 or later); concomitant medication will be 
coded with World Health Organization (WHO) Drug Dictionary, WHO Drug Reference List and 
Anatomical Therapeutic Chemical Classification System, latest versions. Versions of 
dictionaries used for coding will be defined in the Data Management Plan. 
The on-treatment period is defined as the time from first study intervention to the last study 
intervention date + 30 days.
Table 13
Safety Endpoints
Endpoint
Statistical Analysis Methods
Primary
Not applicable
Secondary
AEs
The definitions, procedures for recording, evaluating, follow-up, and reporting of AEs are 
described in Appendix 4. AEs will be coded according to the latest available version of 
the MedDRA. Missing classifications concerning study intervention relationships will be 
considered related to the study interventions.
Analysis will be based on TEAEs, which are events with onset dates during the 
on-treatment period, or events with onset dates before the on-treatment period and 
worsening during the on-treatment period.
The following TEAEs will be presented in summaries by incidence and type according to 
MedDRA SOC and Preferred Term:
!
TEAEs
!
TEAEs related to study interventions.
The following AEs will be listed:
!
SAEs
!
NCI-CTCAE Grade ≥ 3 TEAEs 
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
59/85
Endpoint
Statistical Analysis Methods
!
TEAEs leading to dose modification or temporary/permanent interruption of study 
interventions
!
TEAEs leading to death.
Deaths
Death and primary reason for death will be listed.
Laboratory Values
Baseline values are defined as the last value prior to first administration of study 
intervention in the respective period. Only on-treatment values will be summarized. 
Laboratory values will be graded using NCI-CTCAE (Version 5.0), if applicable. 
Non-gradable parameters will be classified as normal, high, or low.
Summary statistics for:
!
Absolute values
!
Change from baseline (Period 2 only; baseline is the Day 1 pre-dose value in each 
cycle)
!
Worst on-treatment grade (Period 2 only)
Vital Signs
! Summary statistics for baseline and on-treatment values
ECGs
! Summary statistics of all measurements by scheduled time point
Tertiary/Exploratory
Not applicable
AEs = adverse events; ECGs = electrocardiograms; MedDRA = Medical Dictionary for Regulatory Activities;
NCI-CTCAE = National Cancer Institute Common Terminology Criteria for Adverse Events; SAEs = serious 
adverse events; SOC = System Organ Class; TEAE = treatment-emergent adverse event.
9.4.3
Other Analyses
Baseline characteristics will be analyzed on the SAF. Summary statistics will be provided as 
described for continuous/categorical variables in Section 9.4.
For demographic (e.g., age, sex, race, etc.), baseline and safety assessments, continuous 
measurements will be summarized by means of descriptive statistics (i.e. number and percentage 
of observations, number and percentage of missing observations, mean, standard deviation [SD], 
median, the first and third quartile [Q1 and Q3], minimum [Min], and maximum [Max]) and 
categorical data will be summarized by means of frequency tables (i.e., count and percentages), 
if not stated otherwise. 
Analysis of Pharmacokinetics
PK parameters (e.g. Cmax, AUC, t1/2, CL, Vz, and Vss of berzosertib and Cmax, AUC, t1/2 of total 
radioactivity in plasma; Cmax, AUC, t1/2 of total radioactivity in blood) will be calculated using 
noncompartmental methods based on the actual sampling times, listed and tabulated with 
descriptive statistics. The noncompartmental analysis will be outsourced under the supervision 
of the Sponsor and will be performed by PRA – Early Development Services (EDS) using 
Phoenix® WinNonlin® version 8.1 or higher (Certara, L.P., Princeton, NJ, 08540 US). 
Individual plasma concentrations of berzosertib and radioactivity, and amounts excreted in 
urine/feces will be tabulated using the nominal sampling times with descriptive statistics at all 
time points. Excretion of total radioactivity will be calculated based on the administered 
radioactive dose and the relative amount of radioactivity recovered in urine and feces. Graphical 
displays will be produced where appropriate.
Details on the PK analyses will be in the IAP that will be finalized before database lock. 
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
60/85
9.4.4
Sequence of Analyses
After all participants have completed Period 1, the primary report for the study will be generated 
once all data queries are resolved, and the primary database will be soft-locked for Period 1. The 
primary analysis will include all data collected in Period 1 and all planned analyses identified in 
the Clinical Study Protocol, in particular the analysis of the mass balance data. Data from 
Period 2 will be added to the report as an addendum, upon end of study as described in 
Section 4.4, with all study data in-house, all data queries resolved, and the database locked.
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
61/85
10
References 
Konstantinopoulos PA, Cheng SC, Wahner Hendrickson AE, et al. Berzosertib plus gemcitabine 
versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, 
open-label, randomised, phase 2 trial. Lancet Oncol. 2020;21:957-68.
Thomas A, Redon CE, Sciuto L, et al. Phase I study of ATR inhibitor M6620 in combination 
with topotecan in patients with advanced solid tumors. J Clin Oncol. 2018;36(16):1594-602.
Thomas A, Takahashi N, Rajapakse VN, et al. Therapeutic targeting of ATR yields durable 
regressions in small cell lung cancers with high replication stress. Cancer Cell. 2021;39:566-79.
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
62/85
11
Appendices
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
63/85
Appendix 1
Abbreviations
AE(s)
Adverse Event(s)
ALT
Alanine aminotransferase
AMS
Accelerator mass spectrometry
AST
Aspartate aminotransferase
ATM
Ataxia telangiectasia mutated
ATR
Ataxia telangiectasia mutated and Rad3-related 
BCRP
Breast Cancer Resistance Protein
β-HCG
β-human chorionic gonadotropin
BLQ
Below lower limit of quantification
BOI
Beginning of infusion
C
Cycle
CIOMS
Council for International Organizations of Medical Sciences
CRO
Clinical Research Organization
CRU
Clinical Research Unit
CSR
Clinical Study Report
CT
Computed tomography
CTFG
Clinical Trial Facilitation Group
CYP
Cytochrome P450
D
Day
DDI
Drug-drug interaction
DDR
DNA damage response
DRE
Disease-related events
ECG
Electrocardiogram
ECOG PS
Eastern Cooperative Oncology Group Performance Status
eCRF
Electronic Case Report Form
EDC
Electronic data capture
EDS
Early Development Services
EMA
European Medicines Agency
EOI
End of infusion
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
64/85
EORTC
European Organization for the Research and Treatment of Cancer
EOT
End of treatment
FAS
Full Analysis Set
FDA
Food and Drug Administration
FSH
Follicle-stimulating hormone
GCP
Good Clinical Practice
G-CSF
Granulocyte colony-stimulating factor
GMP
Good Manufacturing Practice
Hb
Hemoglobin 
HBV
Hepatitis B virus
HCV
Hepatitis C virus
HIV
Human Immunodeficiency Virus
HRT
Hormonal replacement therapy
IAP
Integrated Analysis Plan
IB
Investigator’s Brochure
ICF
Informed Consent Form
ICH
International Council for Harmonisation
IEC
Independent Ethics Committee
IMP
Investigational Medicinal Product 
IRB
Institutional Review Board
IUD
Intrauterine device
IUS
Intrauterine hormone-releasing system
IV
Intravenous
LAM
Lactational amenorrhea method
MedDRA
Medical Dictionary for Regulatory Activities
MetID
Metabolite identification
MIST
Metabolites in Safety Testing
MRI
Magnetic resonance imaging
NCI-CTCAE
National Cancer Institute Common Terminology Criteria for Adverse 
Events 
NIMP
Noninvestigational Medicinal Product
OATP
Organic anion-transporting polypeptide
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
65/85
PD
Progressive disease
PET-CT
Positron emission tomography computed tomography
P-gp
P-glycoprotein
PK
Pharmacokinetic(s)
PKAS
Pharmacokinetics Analysis Set
PR
Partial response
PRA
PRA Health Sciences
QTL
Quality Tolerance Limit
RECIST 1.1
Response Evaluation Criteria in Solid Tumor Version 1.1
SAE(s)
Serious Adverse Event(s)
SAF
Safety Analysis Set
SCLC
Small Cell Lung Cancer
SCR
Screening (Analysis Set)
SD
Stable disease; standard deviation
SmPC
Summary of product characteristics
SoA
Schedule of Activities
SoC
Standard of care
SOC
System Organ Class
SUSAR
Suspected unexpected serious adverse reaction
TEAE
Treatment-emergent Adverse Event
TR
Total radioactivity
UGT
Uridine diphosphate glucuronosyltransferase
ULN
Upper Limit of Normal
US
United States
WHO
World Health Organization
WOCBP
Woman of Childbearing Potential
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
66/85
Appendix 2
Study Governance
Financial Disclosure
Investigators and Sub-Investigators will provide the Sponsor with sufficient, accurate financial 
information, as requested, for the Sponsor to submit complete and accurate financial certification 
or disclosure statements to the appropriate regulatory authorities. This information is required 
during the study and for 1 year after completion of the study.
Informed Consent Process
! The Investigator or his/her representative will explain the nature of the study to the participant 
or his/her legally-authorized representative (where allowed by local laws and regulations) and 
answer all questions on the study.
! Participants will be informed that their participation is voluntary.
! Participants or their legally-authorized representative (where allowed by local laws and 
regulations) will be required to sign a statement of informed consent that meets the 
requirements of 21 CFR 50; local regulations; ICH guidelines; Health Insurance Portability 
and Accountability Act requirements, where applicable; and the IRB/IEC or study center.
! The medical record will include a statement that written informed consent was obtained 
before the participant was enrolled in the study and the date the written consent was obtained. 
The authorized person obtaining the informed consent will also sign the ICF.
! If the ICF is updated during their participation in the study, participants will be re-consented 
to the most current, approved version.
! Participants who are rescreened are required to sign a new ICF (see Section 5.4 for details).
Data Protection
! The Sponsor will assign a unique identifier to participants after obtaining their informed 
consent. Any participant records or datasets that are transferred to the Sponsor will contain 
the identifier only; participant names or any identifiable information will not be transferred.
! The Sponsor will inform participants that their personal study-related data will be used per 
local data protection and privacy laws. The level of disclosure will also be explained to the 
participant and pregnant partners (if applicable), who will be required to give consent for their 
data to be used, as specified in the informed consent.
! The participant will be informed that his/her medical records may be examined by Clinical 
Quality Assurance auditors or other Sponsor-appointed, authorized personnel, by appropriate 
IRB/IEC members, and by regulatory authority inspectors. All such persons will strictly 
maintain participants’ confidentiality.
! Certain tasks listed above can be delegated to PRA
Study Administrative
The Principal Investigator listed on the title page represents all Investigators for decisions and 
discussions on this study, per ICH GCP. The Principal Investigator will provide expert medical 
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
67/85
input and advice on the study design and execution and is responsible for the review and signoff 
of the clinical study report.
Details of structures and associated procedures will be defined in a separate Project Management 
Plan.
Regulatory and Ethical Considerations
! This study will be conducted in accordance with the protocol and the following:
! Consensus ethical principles derived from international guidelines, including the Declaration 
of Helsinki and Council for International Organizations of Medical Sciences (CIOMS)
International Ethical Guidelines
! Applicable ICH GCP Guidelines
! Applicable laws and regulations
! The protocol, protocol amendments (if applicable), ICF, Investigator’s Brochure, and other 
relevant documents (e.g., advertisements) will be submitted to an IRB/IEC for review and 
approve before the study is initiated.
! Any protocol amendments (i.e., changes to the protocol) will be documented in writing and 
require IRB/IEC approval before implementation of changes, except for changes necessary to 
eliminate an immediate hazard to study participants. When applicable, amendments will be 
submitted to the appropriate Health Authorities.
! The protocol and any applicable documentation will be submitted or notified to the Health 
Authorities in accordance with all local and national regulations for each site.
Emergency Medical Support
! The Sponsor or designee will provide Emergency Medical Support cards to participants for 
use during the study. These provide the means for participants to identify themselves as 
participating in a clinical study. Also, these give health care providers access to any 
information about this participation that may be needed to determine the course of medical 
treatment for the participant. The information on the Emergency Medical Support card may 
include the process for emergency unblinding (if applicable).
! The first point of contact for all emergencies will be the clinical study Investigator caring for 
the participant. Consequently, the Investigator agrees to provide his or her emergency contact 
information on the card. If the Investigator is available when an event occurs, they will answer 
any questions. Any subsequent action (e.g., unblinding) will follow the standard process 
established for Investigators.
When the Investigator is not available, the Phase I facility will provide the appropriate means to 
contact a physician. This includes the provision of a 24-hour contact number at the facility, 
whereby the health care providers will be given access to an appropriate physician to assist with 
the medical emergency and to provide support for the potential unblinding of the participant 
concerned.
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
68/85
Clinical Study Insurance and Compensation to Participants
Insurance coverage will be provided for each country participating in the study. Insurance 
conditions will meet good local standards, as applicable.
Clinical Study Report
After study completion, the Sponsor will write a clinical study report in consultation with the 
Principal Investigator, or other relevant study-appointed committees or groups. This task may be 
delegated to PRA.
Publication
! The results of this study may be published or presented at scientific meetings. If this is 
foreseen, the Investigator agrees to submit all manuscripts or abstracts to the Sponsor before 
submission. This allows Merck to protect proprietary information and to provide comments. 
! The Sponsor will comply with the requirements for publication of study results. Per standard 
editorial and ethical practice, the Sponsor will generally support publication of multicenter 
studies only in their entirety and not as individual site data.
! Authorship will be determined by agreement and in line with International Committee of 
Medical Journal Editors authorship requirements.
Dissemination of Clinical Study Data
! Study results will be shared with study participants
! Merck-sponsored study information and tabular study results will be published on 
www.ClinicalTrials.gov once the drug is approved or the program has been terminated, 
whichever occurs first.
Data Quality Assurance
! All participant study data will be recorded on printed or eCRFs or transmitted to the Sponsor 
or designee electronically (e.g., laboratory data). The Investigator is responsible for verifying 
that data entries are complete, accurate, legible, and timely by physically or electronically 
signing the eCRF. Details for managing eCRFs are in the Data Management Plan.
! The Investigator will maintain accurate documentation (source data) that supports the 
information in the eCRF.
! The Investigator will permit study-related monitoring, quality assurance audits, IRB/IEC 
review, and regulatory agency inspections and provide direct access to the study file and 
source data.
! Quality Tolerance Limits (QTLs) will not be pre-defined in this study because of the 
impracticality of applying QTLs in the limited number of planned participants in this trial.
! Monitoring details describing strategy (e.g., risk-based initiatives in operations and quality 
such as Risk Management and Mitigation Strategies and Analytical Risk-Based Monitoring), 
methods, responsibilities and requirements, including handling of noncompliance issues and 
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
69/85
monitoring techniques (central, remote, or on-site monitoring) are in the Monitoring Plan or 
contracts.
! The Sponsor or designee is responsible for data management of this study, including quality 
checking of the data and maintaining a validated database. Database lock will occur once 
quality control and quality assurance procedures have been completed. Details will be 
outlined in Data Management documents and procedures.
! Study Monitors will perform ongoing source data verification to confirm that data in the eCRF 
are accurate, complete, and verifiable; that the safety and rights of participants are being 
protected; and that the study is being conducted per the currently approved protocol and any 
other study agreements, ICH GCP, and all applicable regulatory requirements.
! The Investigator will retain records and documents, including signed ICFs, pertaining to the 
conduct of this study for 15 years after study completion, unless local regulations, institutional 
policies, or the Sponsor requires a longer retention. No records may be destroyed during the 
retention period without the Sponsor’s written approval. No records may be transferred to 
another location or party without the Sponsor’s written notification.
Source Documents
! Source documents provide evidence for the existence of the participant and substantiate the 
integrity of the data collected.
! The Investigator will maintain source documents that support the data recorded in the eCRFs.
! Data recorded on eCRFs that are transcribed from source documents will be consistent with 
the source documents or the discrepancies will be explained. The Investigator may need to 
request previous medical records or transfer records, depending on the study. Also, current 
medical records will be available.
! Source documents are stored at the site for the longest possible time permitted by the 
applicable regulations, and/or as per ICH GCP guidelines, whichever is longer. The 
Investigator ensures that no destruction of medical records is performed without the Sponsor’s 
written approval.
! Definition of what constitutes source data is found in the eCRF guidelines.
Study and Site Start and Closure
The study start date is when the first participant signs the ICF.
Study and Site Closure
The Investigator may initiate site closure at any time, provided there is reasonable cause and 
enough notice is given in advance of the intended closure.
Reasons for the early closure of a study site by the Sponsor or Investigator may include:
! Failure of the Investigator to comply with the protocol, the requirements of the IRB/IEC 
or local Health Authorities, the Sponsor's procedures, or GCP guidelines
! Inadequate recruitment of participants by the Investigator
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
70/85
! Discontinuation of further development of the Sponsor’s compound
! If the study is prematurely terminated or suspended, the Sponsor will promptly inform the 
Investigators, the IECs/IRBs, the regulatory authorities, and any third-party service 
providers of the reason for termination or suspension, as specified by the applicable 
regulatory requirements. The Investigator will promptly inform the participants and assure 
appropriate participant therapy and/or follow-up.
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
71/85
Appendix 3
Contraception and Barrier Requirements
Definitions:
Woman of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming postmenopausal unless 
permanently sterile, as specified below.
If fertility is unclear (e.g., amenorrhea in adolescents or athletes) and a menstrual cycle cannot 
be confirmed before the first dose of study intervention, consider additional evaluation.
A WOCBP is not:
1.
Premenarchal
2.
A premenopausal female with 1 of the following:
!
Documented hysterectomy
!
Documented bilateral salpingectomy
!
Documented bilateral oophorectomy
Documentation can come from the site personnel’s review of the female’s medical records, 
medical examination, or medical history interview.
For a female with permanent infertility due to an alternate medical cause other than the above, 
(e.g., mullerian agenesis, androgen insensitivity), Investigator discretion applies to determine 
study entry.
3.
A postmenopausal female
!
A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause.
o A high follicle-stimulating hormone (FSH) level in the postmenopausal range 
may be used to confirm a postmenopausal state in a female not using hormonal 
contraception or hormonal replacement therapy (HRT). However, in the absence 
of 12 months of amenorrhea, more than 1 FSH measurement is required in the 
postmenopausal range.
!
A female on HRT and whose menopausal status is in doubt will be required to use 
one of the non-estrogen hormonal highly effective contraception methods if she 
wishes to continue her HRT during the study. Otherwise, she must discontinue HRT 
to allow confirmation of postmenopausal status before study enrollment.
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
72/85
Contraception Guidance:
CONTRACEPTIVES ALLOWED DURING THE STUDY INCLUDE:
Highly Effective Methods That Have Low User Dependency
!
Implantable progestogen-only hormone contraception associated with inhibition of ovulation
!
Intrauterine device (IUD)
!
Intrauterine hormone-releasing system (IUS)
!
Bilateral tubal occlusion
!
Vasectomized partner: a highly effective contraceptive method provided that the partner is the sole sexual 
partner of a WOCBP and the absence of sperm has been confirmed. Otherwise, use an additional highly 
effective method of contraception. The spermatogenesis cycle is approximately 90 days.
Highly Effective Methods That Are User Dependent
!
Combined (estrogen- and progestogen-containing) hormonal contraception associated with inhibition of 
ovulation
!
Oral
!
Intravaginal
!
Transdermal
!
Injectable
!
Progestogen-only hormone contraception associated with inhibition of ovulation
!
Oral
!
Injectable
!
Sexual abstinence: a highly effective method only if defined as refraining from intercourse during the entire 
period of risk associated with the study intervention. The reliability of sexual abstinence needs to be evaluated 
in relation to the duration of the study.
Notes:
Contraceptive use by men or women is consistent with local regulations on the use of contraceptive methods for 
clinical study participants.
Highly effective methods are those with a failure rate of <1% per year when used consistently and correctly. Typical 
use failure rates differ from those when used consistently and correctly.
If locally required, in accordance with Clinical Trial Facilitation Group (CTFG) guidelines, acceptable contraceptive 
methods are limited to those which inhibit ovulation as the primary mode of action.
Periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), 
spermicides only, and lactational amenorrhea method (LAM) are not acceptable methods of contraception for this 
study. Male condom and female condom cannot be used together (due to risk of failure with friction).
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
73/85
Appendix 4
Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow-up, and Reporting
AE Definition
AE Definition
!
An AE is any untoward medical occurrence in a patient or clinical study participant, 
temporally associated with the use of study intervention, whether considered related to 
the study intervention or not.
!
An AE can therefore be any unfavorable and unintended sign (including an abnormal 
laboratory finding), symptom, or disease (new or exacerbated) temporally associated 
with the use of study intervention. For surgical or diagnostic procedures, the 
condition/illness leading to such a procedure is considered as the AE rather than the 
procedure itself.
Events Meeting the AE Definition
!
Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or 
other safety assessments (e.g., ECG, radiological scans, vital signs measurements), 
including those that worsen from baseline and are judged to be more severe than 
expected for the participant’s condition are considered clinically significant in the 
medical and scientific judgment of the Investigator (i.e., not related to progression of 
underlying disease, but may be leading to study intervention discontinuation).
!
Exacerbation of a chronic or intermittent pre-existing condition including either an 
increase in frequency and/or intensity of the condition.
!
New conditions detected or diagnosed after study intervention administration even 
though it may have been present before the start of the study.
!
Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction.
!
Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
intervention or a concomitant medication.
!
“Lack of efficacy” or “failure of expected pharmacological action” per se will not be 
reported as an AE or a SAE.  However, the signs, symptoms, and/or clinical sequelae 
resulting from lack of efficacy will be reported as an AE or a SAE if they fulfill the 
definition of an AE or SAE.
Events NOT Meeting the AE Definition
!
Unless judged by the Investigator to be more severe than expected for the participant’s 
condition, any clinically significant abnormal laboratory findings, other abnormal 
safety assessments that are associated with the underlying disease, the disease/disorder 
being studied within the expectedness for participant’s condition, as judged by the 
Investigator.
!
Medical or surgical procedure (e.g., endoscopy, appendectomy): the condition that 
leads to the procedure is the AE.
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
74/85
!
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital).
!
Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) present or 
detected at the start of the study that do not worsen.
AE/SAEs Observed in Association with Disease Progression
Progression of the disease/disorder being studied assessed by measurement of lesions on 
radiographs or other methods as well as associated clinical signs or symptoms (including 
laboratory abnormalities) will not be reported as AEs/SAEs, unless the participant’s general 
condition is more severe than expected for the his/her condition and/or unless the outcome is 
fatal within the AE reporting period, as defined in Section 8.3.
Other Adverse Events to be Reported Using a Specialized Procedure or Form
All pregnancies occurring during the study and their outcome will be documented on the 
Pregnancy report form and Parent-Child/Fetus Adverse Event Report form as outlined in 
Section 8.3.4.
Overdoses associated with an AE or a SAE are recorded in the eCRF and reported to global 
patient safety in an expedited manner. Overdoses not related to an AE/SAE (without signs or 
symptoms) are recorded in eCRF on treatment forms and are reported to Drug Safety using 
SAE paper form.
SAE Definition
If an event is not an AE per the definition above, then it cannot be an SAE even if serious 
conditions are met (e.g., hospitalization for signs/symptoms of the disease under study, death 
due to progression of disease).
A SAE is defined as any untoward medical occurrence that, at any dose:
a. Results in death
b. Is life-threatening
The term 'life-threatening' in the definition of 'serious' refers to an event in which the 
participant was at risk of death at the time of the event. It does not refer to an event, which 
hypothetically might have caused death, if it were more severe.
c.
Requires inpatient hospitalization or prolongation of existing hospitalization
!
In general, hospitalization signifies that the participant has been detained (usually 
involving at least an overnight stay) at the hospital or emergency ward for observation 
and/or treatment that would not have been appropriate in the physician’s office or
outpatient setting. Complications that occur during hospitalization are AEs. If a 
complication prolongs hospitalization or fulfills any other serious criteria, the event is 
serious. When in doubt as to whether “hospitalization” occurred or was necessary, the 
AE will be considered serious.
!
Hospitalization for elective treatment of a pre-existing condition that did not worsen 
from baseline is not considered an AE.
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
75/85
!
However, all events leading to unplanned hospitalizations or unplanned prolongation 
of an elective hospitalization must be documented and reported as SAEs.
d. Results in persistent disability/incapacity
The term disability means a substantial disruption of a person’s ability to conduct normal 
life functions.
This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and 
accidental trauma (e.g., sprained ankle) which may interfere with or prevent everyday life 
functions but do not constitute a substantial disruption.
e.
Is a congenital anomaly/birth defect
f.
Other situations:
!
Medical or scientific judgment will be exercised in deciding whether SAE reporting is 
appropriate in other situations, such as important medical events that may not be 
immediately life-threatening or result in death or hospitalization but may jeopardize the 
participant or may require medical or surgical intervention to prevent one of the other 
outcomes listed in the above definition. These events are usually considered as serious.
!
Examples of such events include invasive or malignant cancers, intensive treatment in 
an emergency room or at home for allergic bronchospasm, blood dyscrasias or 
convulsions that do not result in hospitalization, or development of drug dependency 
or drug abuse.
Any suspected transmission of an infectious agent via a study intervention is also considered 
an SAE for reporting purposes, as specified below for reporting SAEs.
Recording and Follow-Up of AE and/or SAE
AE and SAE Recording
!
When an AE/SAE occurs, it is the responsibility of the Investigator to review all 
documentation (e.g., hospital progress notes, laboratory reports, and diagnostics reports) 
related to the event.
!
The Investigator will then record all relevant AE/SAE information in the eCRF.
!
As needed, Sponsor/designee may ask for copies of certain medical records (e.g., autopsy 
reports, supplemental lab reports, documents on medical history/concomitant medications, 
discharge letters), as supporting source documentation. All participant identifiers, except 
the participant number, will be redacted on these copies before submission to 
Sponsor/designee.
!
The Investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not the 
individual signs/symptoms) will be documented as the AE/SAE.
!
Specific guidance is in the eCRF Completion and Monitoring Conventions.
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
76/85
Assessment of Causality
!
The Investigator will assess the relationship between study intervention and each AE/SAE 
occurrence:
! Unrelated: Not reasonably related to the study intervention. AE could not medically 
(pharmacologically/clinically) be attributed to the study intervention. A reasonable 
alternative explanation will be available.
! Related: Reasonably related to the study intervention. AE could medically 
(pharmacologically/clinically) be attributed to the study intervention.
!
A “reasonable possibility” of a relationship conveys that there are facts, evidence, and/or 
arguments to suggest a causal relationship, rather than a relationship cannot be ruled out.
!
The Investigator will use clinical judgment to determine the relationship.
!
Alternative causes, such as underlying disease(s), concomitant therapy, and other risk 
factors, as well as the temporal relationship of the event to study intervention 
administration will be considered and investigated.
Assessment of Intensity
Investigators will reference the NCI-CTCAE, Version 5.0 (publication date: 27 Nov 2017), a 
descriptive terminology that can be used for AE reporting.
A general grading (severity/intensity; hereafter referred to as severity) scale is provided at the 
beginning of the above referenced document, and specific event grades are also provided.
If the severity for an AE is not specifically graded by NCI-CTCAE, the Investigator is to use 
the general NCI-CTCAE definitions of Grade 1 through Grade 5, using his or her best medical 
judgment.
The 5 general grades are:
!
Grade 1 or Mild
!
Grade 2 or Moderate
!
Grade 3 or Severe
!
Grade 4 or Life-threatening
!
Grade 5 or Death
Any clinical AE with severity of Grade 4 or 5 must also be reported as an SAE. However, a 
laboratory abnormality of Grade 4, such as anemia or neutropenia, is considered serious only 
if the condition meets one of the serious criteria specified below.
If death occurs, the primary cause of death or event leading to death will be recorded and 
reported as an SAE. “Fatal” will be recorded as the outcome of this specific event and death 
will not be recorded as separate event. Only, if no cause of death can be reported (e.g., sudden 
death, unexplained death), the death per se might then be reported as an SAE.
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
77/85
!
The Investigator will also consult the IB and/or Product Information, for marketed 
products, in his/her assessment.
!
For each AE/SAE, the Investigator will document in the medical notes that he/she has 
reviewed the AE/SAE and assessed causality.
!
There may be situations when an SAE has occurred, and the Investigator has minimal 
information to include in the initial report to the Sponsor or its designee. To meet the 
reporting timeline, the causality assessment is not required for the initial report.
!
The Investigator may change his/her causality assessment after considering follow-up 
information and send a SAE follow-up report with the updated causality assessment.
!
The causality assessment is one of the criteria used when determining regulatory reporting 
requirements.
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
78/85
Follow-up of AEs and SAEs
!
The Investigator will perform or arrange for the conduct of supplemental measurements 
and/or evaluations, as medically indicated or as requested by the Sponsor to elucidate the 
nature and/or causality of the AE or SAE, as fully as possible. This may include additional 
laboratory tests or investigations, histopathological examinations, or consultation with 
other health care professionals.
!
If a participant dies during participation in the study or during a recognized follow-up 
period, the Investigator will provide the Sponsor/designee with a copy of any post-mortem 
findings including histopathology.
!
New or updated information will be recorded in the originally completed eCRF.
!
The Investigator will submit any updated SAE data to Sponsor/designee within 24 hours 
of receipt of the information.
Reporting of SAEs
SAE Reporting by an Electronic Data Collection Tool
!
The primary mechanism for reporting an SAE in multicenter studies to the Sponsor or its 
designee will be the electronic data collection tool.
!
If the electronic system is unavailable, then the site will use the paper SAE form, specified 
below, to report the event within 24 hours. This applies for this study.
!
The site will enter the SAE data into the electronic system as soon as it becomes available.
!
After the study is completed at a site, the electronic data collection tool will be taken off-
line to prevent the entry of new data or changes to existing data.
!
If a site receives a report of a new SAE from a study participant or receives updated data 
on a previously reported SAE after the electronic data collection tool has been taken off-
line, then the site can report this information on a paper SAE form or to the Sponsor’s 
safety department.
!
By exception, an SAE (or follow-up information) may be reported by telephone. The site 
will complete the electronic SAE data entry immediately thereafter.
SAE Reporting by a Paper Form
!
SAE reporting on a paper report form may be used in single center studies in addition to 
the standard eCRF and as a back-up method for an electronic data capture (EDC) system 
failure. The form includes completion instructions for the Investigator, names, addresses, 
and telephone and fax numbers. All information from the paper form will be transcribed 
into the electronic form as soon as the system becomes available.
!
Facsimile transmission (fax to mail) of the paper form or any follow-up information is the 
preferred method for transmission and will be done within 24 hours to the Sponsor or its 
designee.
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
79/85
!
In rare circumstances and in the absence of facsimile equipment, notification by telephone 
is acceptable with a copy of the form sent by overnight mail or courier service.
!
Initial notification via telephone does not replace the need for the Investigator to complete 
and sign the form within 24 hours after becoming aware of the event.
!
Additional documents (e.g. laboratory reports, autopsy report, hospital discharge letter) 
and relevant pages from the eCRF may be required in addition (e.g. medical history, 
concomitant medication). The data provided will be consistent with the information in the 
eCRF.
Reporting of Adverse Events of Special Interest
Not applicable; no adverse events of special interest have been identified.
Reporting of Pregnancies
!
Pregnancy will be reported whether related to the study intervention using the applicable 
paper form.
!
The applicable form will be used to report if an abnormal outcome of the pregnancy occurs 
and the child/fetus sustains an event.
!
Facsimile transmission (fax to mail) of the paper form or any follow-up information is the 
preferred method for transmission and will be done within 24 hours to the Sponsor or its 
designee.
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
80/85
Appendix 5
Eastern Cooperative Oncology Group Performance Status
Eastern Cooperative Oncology Group Performance Status
Grade
Description
0
Fully active, able to carry on all pre-disease performance without restriction
1
Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or 
sedentary nature, for example, light housework, office work
2
Ambulatory and capable of all self-care, but unable to carry out any work activities; up and 
about > 50% of waking hours
3
Capable of only limited self-care, confined to bed or chair > 50% of waking hours
4
Completely disabled; cannot carry on any self-care; totally confined to bed or chair
5
Dead
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
81/85
Appendix 6
Clinical Laboratory Tests
The protocol-required clinical laboratory assessments are in the following table:
Table 14
Clinical Laboratory Assessments
Laboratory Assessments1
Parameters
Hematology
Platelet count
MCV
White Blood Cell 
Count with 
Differential:
!
Neutrophils
!
Lymphocytes
!
Monocytes
!
Eosinophils
!
Basophils
Hemoglobin
MCH
Hematocrit
Coagulation
Prothrombin time/INR
Activated partial thromboplastin time
Biochemistry2
BUN or 
Urea3
Potassium
Aspartate 
aminotransferase
Bilirubin (i.e., total)
Direct bilirubin
Creatinine
Sodium
Alanine 
aminotransferase
Protein4
Glucose
Calcium
Alkaline phosphatase
Albumin
Magnesium
Phosphate
Notes:
1
Laboratory assessments, e.g. hematology, chemistry, etc., will be performed locally.
2
Details of liver chemistry stopping criteria and required actions and follow-up assessments after liver 
stopping or monitoring event are given in Section 7.1. 
3
Urea can be performed only when BUN cannot be done; the same test should be performed consistently for 
each participant for the duration of the study.
4
A measurement of the total protein.
Other Screening Tests
!
FSH and estradiol (as needed if not a woman of childbearing potential 
only).
!
Serum and urine human chorionic gonadotropin pregnancy test (as needed 
for women of childbearing potential).
!
Covid 19 PCR testing will be performed at D-1 during Period 1.
!
Urine cotinine testing will be performed at Screening and at D-1.
BUN = blood urea nitrogen; FSH = follicle-stimulating hormone; INR = international normalized ratio; MCH = mean 
corpuscular hemoglobin; MCV = mean corpuscular volume; PCR = polymerase chain reaction
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
82/85
 
 
 
 
 
 
 
 
 
 
 
 
 
 
'RFXPHQW1R
2EMHFW1R
*OREDO9HUVLRQ,'CCI
CCI
CCI
CCI


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
83/85
Appendix 8
Protocol Amendment History
Not applicable
Document No. 0900babe815fff85v3.0
Object No. 0900babe81670c46
Global Version ID: 78691_1309431_6418641


Berzosertib
Human Mass Balance Study
MS201923_0008
C O N F I D E N T I A L
I N F O R M A T I O N
84/85
Appendix 9
Sponsor Signature Page
Study Title:
Phase I study to evaluate the mass balance, 
pharmacokinetics (PK), metabolism and excretion of 
berzosertib 
(intravenous) 
containing 
microtracer 
[14C]berzosertib in participants with advanced solid 
tumors
Regulatory Agency Identifying 
Number:
EudraCT: 2021-002226-24
Clinical Study Protocol Version:
15 June 2021/Version 1.0
I approve the design of the clinical study:
___________
_______________
____________________________
Signature
Date of Signature
Name, academic degree:
, MD
Function/Title:
Institution:
, Merck KGaA
Address:
Telephone number:
E-mail address:
'RFXPHQW1R
2EMHFW1R
18JUN2021
*OREDO9HUVLRQ,'
PPD
PPD
PPD
PPD
PPD
PPD
CCI
CCI
CCI
PPD


*OREDO9HUVLRQ,'
PPD
PPD
PPD
PPD
PPD
CCI
CCI
CCI
PPD

SAP_001.pdf: 
Berzosertib 
                                                                                    Human Mass Balance Study 
MS201923_0008                                                                                                                             Version 1.0 
 
 
 
 
C O N F I D E N T I A L 
I N F O R M A T I O N 
1/48 
 
 
 
 
 
Integrated Analysis Plan  
Study Number: 
MS201923_0008 
Clinical Study Protocol 
Title: 
Phase I study to evaluate the mass balance, 
pharmacokinetics (PK), metabolism and excretion 
of berzosertib (intravenous) containing microtracer 
[14C]berzosertib in participants with advanced solid 
tumors 
Study Phase: 
Phase I 
Merck Compound: 
Berzosertib 
Protocol Version: 
15 June 2021/Version 1.0 
 
Integrated Analysis Plan 
Author: 
 
Coordinating Author 
 
, Merck 
 
Function 
Author(s) / Data Analyst(s) 
 
 
 
 
 
  
 
 
 
 
 
Integrated Analysis Plan 
Date and Version: 
07-Dec-2022, Version 1.0 
Integrated Analysis Plan 
Reviewers: 
 
Function 
Name 
 
, Merck 
 
, Merck 
 
, 
Merck Healthcare KGaA 
 
, 
Merck Healthcare KGaA 
 
Global Version ID: 
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
CCI


Berzosertib 
                                                                                    Human Mass Balance Study 
MS201923_0008                                                                                                                             Version 1.0 
 
 
 
 
C O N F I D E N T I A L 
I N F O R M A T I O N 
2/48 
 
 
 
 
, 
Merck Healthcare KGaA 
 
, 
Merck 
 
, 
Merck 
 
, 
EMD Serono 
 
 EMD 
Serono 
 
 
Confidential 
This document is the property of Merck Healthcare KGaA, Darmstadt, Germany, or one of its affiliated companies. 
It is intended for restricted use only and may not - in full or part - be passed on, reproduced, published or used without 
express permission of Merck Healthcare KGaA, Darmstadt, Germany or its affiliate.  
Copyright © 2022 by Merck Healthcare KGaA, Darmstadt, Germany or its affiliate. All rights reserved. 
Global Version ID: 
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
CCI


Berzosertib 
                                                                                    Human Mass Balance Study 
MS201923_0008                                                                                                                             Version 1.0 
 
 
 
 
C O N F I D E N T I A L 
I N F O R M A T I O N 
3/48 
 
 
 
 
Approval Page  
 
Integrated Analysis Plan: MS201923_0008  
Phase I study to evaluate the mass balance, pharmacokinetics (PK), metabolism and excretion 
of berzosertib (intravenous) containing microtracer [14C]berzosertib in participants with 
advanced solid tumors 
Approval of the IAP by all Merck Data Analysis Responsible has to be documented within EDMS 
via eSignature. With the approval, the Merck responsible for each of the analysis also takes 
responsibility that all reviewers’ comments are addressed adequately. 
By using eSignature, the signature will appear at the end of the document. 
Global Version ID: CCI


Berzosertib 
                                                                                    Human Mass Balance Study 
MS201923_0008                                                                                                                             Version 1.0 
 
 
 
 
C O N F I D E N T I A L 
I N F O R M A T I O N 
4/48 
 
 
 
 
1 
Table of Contents  
Approval Page 
3 
1 
Table of Contents ..................................................................................4 
2 
List of Abbreviations and Definition of Terms ....................................7 
3 
Modification History ............................................................................9 
4 
Purpose of the Integrated Analysis Plan ...............................................9 
5 
Objectives and Endpoints ...................................................................10 
6 
Overview of Planned Analyses ...........................................................11 
7 
Changes to the Planned Analyses in the Clinical Study Protocol ......12 
8 
Analysis Sets and Subgroups ..............................................................12 
8.1 
Definition of Analysis Sets .................................................................12 
8.2 
Subgroup Definition and Parameterization ........................................13 
9 
General Specifications for Data Analyses ..........................................13 
9.1 
Definition of Baseline and Change from Baseline .............................14 
9.2 
Study Day / Study Intervention Day ...................................................15 
9.3 
Definition of Duration and “Time Since” Variables ..........................15 
9.4 
Conversion Factors .............................................................................15 
9.5 
Definition of On-treatment Period ......................................................15 
9.6 
Exposure time .....................................................................................16 
9.7 
Imputation of Missing Data ................................................................16 
9.8 
Age at Time of an Event .....................................................................18 
10 
Study Participants ...............................................................................18 
10.1 
Disposition of Participants and Discontinuations ...............................18 
10.2 
Protocol Deviations / Exclusion from Analysis Sets ..........................19 
10.2.1 
Important Protocol Deviations ............................................................19 
10.2.2 
Reasons Leading to the Exclusion from an Analysis Set ...................19 
11 
Demographics and Other Baseline Characteristics .............................19 
Global Version ID: CCI


Berzosertib 
                                                                                    Human Mass Balance Study 
MS201923_0008                                                                                                                             Version 1.0 
 
 
 
 
C O N F I D E N T I A L 
I N F O R M A T I O N 
5/48 
 
 
 
 
11.1 
Demographics .....................................................................................19 
11.2 
Medical History ..................................................................................20 
11.3 
Other Baseline Characteristics ............................................................20 
11.4 
Prior Anti-cancer Therapy ..................................................................21 
12 
Previous or Concomitant Therapies/Procedures .................................21 
13 
Study Intervention: Compliance and Exposure ..................................21 
14 
Efficacy Analyses (Period 2 only) ......................................................23 
14.1 
Tertiary/ ExploratoryObjective: Objective Response .........................23 
14.1.1 
Tertiary/ Exploratory Estimand ..........................................................23 
15 
Safety Analyses ..................................................................................24 
15.1 
Adverse Events ...................................................................................25 
15.1.1 
All Adverse Events .............................................................................26 
15.1.2 
Adverse Events Leading to Discontinuation of Study Intervention ...28 
15.2 
Deaths, Other Serious Adverse Events, and Other Significant 
Adverse Events ...................................................................................28 
15.2.1 
Deaths .................................................................................................28 
15.2.2 
Serious Adverse Events ......................................................................28 
15.2.3 
Other Significant Adverse Events ......................................................28 
15.3 
Clinical Laboratory Evaluation ...........................................................29 
15.4 
Vital Signs ..........................................................................................29 
15.5 
Other Safety or Tolerability Evaluations ............................................30 
16 
Analyses of Other Endpoints/Estimands ............................................31 
16.1 
Pharmacokinetics ................................................................................31 
16.1.1 
Descriptive Statistics of PK Concentration Data ................................31 
16.1.1.1 
Plasma and Whole Blood ....................................................................31 
16.1.1.2 
Free fraction (% unbound) of berzosertib ...........................................32 
16.1.1.3 
Urine and Feces ..................................................................................32 
16.1.1.4 
Vomitus...............................................................................................32 
Global Version ID: CCI


Berzosertib 
                                                                                    Human Mass Balance Study 
MS201923_0008                                                                                                                             Version 1.0 
 
 
 
 
C O N F I D E N T I A L 
I N F O R M A T I O N 
6/48 
 
 
 
 
16.1.2 
Descriptive Statistics of PK Parameter Data ......................................32 
16.1.2.1 
Plasma and Whole Blood ....................................................................32 
16.1.2.2 
Urine and Feces ..................................................................................33 
16.1.3 
General Specifications for PK Concentration and PK Parameter 
Data .....................................................................................................33 
16.1.4 
Estimation of Pharmacokinetic Parameters ........................................34 
16.1.4.1 
Estimation of Pharmacokinetic Parameters in Plasma and Whole 
Blood...................................................................................................34 
16.1.4.2 
Estimation of Pharmacokinetic Parameters in Urine and Feces .........37 
16.1.5 
Statistical Analysis of PK Parameter Data .........................................38 
16.1.6 
Presentation of PK Concentration and PK Parameter Data – 
Period 1 ADME ..................................................................................38 
16.1.6.1 
Listings and Tables .............................................................................38 
16.1.6.2 
Graphical Summaries and Individual plots (PK Analysis Set) ...........39 
16.1.6.3 
Metabolite Profiling (Period 1) ...........................................................40 
16.2 
Further Other Endpoint(s) ...................................................................40 
17 
References ...........................................................................................40 
18 
Appendices .........................................................................................41 
18.1 
Appendix 1        List of Tables, Figures and Listings .........................41 
18.2 
Appendix 2        Criteria for infusion related reactions (IRRS) and 
infusion site reactions (ISRs) ..............................................................47 
 
Global Version ID: CCI


Berzosertib 
                                                                                    Human Mass Balance Study 
MS201923_0008                                                                                                                             Version 1.0 
 
 
 
 
C O N F I D E N T I A L 
I N F O R M A T I O N 
7/48 
 
 
 
 
2 
List of Abbreviations and Definition of Terms  
 
ADaM 
Analysis Data Model 
AE 
Adverse Event 
BMI 
Body Mass Index 
BSA 
Body Surface Area 
CDISC 
Clinical Data Interchange Standards Consortium 
CI 
Confidence Interval 
(e)CRF 
(electronic) Case Report Form 
CSP 
Clinical Study Protocol 
CSR 
Clinical Study Report 
DI 
Dose Intensity 
ECG 
Electrocardiogram 
ECOG PS 
Eastern Co-operative of Oncology Group (Performance Status) 
EDS 
Early Development Services 
EMA 
European Medicines Agency 
EudraCT 
European Union Drug Regulating Authorities Clinical Trials 
FU 
Follow-up 
GBS 
Global Biostatistics 
IAP 
Integrated Analysis Plan 
ICH 
International Conference on Harmonization 
IRR 
Infusion Related Reactions 
ISR 
Infusion Site Reactions 
MCAR 
Missing Completely at Random 
MedDRA 
Medical Dictionary for Regulatory Activities 
MTD 
Maximum Tolerated Dose 
NA 
Not Applicable 
Global Version ID: CCI


Berzosertib 
                                                                                    Human Mass Balance Study 
MS201923_0008                                                                                                                             Version 1.0 
 
 
 
 
C O N F I D E N T I A L 
I N F O R M A T I O N 
8/48 
 
 
 
 
NC 
Not Calculated 
Nd 
Not done 
NCI-CTCAE 
National Cancer Institute – Common Terminology Criteria for Adverse 
Events 
PD 
Progressive Disease or Protocol Deviation or Pharmacodynamics 
PRO 
PT 
Patient-Reported Outcomes 
Preferred Term 
PK 
Pharmacokinetics 
PR 
Partial Response 
RDI 
Relative Dose Intensity 
SAE 
Serious Adverse Event 
SCR 
Screening analysis set 
SD 
Stable Disease or Standard Deviation 
SDTM 
Study Data Tabulation Model 
SMC 
Safety Monitoring Committee 
SOC 
System Organ Class 
TEAE 
Treatment-Emergent Adverse Event 
TLF 
Tables, Listings, and Figures 
WHO-DD 
World Health Organization Drug Dictionary 
 
Global Version ID: CCI


Berzosertib 
                                                                                    Human Mass Balance Study 
MS201923_0008                                                                                                                             Version 1.0 
 
 
 
 
C O N F I D E N T I A L 
I N F O R M A T I O N 
9/48 
 
 
 
 
3 
Modification History  
Unique 
Identifier for 
Version 
Date of 
IAP Version 
Author 
Changes from the Previous Version 
1.0 
06.12.2022 
 
This is the first version of the IAP 
4 
Purpose of the Integrated Analysis Plan  
The purpose of this IAP is to document technical and detailed specifications for the analysis of 
data collected for CSP MS201923_0008. Results of the analyses described in this IAP will be 
included in the CSR. Additionally, the planned analyses identified in this IAP may be included in 
regulatory submissions or future manuscripts. Any post-hoc, or unplanned analyses performed to 
provide results for inclusion in the CSR but not identified in this prospective IAP will be clearly 
identified in the CSR. 
The IAP is based upon Section 9 (Statistical considerations) of the CSP and protocol amendments 
and is prepared in compliance with ICH E9. It describes analyses planned in the CSP and protocol 
amendments. 
The wording used in this IAP is chosen to best match the respective wording in the CSP template, 
the CSR template, CDISC requirements and special requirements for table layouts. Therefore, the 
following approach is used: 
Generally, the term “participant” will be used instead of “subject” or “patient”. However, in tables 
and listings the term “subject” will be used to match CDISC requirements, except for in-text tables 
where “participant” will be used to match the CSR and CSP templates. Similarly, the term “study 
intervention” will be used in this document instead of “treatment” to match CSP and CSR 
templates, however, tables and listings will use “treatment” for brevity reasons. Exceptions from 
this rule are commonly used terms like “on-treatment”, “treatment-emergent”, “treatment policy”, 
“subject-years”, “by-subject”, or names of CRF pages like “Treatment Termination” page. 
 
 
 
 
Global Version ID: 
PPD
CCI


Berzosertib 
                                                                                    Human Mass Balance Study 
MS201923_0008                                                                                                                             Version 1.0 
 
 
 
 
C O N F I D E N T I A L 
I N F O R M A T I O N 
10/48 
 
 
 
 
 
5 
Objectives and Endpoints  
 
Objectives 
Endpoints (Outcome Measures) 
IAP section 
Period 1 
 
Primary 
 
To determine the rates and routes of excretion and 
mass balance of berzosertib following single 
intravenous administration of 210 mg/m2 of [14C] 
berzosertib to participants with advanced solid 
tumors. 
• 
Percent urinary recovery (feurine) of total radioactivity 
over the entire period of collection. 
16 
• 
Percent fecal recovery (fefeces) of total radioactivity 
over the entire period of collection.  
• 
Percent total recovery in urine and feces (fetotal) 
combined of total radioactivity over the entire period 
of collection.  
To characterize the PK of berzosertib in plasma and 
urine; and of drug-related material (total radioactivity) 
in plasma and whole blood to participants with 
advanced solid tumors. 
• 
 Plasma Cmax of berzosertib 
• 
Plasma AUC0-tlast of berzosertib 
• 
Plasma AUC0-∞ of berzosertib 
• 
Plasma t1/2 of berzosertib 
• 
Plasma CL of berzosertib 
• 
Plasma Vz of berzosertib 
• 
Plasma Vss of berzosertib 
• 
Plasma Cmax of total radioactivity 
16 
• 
Plasma AUC0-tlast of total radioactivity 
• 
Plasma AUC0-∞ of total radioactivity 
• 
Plasma t1/2 of total radioactivity 
• 
Blood Cmax of total radioactivity 
• 
Blood AUC0-tlast of total radioactivity 
• 
Blood AUC0-∞ of total radioactivity 
• 
Cumulative amount of berzosertib excreted in urine 
(Ae-∞ urine) 
• 
Fraction of administered berzosertib that is excreted 
unchanged in urine: fe(%) = Ae-∞urine/Dose 
• 
Renal clearance (CLR) 
Secondary 
 
To evaluate the safety and tolerability of berzosertib 
in participants with advanced solid tumors. 
• 
Occurrence of treatment-emergent adverse events 
(TEAEs) and treatment-related adverse events 
(AEs) 
15 
Global Version ID: CCI


Berzosertib 
                                                                                    Human Mass Balance Study 
MS201923_0008                                                                                                                             Version 1.0 
 
 
 
 
C O N F I D E N T I A L 
I N F O R M A T I O N 
11/48 
 
 
 
 
Objectives 
Endpoints (Outcome Measures) 
IAP section 
• 
Occurrence of clinically significant changes in vital 
signs, laboratory parameters and 12-lead ECG 
findings. 
 
Period 2 
 
Secondary 
 
To evaluate the safety and tolerability of berzosertib 
+ topotecan in participants with advanced solid 
tumors. 
• 
Occurrence of treatment-emergent adverse events 
(TEAEs) and treatment-related adverse events (AEs) 
15 
• 
Occurrence of clinically significant changes in vital 
signs, laboratory parameters and 12-lead ECG 
findings. 
6 
Overview of Planned Analyses  
All final, planned analyses identified in the CSP and in this IAP will be performed only after the 
last subject has completed the last visit, i.e., end of trial visit/early termination visit with all trial 
data in-house, all data queries resolved, and the database locked for EDC (ICON terminology) or 
Global Version ID: CCI
CCI
CCI


Berzosertib 
                                                                                    Human Mass Balance Study 
MS201923_0008                                                                                                                             Version 1.0 
 
 
 
 
C O N F I D E N T I A L 
I N F O R M A T I O N 
12/48 
 
 
 
 
integrated lock (Merck terminology). There would only be one integrated final analysis at the end 
of the study. 
A data review meeting will be held prior to database lock. In addition, no database can be locked 
until this IAP has been approved. 
7 
Changes to the Planned Analyses in the Clinical Study 
Protocol  
• For the objective of identifying and quantifying berzosertib and its metabolites in excreta (urine 
and feces) and plasma in order to elucidate key biotransformation pathways and clearance 
mechanisms of berzosertib in participants with advanced solid tumors, % of drug-related 
material will serve as an endpoint (outcome measure) instead of Metabolite AUC in plasma. 
The Following objectives will not be pursued although planned in the CSP: 
 
8 
Analysis Sets and Subgroups  
8.1 
Definition of Analysis Sets  
For purposes of analysis, the following populations are defined: 
Global Version ID: CCI
CCI


Berzosertib 
                                                                                    Human Mass Balance Study 
MS201923_0008                                                                                                                             Version 1.0 
 
 
 
 
C O N F I D E N T I A L 
I N F O R M A T I O N 
13/48 
 
 
 
 
Screening 
The screening analysis set (SCR) will include all participants who provided signed 
informed consent, regardless of study intervention status in the trial. This set will be used 
for subject disposition.  
Safety 
The Safety Analysis Set (SAF) will include all participants who have received any dose of 
any study intervention. Participants will be analyzed according to the actual study 
intervention they receive. 
Pharmacokinetic 
The Pharmacokinetic (PK) Analysis Set is a subset of the SAF will consist of all 
participants who receive at least one dose of IMP, in Period 1 and provide at least one 
measurable post-dose concentration. A measurement below lower limit of quantification 
(BLQ) is considered a valid measurement. All PK analyses will be based on this analysis 
set. 
A participant who has any missing urine or feces samples that impact assessment of 
mass balance or does not have sufficient PK sampling to derive the primary PK 
parameters, is not considered evaluable. Participants will be analyzed according to the 
actual study intervention they received.  If a subject takes any medication likely to affect the 
PK of Berzosertib. Subject will be included in PK Analysis Set , but  may be excluded 
from summary statistics. 
The following table summarizes the use of the analysis sets in the different analyses.  
 
Analysis Set 
Analyses 
Screening 
Safety Set  
PK 
Disposition summaries 
✓ 
✓ 
✓* 
Demographic summaries 
 
✓ 
✓* 
Compliance and Exposure 
 
✓ 
 
Safety Assessments 
 
✓ 
 
PK Concentrations 
 
✓ 
 
PK Parameters 
 
 
✓ 
Safety and Tolerability 
 
✓ 
 
Efficacy Analyses 
 
✓ 
 
*only to be created if there is a difference between Safety Analysis Set (SAF) and PK 
8.2 
Subgroup Definition and Parameterization  
Not applicable. 
9 
General Specifications for Data Analyses  
Statistical analyses will be performed using the computer program package SAS® System for 
Windows™ (Version 9.4 or later; SAS Institute, Cary, North Carolina, USA). 
Global Version ID: CCI


Berzosertib 
                                                                                    Human Mass Balance Study 
MS201923_0008                                                                                                                             Version 1.0 
 
 
 
 
C O N F I D E N T I A L 
I N F O R M A T I O N 
14/48 
 
 
 
 
The results of this clinical study will be reported using summary tables, figures, and data listings, 
as appropriate. All data will be summarized by study intervention and/or scheduled time point, as 
appropriate. 
For demographic, baseline and safety assessments, continuous measurements will be summarized 
by means of descriptive statistics (i.e., number and percentage of observations, number and 
percentage of missing observations, mean, standard deviation [SD], median, minimum, and 
maximum) and categorical data will be summarized by means of frequency tables (i.e., count and 
percentages), if not stated otherwise. Mean, Median, Min, Max will have the same precision as the 
SDTM data (decimal places). SD will be presented with one decimal place more than the mean. 
For subject disposition and demographic tables, the denominator will be the number of subjects in 
the analysis set. Counts of missing observations will be included as a separate category. 
Repeated laboratory assessments will be flagged as repeats in the subject data listings and not 
included in summary tables statistics (unless the scheduled measurement was considered 
unreliable, e.g., due to technical reasons, and needed to be replaced by an unscheduled repeat 
measurement). 
The following study intervention label will be used in the tables, figures and listings (TLFs):  
• Period 1: [14C]Berzosertib 
• Period 2: Berzosertib + Topotecan    
The following Figure depicts the actual Treatment Schema for Period 1 and 2:  
 
 
9.1 
Definition of Baseline and Change from Baseline  
If not otherwise specified, “baseline” refers to the last scheduled measurement before 
administration of the first study intervention.  However, if a participant is missing the baseline 
Global Version ID: CCI


Berzosertib 
                                                                                    Human Mass Balance Study 
MS201923_0008                                                                                                                             Version 1.0 
 
 
 
 
C O N F I D E N T I A L 
I N F O R M A T I O N 
15/48 
 
 
 
 
collection, the previous non-missing evaluation predose could become the baseline value. If no 
baseline or previous to baseline evaluations exist, then the baseline value will be treated as 
missing. The last observation can be an unscheduled / repeated measurement. Unscheduled 
assessments post treatment start will not be used for analysis by timepoint, but are to be 
considered for analysis like identifying maximum on- treatment value. 
Absolute and percent changes from baseline are defined as  
 
absolute change = visit value – baseline value 
 
percent change = 100 * (visit value – baseline value) / baseline value 
9.2 
Study Day / Study Intervention Day  
Day 1 is the day of start of study intervention, the day before is Day -1 (no Day 0 is defined). Study 
day / Study intervention day is defined relative to Day 1. 
9.3 
Definition of Duration and “Time Since” Variables  
Durations in days will be calculated by the difference of start and stop date + 1 (if not otherwise 
specified). 
The time since an event (e.g. time since first diagnosis) will be calculated as reference date minus 
date of event 
9.4 
Conversion Factors  
The following conversion factors will be used to convert days into months or years:  
1 week = 7 days, 1 month = 30.4375 days, 1 year = 365.25 days. 
9.5 
Definition of On-treatment Period  
The on-treatment period is defined as the time from the first dose of study intervention day in 
period 1 to the last administration day of study intervention + 30 days, or death, whichever occurs 
first. The on-treatment period consists of two distinct periods: 
• Period 1 is defined as the time from the first dose of study intervention day in period 1 to 
until start of the subsequent administration of any study drug intervention in Period 2 or 30 
days after period 1 dosing if there is no further dosing in period 2. 
Global Version ID: CCI


Berzosertib 
                                                                                    Human Mass Balance Study 
MS201923_0008                                                                                                                             Version 1.0 
 
 
 
 
C O N F I D E N T I A L 
I N F O R M A T I O N 
16/48 
 
 
 
 
• Period 2 is defined as time from end of Period 1 (administration of study intervention in 
Period 2) to the last administration day of study intervention + 30.  
The attribution of AEs during Period 1 and 2 and overall is added in Section 15. 
9.6 
Exposure time  
Analysis will be performed for the total on-treatment period only. Duration will be calculated 
differently based on the dosing days and frequency as follows.  
Participants will receive 2 infusions of Berzosertib on Days 2 and 5 in each 21-day cycle. Hence, 
duration of Berzosertib therapy is calculated as follows: 
𝐷𝑢𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝐵𝑒𝑟𝑧𝑜𝑠𝑒𝑟𝑡𝑖𝑏 (𝑤𝑒𝑒𝑘𝑠) = 
(𝑑𝑎𝑡𝑒 𝑜𝑓 𝑙𝑎𝑠𝑡 𝑑𝑜𝑠𝑒−𝑑𝑎𝑡𝑒 𝑜𝑓 𝑓𝑖𝑟𝑠𝑡 𝑑𝑜𝑠𝑒+ 18)
7
 
Participants will receive 5 infusions of Topotecan on Days 1 through Day 5 in each 21-day cycle. 
Hence, duration of Topotecan therapy is calculated as follows: 
𝐷𝑢𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑇𝑜𝑝𝑜𝑡𝑒𝑐𝑎𝑛 (𝑤𝑒𝑒𝑘𝑠) = 
(𝑑𝑎𝑡𝑒 𝑜𝑓 𝑙𝑎𝑠𝑡 𝑑𝑜𝑠𝑒−𝑑𝑎𝑡𝑒 𝑜𝑓 𝑓𝑖𝑟𝑠𝑡 𝑑𝑜𝑠𝑒+ 17)
7
 
9.7 
Imputation of Missing Data  
In this Phase I PK study, missing observations will be assumed to be missing completely at random 
(MCAR). No action will be taken to handle missing data. A participant who withdraws prior to the 
last planned observation in a study period will be included in the analyses up to the time of 
discontinuation.  
Unless otherwise specified, all data will be evaluated as observed, and no imputation method for 
missing values will be used. 
Missing statistics, e.g. when they cannot be calculated, should be presented as “nc” (not 
calculated). For example, if n=1, the measure of variability (SD) cannot be computed and should 
be presented as “nc”. 
Incomplete AE-related dates will be imputed as follows:  
• In case the onset date is missing completely or missing partially but the onset month and year, 
or the onset year are equal to the start of study intervention then the onset date will be imputed 
by the minimum of start of study intervention and AE resolution date (if not missing). 
Global Version ID: CCI


Berzosertib 
                                                                                    Human Mass Balance Study 
MS201923_0008                                                                                                                             Version 1.0 
 
 
 
 
C O N F I D E N T I A L 
I N F O R M A T I O N 
17/48 
 
 
 
 
• In all other cases, the missing onset day or missing onset month will be imputed by 1.  
• Incomplete stop dates will be imputed by the last day of the month (if day is missing only), if 
not resulting in a date later than the date of participant’s death. In the latter case, the date of 
death will be used to impute the incomplete stop date. 
• In all other cases, the incomplete stop date will not be imputed. 
Incomplete dates for disease history (e.g. initial diagnosis date) will be imputed as follows: 
• If the day is missing, it will be imputed to the 15th day of the month.  
• If both day and month are missing and the year is prior to the year of the first study intervention, 
the month and day will be imputed as July 1st. 
• If both day and month are missing and the year is the same as the year of the first study 
intervention, the month and day will be imputed as January 1st.  
Incomplete prior/concomitant medication and concomitant procedures start and stop dates 
will be imputed as in Table 1.  
For the derivation of previous and concomitant medications and Concomitant Procedures 
following rules will be applied: 
Previous Medication: 
• Start date ≤ Start of study medication OR 
• Start date = Missing 
Concomitant Medication and Concomitant Procedures: 
• End date ≥ Start of study medication AND (Start date ≤ End of study medication +30 days 
OR Start date=Missing) OR 
• End date = Missing AND (Start date ≤ End of study medication +30 days OR Start date = 
Missing) 
The derivation is based on the following principles 
• Imputation leads to maximum reasonable duration 
• Worst case: If medication is administered the same day as start of study medication, 
medication is classified as concomitant and previous 
Global Version ID: CCI


Berzosertib 
                                                                                    Human Mass Balance Study 
MS201923_0008                                                                                                                             Version 1.0 
 
 
 
 
C O N F I D E N T I A L 
I N F O R M A T I O N 
18/48 
 
 
 
 
Table 1 
Imputation rules for missing/incomplete start/end dates of medication/ 
procedures  
 
Start Date 
End Date 
Day missing only 
Day = 1 
Day = Last day of month 
Month missing 
Day = 1 
Month = Jan 
Day = 31 
Month = Dec 
Year missing 
Date = Missing 
No imputation 
All 
if imputed date > date of death: 
imputation by date of death 
9.8 
Age at Time of an Event  
If Age at the Time of an Event is derived, the following algorithm will be used for the derivation 
• Year of Event minus Year of Birth 
10 
Study Participants  
10.1 
Disposition of Participants and Discontinuations  
This following will be presented in a summary table, by period:  
• Total number of participants screened (i.e., participants who gave informed consent) 
• Number of screened participants who discontinued from the trial prior to dosing overall 
and grouped by the main reason for discontinuation: 
o Subject did not meet all eligibility criteria (including which criterion) 
o Withdrawal by subject 
o Progressive Disease 
o Adverse Events 
o Lost to follow-up 
o Other  
• Number and percentage of  treated subjects 
• Number and percentage of  Subjects that received no treatment  (per end of treatment 
status ) 
•  Number and percentage of  Subjects  Treatment ongoing (per end of treatment status ) 
•  Number and percentage of  Subjects completed (per end of treatment and end of study 
status ) 
Global Version ID: CCI


Berzosertib 
                                                                                    Human Mass Balance Study 
MS201923_0008                                                                                                                             Version 1.0 
 
 
 
 
C O N F I D E N T I A L 
I N F O R M A T I O N 
19/48 
 
 
 
 
• Number and percentage of treated participants who discontinued the study or treatment, 
with the primary reason of discontinuation by end of treatment and end of study status: 
o Adverse event 
o Lost to follow-up 
o Protocol non-compliance 
o Death 
o Withdrawal by subject 
o Other [(COVID-19 related and COVID-19-non-related)] 
A listing of discontinued participants will be provided along with a listing for eligibility 
determination - in-/exclusion criteria. 
10.2 
Protocol Deviations / Exclusion from Analysis Sets  
10.2.1 
Important Protocol Deviations  
Listings of important protocol deviations will be provided including the date and relative day in 
relation to dosing in the relevant period. A distinction will be made between important protocol 
deviations due to COVID-19 versus not due to COVID-19. The respective important protocol 
deviations will be flagged accordingly. 
10.2.2 
Reasons Leading to the Exclusion from an Analysis Set  
All criteria/reasons leading to the exclusion of a subject from an analysis set will be listed based 
on the safety set.  
Reasons for excluding individual PK concentrations will also be listed separately and flagged in 
the main listing based on the safety analysis set. 
11 
Demographics and Other Baseline Characteristics  
11.1 
Demographics  
Summaries will be given for both the safety and the PK set, if different. 
Demographic characteristics will be listed by subject and summarized using the following 
information from the Screening/Baseline Visit case report form (CRF) pages.  
Demographic characteristics: 
• Sex: male  
Global Version ID: CCI


Berzosertib 
                                                                                    Human Mass Balance Study 
MS201923_0008                                                                                                                             Version 1.0 
 
 
 
 
C O N F I D E N T I A L 
I N F O R M A T I O N 
20/48 
 
 
 
 
• Race: American Indian or Alaska Native, Asian, Black or African American, Native 
Hawaiian or other Pacific Islander, White, White + Black or African American, White + 
Asian, Asian + Black or African American, Other 
• Ethnic origin: Hispanic or Latino, Not Hispanic or Latino  
• Age (years) 
• Age categories {< 65 years,  ≥ 65 years (65-74, 75-84, ≥85 years)} 
11.2 
Medical History  
Medical history will be coded using the Medical Dictionary for Regulatory Activities (MedDRA), 
using Version 25.0 or later, and listed.  
11.3 
Other Baseline Characteristics  
Other baseline characteristics will be listed by participants and only height, weight and BMI  
summarized using the following information from the Screening/Baseline Visit CRF pages.  
 
Other baseline characteristics: 
• Height (cm) at Baseline 
• Weight (kg) at Baseline 
• Body Mass Index (BMI) (kg/m²) at Baselines 
• BSA (Body Surface Area) (m²) 
• Medical History 
• Disease History   
• Serum and urine human chorionic gonadotropin (β-hCG) pregnancy test,  
• Follicle stimulating hormone (FSH) and estradiol test 
 
BMI will be re-derived (i.e., not taken directly from the database) according to the following 
formula: 
BMI (kg/m²) = weight (kg) / (height (m) * height (m)) 
BSA will be derived according to the following formula: 
BSA [m²] =√ 
ℎ𝑒𝑖𝑔ℎ𝑡[𝑐𝑚]×𝑤𝑒𝑖𝑔ℎ𝑡[𝑘𝑔]
3600
 
Global Version ID: CCI


Berzosertib 
                                                                                    Human Mass Balance Study 
MS201923_0008                                                                                                                             Version 1.0 
 
 
 
 
C O N F I D E N T I A L 
I N F O R M A T I O N 
21/48 
 
 
 
 
11.4 
Prior Anti-cancer Therapy  
The prior anti-cancer therapies are collected under the “Prior Anti-Cancer Drug Therapies 
Details”, “Prior Anti-Cancer Radiotherapy Details” and “Prior Anti-Cancer Surgeries Details” 
CRF pages  
The listings of prior anti-cancer treatments and procedures will also be provided as follows. These 
will include the participant identification number, and all the relevant collected data-fields on the 
corresponding CRF pages. 
• Listing of prior anti-cancer drug therapies  
• Listing of prior anti-cancer radiotherapy  
• Listing of prior anti-cancer surgeries 
12 
Previous or Concomitant Therapies/Procedures  
 
Medications will be presented for the Safety Analysis Set. 
Previous medications are defined as any medication discontinued prior to the administration of 
study intervention. Concomitant medications are defined as any medication taken during the 
course of the study, with a starting date greater than or equal to the administration of the first study 
intervention, or with a starting date prior to the administration of the first study intervention and 
ongoing at the time of the administration of study intervention. 
The World Health Organization Drug dictionary (WHO-DD), latest version, will be used for 
coding of prior and concomitant medications and they will be described using Preferred Term (PT) 
as applicable. 
Previous and concomitant medications will be listed. Concomitant procedures, if any, will also be 
listed.  
 
13 
Study Intervention: Compliance and Exposure  
The following analyses will be performed based on the SAF by treatment group as needed. 
A listing of date and time of each drug administration sorted by participant and date of drug 
administration including information on total absolute planned dose, percent of total planned 
volume given and if the infusion was fully administered. In addition to this a listing will be 
Global Version ID: CCI


Berzosertib 
                                                                                    Human Mass Balance Study 
MS201923_0008                                                                                                                             Version 1.0 
 
 
 
 
C O N F I D E N T I A L 
I N F O R M A T I O N 
22/48 
 
 
 
 
provided for exposure duration, number of infusions, cumulative actual treatment dose and actual 
dose intensity per Subject. 
The summary of study intervention exposure (dosing) of each drug administration will be 
presented including the following information: 
• Exposure duration (weeks): overall distribution and by categories of  ≤ 3 weeks, > 3 – 6 weeks, 
> 6 – 9 weeks, > 9 -12 weeks, > 12 – 18 weeks, >18 – 24 weeks, >24 – 30, >30 – 36, and every 
9 weeks after 36 weeks 
• Total number of infusions received: For each study intervention, total number of infusions is 
calculated as the sum of the actual number of infusions that a participant received across cycles, 
regardless of infusion delays, interruptions, or any other types of deviations from the protocol 
required schedules. An infusion is regarded to be administered if either the actual dose received 
is > 0 or the duration of the infusion is > 0. 
• Cumulative Actual Treatment dose (mg/m2): Cumulative dose (mg/m2) will be presented for 
each Drug as the sum of the BSA-adjusted actual dose amount that a participant received. This 
will be calculated for each 21 day period/cycle, e.g. Day 1-21, 22-42, 43-64, etc. and also over 
the entire treatment period.  
BSA-adjusted actual dose amount (mg/m2) = actual dose amount (mg) / BSA (m2) 
The actual dose amount (mg) is taken at each dosing day from “Actual dose” on the relevant 
CRF pages at each dosing day. BSA will be derived as mentioned in Section 11.3 using the 
most recent height and weight entries.  In case the BSA is missing the latest BSA available will 
be used for calculation following the Last Observation Carried Forward principle. If BSA 
cannot be derived due to missing weight and/or height data, data from the last available visit 
will be used instead. 
• Actual Dose Intensity (DI): The DI per week is calculated for each study intervention as 
follows: 
𝐴𝑐𝑡𝑢𝑎𝑙 𝐷𝐼 (𝑚𝑔/𝑚2 𝑤𝑒𝑒𝑘) = 𝑡𝑜𝑡𝑎𝑙 𝑐𝑢𝑚𝑢𝑙𝑎𝑡𝑖𝑣𝑒 𝑑𝑜𝑠𝑒 (𝑚𝑔𝑚2
⁄
)
𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 𝑑𝑢𝑟𝑎𝑡𝑖𝑜𝑛 (𝑤𝑒𝑒𝑘𝑠)
⁄
 
• Relative Dose Intensity (RDI): The RDI (%) is calculated for each study intervention by 
dividing the DI by the planned dose intensity per week of the appropriate study intervention. 
Planned dose intensity per week will be derived by dividing planned dose (mg/m2) by duration 
of therapy (weeks). 
Global Version ID: CCI


Berzosertib 
                                                                                    Human Mass Balance Study 
MS201923_0008                                                                                                                             Version 1.0 
 
 
 
 
C O N F I D E N T I A L 
I N F O R M A T I O N 
23/48 
 
 
 
 
 
14 
Efficacy Analyses (Period 2 only) 
The following analyses on efficacy estimands will be performed based on the SAF except when 
otherwise stated. 
14.1 
Tertiary/ ExploratoryObjective: Objective Response  
14.1.1 
Tertiary/ Exploratory Estimand  
Endpoint 
Derivation of BoR and a corresponding listing according to RECIST 1.1, Eisenhauer EA, et. al., 
as assessed by the Investigator.  
OR is defined as a confirmed BOR of complete response (CR) or partial response (PR). 
Confirmation of the response according to RECIST 1.1 is required no sooner than 4 weeks after 
the initial documentation of CR or PR. Patients with BOR of NE are considered as non-responders 
for OR. 
Confirmed BOR is derived as follows: 
• CR = at least two determinations of CR at least 4 weeks apart (with no PD in between)  
• PR = at least two determinations of PR or better (PR followed by PR or PR followed by 
CR) at least 4 weeks apart (and not qualifying for a CR), with no PD in between  
• SD (applicable only to participant with measurable disease at baseline) = at least one SD 
assessment (or better) ≥ 6 weeks after start date (and not qualifying for CR or PR), i.e. 
Study Day 42 or later. 
• Non-CR/non-PD (applicable only to participants with non-measurable disease at baseline) 
= at least one non-CR/non-PD assessment (or better) ≥ 6 weeks (42 days) after start date 
(and not qualifying for CR or PR). 
• PD = PD ≤ 12 weeks (84 days) after start date (and not qualifying for CR, PR, non-CR/non-
PD or SD). The condition PD in or out of the respective timeframe addresses a missing 
data situation in view of determining best overall response as PD or NE, respectively. 
Clinical deterioration will not be considered as documented disease progression. 
• Not Evaluable (NE):  all other cases. 
Global Version ID: CCI


Berzosertib 
                                                                                    Human Mass Balance Study 
MS201923_0008                                                                                                                             Version 1.0 
 
 
 
 
C O N F I D E N T I A L 
I N F O R M A T I O N 
24/48 
 
 
 
 
SD can follow PR only in the rare case that tumor increases by less than 20% from the nadir, but 
enough that a previously documented 30% decrease from baseline no longer holds.  If this occurs 
the sequence PR-SD-PR is considered a confirmed PR.  A sequence of PR – SD – SD – PD would 
be a best response of SD if the minimum duration for SD definition has been met. 
The date of the overall response assessment is the earliest date for imaging of target, non-target 
and new lesions of images taken at that response assessment. 
Population 
Patients with advanced solid tumors. 
Treatment 
Berzosertib + topotecan 
Intercurrent Event Strategy 
• Discontinuation of treatment: Treatment-policy strategy, i.e., regardless of the intercurrent 
event 
• Start of subsequent anticancer treatment: while not treated with subsequent anticancer 
therapy strategy; i.e., ignoring tumor assessments after the intercurrent event. If a tumor 
assessment was performed on the same day as start of new anti-cancer therapy, it will be 
assumed that the tumor assessment was performed prior to the start of the new anti-cancer 
therapy, therefore the tumor assessment will be included in the assessment of BOR.  
• Progression according to RECIST 1.1: While not progressed strategy, i.e., considering 
assessments up to the intercurrent event 
Population Level Summary 
 Overall response and BoR will be derived and provided via listings. Additionally, no summary 
tables are planned.. 
15 
Safety Analyses  
This section includes specifications for summarizing safety endpoints that are common across 
clinical studies such as adverse events, laboratory tests and vital signs. 
All safety analyses will be performed for the Safety Analysis Set and will be presented by study 
intervention (period). An additional column for all active doses of study intervention may be 
presented when specified.  
Global Version ID: CCI


Berzosertib 
                                                                                    Human Mass Balance Study 
MS201923_0008                                                                                                                             Version 1.0 
 
 
 
 
C O N F I D E N T I A L 
I N F O R M A T I O N 
25/48 
 
 
 
 
Safety analyses will be done on the Safety Analysis Set and according to the as-treated principle.  
15.1 
Adverse Events  
All AEs recorded during the course of the study will be coded with the MedDRA, version 25.0 or 
later and assigned to a System Organ Class (SOC) and a Preferred Term (PT).  
Treatment-emergent AEs (TEAEs) are those events with onset dates on or after the first 
administration of study intervention. Any AE occurring before the administration of study 
intervention on Day 1 and resolved before administration of study intervention or not worsening 
after administration of study intervention will be included in the AE listings, but will not be 
included in the summary tables (unless otherwise stated). These will be referred to as “pre-
treatment” AEs.  An AE occurring after administration of study intervention will be counted 
towards the last treatment received before the onset, even if the event is not resolved at the 
beginning of the following intervention period. An AE that worsens during a later intervention 
period will be counted towards both treatments. 
TEAEs will be presented by respective Periods and Overall.  TEAE flags will be created in line 
with the attribution of TEAEs as follows: 
Period 1: Any AE that starts in Period 1, i.e. any AE with onset after start of first drug 
administration and before the start of further drug administration in Period 2 
Period 2: Any new AE that was not existent in Period 1 and started in Period 2. Any AE that starts 
in Period 1 and worsens in Period 2.  
Overall: An AE will be counted only once in the Overall attribution even if it is existent in Period 
1 and worsens in Period 2.  
In case AE-related dates are partial, the available information will be used in a conservative 
approach to determine whether the AE is treatment-emergent as described in Section 9.  
All analyses described in this section will be based on TEAEs if not otherwise specified.  
Unless otherwise specified, TEAEs will be summarized by number and percentage of participants 
with the TEAE in the category of interest, as well as the number of events, by study intervention 
(period), primary SOC sorted alphabetically and PTs within each SOC in decreasing frequency 
(based on the total column).  
Global Version ID: CCI


Berzosertib 
                                                                                    Human Mass Balance Study 
MS201923_0008                                                                                                                             Version 1.0 
 
 
 
 
C O N F I D E N T I A L 
I N F O R M A T I O N 
26/48 
 
 
 
 
15.1.1 
All Adverse Events  
Treatment-emergent AEs and participants experiencing TEAEs will be summarized by study 
intervention or period and overall in the following tables. Additionally, for Period 2 these tables 
will also provide relevant information on individual drug Topotecan or Berzosertib related events: 
• Overall Overview table, showing the number and percentage of participants with 
Any TEAE  
Any Study Drug related TEAE 
Any Berzosertib related TEAE 
Any Topotecan related TEAE 
Any serious TEAE 
Any Study Drug related serious TEAE 
Any Berzosertib related serious TEAE 
Any Topotecan related serious TEAE 
Any Grade >=3 (severe) TEAE 
Any Grade >=4 (life-threatening) TEAE 
Any Study Drug related Grade >=3 (severe) TEAE 
Any Berzosertib related Grade >=3 (severe) TEAE 
Any Topotecan related Grade >=3 (severe) TEAE 
Any Study Drug related Grade >=4 (life-threatening) TEAE 
Any Berzosertib related Grade >=4 (life-threatening) TEAE 
Any Topotecan related Grade >=4 (life-threatening) TEAE 
Any TEAE leading to Study discontinuation 
Any Related TEAE leading to Study discontinuation 
Any Berzosertib Related TEAE leading to Study discontinuation 
Any Topotecan Related TEAE leading to Study discontinuation 
Any TEAE leading to death            
Any Study Drug related TEAE leading to death 
Any Berzosertib related TEAE leading to death 
Global Version ID: CCI


Berzosertib 
                                                                                    Human Mass Balance Study 
MS201923_0008                                                                                                                             Version 1.0 
 
 
 
 
C O N F I D E N T I A L 
I N F O R M A T I O N 
27/48 
 
 
 
 
Any Topotecan related TEAE leading to death 
Any TEAE leading to temporary discontinuation of at least one study drug 
Any TEAE leading to temporary discontinuation of Berzosertib 
Any TEAE leading to temporary discontinuation of Topotecan 
Any TEAE leading to permanent discontinuation of at least one study drug 
Any TEAE leading to permanent discontinuation of Berzosertib 
Any TEAE leading to permanent discontinuation of Topotecan 
Any TEAE leading to dose reduction of at least one study drug 
Any TEAE leading to dose reduction of Berzosertib 
Any TEAE leading to dose reduction of Topotecan 
• 
.The number and percentage of participants with at least one TEAE by SOC 
and PT by Periods and Overall 
• 
 The number and percentage of participants with at least one TEAE by Trial 
Drug Relationship, SOC and PT by Periods and Overall 
• 
 The number and percentage of participants with at least one TEAE by Trial 
Drug Relationship, SOC and PT by Drugs for Period 2 
• 
The number and percentage of participants with at least one TEAE by Worst 
Severity Grade, SOC and PT by Periods and Overall 
• 
The number and percentage of participants with at least one related TEAE by 
Worst Severity Grade, SOC and PT by Periods and Overall 
• 
 The number and percentage of participants with at least one related TEAE by 
Worst Severity Grade, SOC and PT by Drugs for Period 2 
 
Additionally, listings will be provided for TEAEs, pre- treatment AEs and TEAEs Leading to Trial 
Treatment Discontinuation  
Within each level of TEAE term, if a participant experiences more than one occurrence, the 
participant will only be counted once for that TEAE. 
If an AE is reported for a given participant more than once during treatment, the worst severity 
and the worst relationship to study intervention will be tabulated. 
Global Version ID: CCI


Berzosertib 
                                                                                    Human Mass Balance Study 
MS201923_0008                                                                                                                             Version 1.0 
 
 
 
 
C O N F I D E N T I A L 
I N F O R M A T I O N 
28/48 
 
 
 
 
Adverse events related to any study intervention are those events with relationship missing, 
unknown or related. 
In case a participant had events with missing and non-missing severity, the maximum non-missing 
severity will be displayed.  
15.1.2 
Adverse Events Leading to Discontinuation of Study 
Intervention  
A listing of TEAEs leading to permanent discontinuation of a trial treatment will be provided. 
15.2 
Deaths, Other Serious Adverse Events, and Other Significant 
Adverse Events  
15.2.1 
Deaths  
Listing of deaths, if any, will be provided displaying date and cause of death (including TEAE 
leading to death and relatedness to trial treatment, when applicable), and date and time of treatment 
administration.  
15.2.2 
Serious Adverse Events  
A listing of SAEs, if any, will be provided. 
15.2.3 
Other Significant Adverse Events  
For this study, no Adverse Events of Special Interest (AESI(s)) have been identified other than 
Infusion Related Reactions (IRR) and Infusion site reactions (ISR). IRRs are identified based on a 
list of MedDRA PTs, see Appendix 2 in Section 18.2 and divided into reactions versus signs and 
symptoms. 
Reactions of IRR: should be considered when onset is during berzosertib and/or topotecan 
infusion or within 24 hours of infusion and resolution on the same day or the day after onset for 
any infusion-related reaction, drug hypersensitivity, anaphylactic reaction, hypersensitivity and/or 
Type 1 hypersensitivity. 
Signs and symptoms of IRRs and hypersensitivity/allergic reactions: should be considered 
when onset is during berzosertib and/or topotecan infusion or within 24 hours of infusion and 
resolution on the same day or the day after onset.  
Global Version ID: CCI


Berzosertib 
                                                                                    Human Mass Balance Study 
MS201923_0008                                                                                                                             Version 1.0 
 
 
 
 
C O N F I D E N T I A L 
I N F O R M A T I O N 
29/48 
 
 
 
 
The listing of all IRRs will be provided with the relevant information.  
Infusion site reactions (ISR) are considered identified risks (non-important) and are likely 
associated with berzosertib treatment if the infusion site reaction develops during infusion or 
within 24 hours of berzosertib administration (with resolution on the same day or the day after 
onset). 
ISR have been reported using a variety of terms to describe the same biologic event, including 
catheter site pain, catheter site pruritus, catheter site rash, catheter site-related reaction, infusion 
site discomfort, infusion site erythema, infusion site extravasation, infusion site pruritus, infusion 
site rash, infusion site reaction, injection site rash, and injection site reaction. See Appendix 17.2 
for the detailed MedDRA PTs. 
The same listings described above for IRR will be provided for ISR. 
15.3 
Clinical Laboratory Evaluation  
Listings and summary statistics at each assessment time will be presented using the Système 
International (SI) units. Normal ranges will be provided by the central laboratory, and out of range 
flags will be calculated based on the normal ranges. Laboratory data not transferred from the 
central laboratory in SI units will be converted to SI units before processing. Both original units 
and SI units will be provided in the SDTM domain. 
Continuous clinical laboratory data for hematology and clinical chemistry will be summarized by 
study intervention and time point using descriptive statistics for baseline (see definition in Section 
9), each evaluation during the study, and change from baseline to each evaluation.  
Listings of all clinical laboratory data for each participant will be provided, with values outside 
the normal ranges indicated. Listings of abnormal test results (low and high) will be provided.  
15.4 
Vital Signs  
Vital signs data will be summarized by study intervention and time point using descriptive statistics 
for baseline (see definition in Section 9), each evaluation during the study, and change from 
baseline to each evaluation. Listing of vital signs data will be provided.  
Vital signs assessments will include: 
• Blood Pressure including position (Standing, Supine, Sitting, Semi-recumbent): 
o Systolic Blood Pressure  
Global Version ID: CCI


Berzosertib 
                                                                                    Human Mass Balance Study 
MS201923_0008                                                                                                                             Version 1.0 
 
 
 
 
C O N F I D E N T I A L 
I N F O R M A T I O N 
30/48 
 
 
 
 
o Diastolic Blood Pressure  
• Supine pulse rate 
• Respiratory rate 
• Tympanic or body temperature 
• Weight (at Screening only) 
• Height (at Screening only) 
15.5 
Other Safety or Tolerability Evaluations  
ECG data will be summarized by study intervention and time point using descriptive statistics for 
baseline (see definition in Section 9), each evaluation during the study, and change from baseline 
to each evaluation. Listing of ECG data and of clinically significant ECG findings for individual 
participant will be provided.  
The time intervals (PR, QRS, RR, QT and corrected QT intervals [based on Fridericia’s formula, 
QTcF]) will be summarized descriptively by study intervention. 
The Fridericia’s Correction (QTcF) is derived as follows:  
Fridericia’s Correction (QTcF)  
𝑄𝑇𝑐𝑓=
QT
√𝑅𝑅
3
  
where: RR = RR-interval measured in seconds. 
All ECG measurements will be listed, with abnormalities indicated. Investigator reported 
interpretation results will be listed, in addition to a listing for ECOG. 
 
Global Version ID: CCI


Berzosertib 
                                                                                    Human Mass Balance Study 
MS201923_0008                                                                                                                             Version 1.0 
 
 
 
 
C O N F I D E N T I A L 
I N F O R M A T I O N 
31/48 
 
 
 
 
16 
Analyses of Other Endpoints/Estimands  
16.1 
Pharmacokinetics  
PK evaluation will be performed by ICON plc EDS.   
All statistical analyses and descriptive summaries of PK data will be performed on the PK analysis 
set (PKAS). 
Accelerator mass spectrometry (AMS) analysis is used to determine total radioactivity (TR) and 
perform metabolite profiling. Depending on the excretion profile of [14C]berzosertib, traditional 
radioactivity detection methods such as liquid scintillation counting will also be explored for 
recovery of TR and mass balance determination. 
16.1.1 
Descriptive Statistics of PK Concentration Data  
16.1.1.1 
Plasma and Whole Blood  
PK concentrations will be descriptively summarized using: number of non-missing observations 
(n), arithmetic mean (Mean), standard deviation (SD), coefficient of variation (CV%), minimum 
(Min), median (Median) and maximum (Max).  
Descriptive statistics will only be calculated for n>2 in which a measurement of BLQ represents a 
valid measurement and will be taken as zero for summary statistics of PK concentration data. In 
case n ≤2, individual data will be presented (min, max) in summary tables. 
Descriptive statistics of PK concentration data will be calculated using values with the same 
precision as the source data and rounded for reporting purposes only. PK concentrations will be 
carried over with full precision as provided in the source data without any rounding applied to 
CDISC SDTM PC and ADaM PC domains 
The following conventions will be applied when reporting descriptive statistics of PK 
concentration data: 
n 
: 0 decimal place 
Mean, Min, Median, Max, SD  
: 3 significant digits 
CV% 
: 1 decimal place 
Global Version ID: CCI


Berzosertib 
                                                                                    Human Mass Balance Study 
MS201923_0008                                                                                                                             Version 1.0 
 
 
 
 
C O N F I D E N T I A L 
I N F O R M A T I O N 
32/48 
 
 
 
 
16.1.1.2 
Free fraction (% unbound) of berzosertib  
Free fraction (%unbound) of berzosertib in plasma may be summarized by time points and pool of 
time points as permitted by the data.  
16.1.1.3 
Urine and Feces  
Individual berzosertib (urine) and total radioactivity (urine and feces) excretion data (concentrations, 
volumes (urine), weights (feces)) will be listed per collection interval. Berzosertib and total 
radioactivity (cumulative) amount, % of dose and excretion rate data per collection interval will be 
tabulated together with summary statistics. Summary statistics (number of non-missing observations 
(n), arithmetic mean (Mean), standard deviation (SD), coefficient of variation (CV%), minimum 
(Min), median (Median) and maximum (Max)) will be provided by analyte and collection interval. 
In addition, for the metabolites from the pooled metabolite profiling sample the percentage of the dose 
(%) will be calculated.  
16.1.1.4 
Vomitus  
In case vomitus is collected, total radioactivity will be assayed and results listed. 
16.1.2 
Descriptive Statistics of PK Parameter Data  
16.1.2.1 
Plasma and Whole Blood  
PK parameter data will be descriptively summarized using: number of non-missing observations 
(n), arithmetic mean (Mean), standard deviation (SD), coefficient of variation (CV%), minimum 
(Min), median (Median), maximum (Max), geometric mean (GeoMean), the geometric coefficient 
of variation (GeoCV) and the 95% confidence interval for the GeoMean (LCI 95% GM, UCI 95% 
GM). For PK parameters related to time (e.g. tmax, tlag, tlast), only n, Min, Median, and Max may be 
reported.  
Descriptive statistics will only be calculated for a PK parameter when n>2. In case n 
≤2, individual data will be presented (min, max) in summary tables.  
PK parameters read directly from the measurements (i.e. Cmax) will be reported with the same 
precision as the source data. All other PK parameters will be reported to 3 significant figures. 
Descriptive statistics of PK parameter data will be calculated using full precision and rounded for 
reporting purposes only. 
Global Version ID: CCI


Berzosertib 
                                                                                    Human Mass Balance Study 
MS201923_0008                                                                                                                             Version 1.0 
 
 
 
 
C O N F I D E N T I A L 
I N F O R M A T I O N 
33/48 
 
 
 
 
PK parameters will be provided with full precision, without any rounding applied to CDISC SDTM 
PP and ADaM PP domains. 
The following conventions will be applied when reporting descriptive statistics of PK parameter 
data: 
n 
0 decimal place  
Mean, Min, Median, Max, GeoMean, 95% CI, SD:  
3 significant digits 
CV%, GeoCV%: 
1 decimal place 
16.1.2.2 
Urine and Feces  
PK parameter data will be descriptively summarized: number of observations (n), arithmetic mean, 
SD, CV%, Min, Median, Max.  
Descriptive statistics of cumulative amount excreted and excretion rate will be calculated using 
values with the same precision as the source data, and rounded for reporting purposes only. The 
following conventions will be applied when reporting descriptive statistics of PK excretion data:  
Mean, Min, Median, Max, SD 
: 3 significant digits  
CV% 
: 1 decimal place  
The % of the dose will be reported with 1 decimal place. 
16.1.3 
General Specifications for PK Concentration and PK 
Parameter Data  
Predose samples that occur before the first drug administration per period will be assigned a time 
of 0 hours, as if the sample had been taken simultaneously with the study intervention 
administration.  
Predose samples which have been taken after the subsequent dosing will be reported as a protocol 
deviation. The resulting concentrations will be included in concentration listings but excluded from 
descriptive statistics of concentrations and from PK parameter estimation.  
Values below the lower limit of quantification (BLQ) will be taken as zero for summary statistics 
of PK concentration data, PK parameter estimation (e.g. AUC) and for graphical presentations.  
Missing concentrations (e.g. no sample, insufficient sample volume for analysis, no result or result 
not valid) will be reported and used generally as “N.R.”. A participant who withdraws prior to the 
last planned observation will be included in the analyses up to the time of discontinuation. 
Global Version ID: CCI


Berzosertib 
                                                                                    Human Mass Balance Study 
MS201923_0008                                                                                                                             Version 1.0 
 
 
 
 
C O N F I D E N T I A L 
I N F O R M A T I O N 
34/48 
 
 
 
 
PK concentrations which are erroneous due to a sampling processing or analytical error (as 
documented in the bioanalytical report) may be excluded from summary statistics and PK 
parameter calculation if agreed by the Sponsor. In this case the rationale for exclusion will be 
provided in the CSR. Any other PK concentrations that appear implausible to the Clinical 
Pharmacologist/Clinical PK Scientist will not be excluded from the analysis. Any implausible data 
will be documented in the CSR.  
If important protocol deviations occurred likely to affect the PK profile of participants as specified 
in Section 10.2, the impacted concentrations and PK parameters will be excluded from summary 
statistics and further statistical evaluation.  
Any PK concentrations or PK parameters excluded from summary statistics will be included in 
participants listings and flagged; a reason for exclusion will be detailed in the CSR (e.g. a footnote 
or a table of exclusions). Any flags should be included in the study specific CDISC data sets 
(ADAM and SDTM). 
PK concentrations and PK parameters excluded from summary statistics will not be included in 
mean/median figures. Mean/median plots will only contain values where n>2. In case 
≤2, individual participant profiles may be included in mean/median plots.  
In case of missing or incomplete urine/feces samples, affected urine/feces PK parameters might 
not be calculated. 
16.1.4 
Estimation of Pharmacokinetic Parameters  
The computer program Phoenix® WinNonlin® version 8.1, or higher (Certara, L.P., Princeton, 
New Jersey, USA) will be used to derive PK parameters applying non-compartmental analysis 
(NCA).  
The statistical software SAS® (Statistical Analysis System, SAS-Institute, Cary NC, USA, 
windows version 9.4 or higher) may be used to generate additional PK parameters, produce tables, 
listings and figures.  
16.1.4.1 
Estimation of Pharmacokinetic Parameters in Plasma and 
Whole Blood  
PK parameters will be calculated using the actual elapsed time since dosing. In cases where the 
actual sampling time is missing, calculations may be performed using the nominal time. Details 
(e.g. number of samples, participants affected) will be described in the CSR. In cases actual dosing 
Global Version ID: CCI


Berzosertib 
                                                                                    Human Mass Balance Study 
MS201923_0008                                                                                                                             Version 1.0 
 
 
 
 
C O N F I D E N T I A L 
I N F O R M A T I O N 
35/48 
 
 
 
 
time is missing, scheduled time might be used for NCA after performance of adequate plausibility 
checks and agreement with the sponsor. Decision and rational should be included in the CSR.  
The following PK parameters will be calculated for berzosertib and MSC2699092A (M11) and 
total radioactivity in plasma and whole blood when appropriate: 
Symbol 
Definition 
AUC0-tlast 
The area under the concentration-time curve (AUC) from time zero (= dosing time) to the last 
sampling time (tlast) at which the concentration is at or above the lower limit of quantification. 
Calculated using the mixed log-linear trapezoidal rule (linear up, log down). 
AUC0-∞ 
The AUC from time zero (dosing time) extrapolated to infinity, based on the predicted value for the 
concentration at tlast, as estimated using the linear regression from λz determination. AUC0-∞ =
AUC0-tlast + Clast pred/ λz, where Clast pred is the predicted plasma concentration at the last sampling 
time point, calculated from the log-linear regression line for λz determination at which the 
measured plasma concentration is at or above LLOQ 
AUC0-t 
The partial area under the concentration-time curve (AUC) from time zero (= dosing time) to a 
defined time ‘t’. Calculated using the mixed log-linear trapezoidal rule (linear up, log down). 
Timepoint ‘t’ will be defined upon receipt of the metabolite profiling data. 
AUC0-96 
The partial area under the concentration-time curve (AUC) from time zero (= dosing time) to 96
hours after dosing, calculated using the mixed log-linear trapezoidal rule (linear up, log down). In
cases where the actual observation time is not equal to the scheduled observation time, AUC0-96
will be calculated based on the estimated concentration at 96 hours, and not the concentration at 
the actual observation time. 
Cmax 
Maximum observed concentration of Berzosertib, MSC2699092A or total radioactivity 
Ceoi 
The observed concentration at the end of the infusion period. 
CL (berzosertib 
only) 
The total body clearance of study intervention following intravenous administration, CL = Dose/ 
AUC0-∞ 
tmax 
The time to reach the maximum observed concentration collected during a dosing interval. 
t1/2 
Terminal half-life of Berzosertib, MSC2699092A or total radioactivity, calculated as ln(2)/λz 
tlast 
The last sampling time at which the concentration is at or above the lower limit of quantification 
λz 
Terminal rate constant determined from the terminal slope of the log- transformed concentration 
curve of Berzosertib, MSC2699092A or total radioactivity using linear regression on terminal data 
points of the curve 
VZ (berzosertib 
only)  
The volume of distribution during the terminal phase following intravenous administration. VZ = 
Dose/(AUC0-∞*λz). 
VSS (berzosertib 
only)  
An estimate of the volume of distribution at steady-state based on the last predicted concentration, 
calculated as CL * MRTiv. 
MRTiv (berzosertib 
only) 
The mean residence time extrapolated to infinity, calculated as (AUMC0-∞/AUC0-∞)-T/2, where T is 
the infusion duration. AUMC is the total area under the first moment curve. 
Global Version ID: CCI


Berzosertib 
                                                                                    Human Mass Balance Study 
MS201923_0008                                                                                                                             Version 1.0 
 
 
 
 
C O N F I D E N T I A L 
I N F O R M A T I O N 
36/48 
 
 
 
 
Symbol 
Definition 
M/P(AUC0-∞)  
Molecular 
weight-corrected 
ratio 
of 
MSC2699092A 
AUC0-∞ 
to 
parent 
AUC0-∞.
M/P(AUC0-∞) = (AUC0-∞metabolite × MWparent) / (AUC0-∞parent × MWmetabolite). Ratios are
presented in %. 
MRTR(AUC0-∞)  
Molecular weight-corrected metabolite ratio of AUC0-∞ to total radioactivity. AUC0-∞ for parent and
for MSC2699092A divided by the total radioactivity AUC0-∞ (corrected by MW of parent). Ratios 
are presented in %. 
 
Total radioactivity will be given in ng eq/mL. Metabolite profiling data will be given in % ROI (% 
of drug-related exposure) for plasma and % of dose for excreta. 
Additional PK parameters may be calculated where appropriate. Units for PK parameter output 
will be based on concentration and dose units used in the study, unless otherwise specified. In case 
concentration data units change within the study, PK parameters will be reported using consistent 
units throughout study outputs.  
The parameters Cmax, tlast, and tmax will be obtained directly from the concentration-time profiles. 
If Cmax occurs at more than one timepoint, tmax will be assigned to the first occurrence of Cmax. 
In cases where the actual observation time is not equal to the scheduled observation time, e.g. 
AUC0-24, the parameter will be calculated by extrapolation to the given time point, e.g. 24 h,  
provided λz is estimable. In case suitable regression cannot be performed, partial areas may be 
calculated using the concentration at given time point, e.g. 24 h if actual sampling time is within 
10% of the nominal sampling time. 
In cases BLQ concentrations occur at the end of the collection interval, these concentrations might 
be set to missing for calculations of partial AUCs after agreement with the Sponsor. This is an 
exemption to the general BLQ handling rule and should be applied in case its application would 
result in estimation of implausible partial AUC values. Implausibility is considered in cases partial 
AUCs were greater than AUC0-∞.  
The following PK parameters will be calculated for diagnostic purposes and listed, but will not be 
summarized: 
• First (λz low) and last (λz up) time point of the time interval of the log-linear regression to 
determine λz.  
• Number of data points (Nλ) included in the log-linear regression analysis to determine λz. 
• Goodness of fit statistic (adjusted Rsq) for calculation of λz. 
Global Version ID: CCI


Berzosertib 
                                                                                    Human Mass Balance Study 
MS201923_0008                                                                                                                             Version 1.0 
 
 
 
 
C O N F I D E N T I A L 
I N F O R M A T I O N 
37/48 
 
 
 
 
• AUC from time tlast extrapolated to infinity given as percentage of AUC0-. (AUCextra%) 
• Span ratio of interval over which t1/2 was estimates/t1/2 
The regression analysis should contain data from at least 3 different time points in the terminal 
phase consistent with the assessment of a straight line on the log-transformed scale. Phoenix 
WinNonlin “best fit” methodology will be used as standard. If warranted, further adjustment may 
be made by the pharmacokineticist, after agreement with the Sponsor. The last quantifiable 
concentration >LLOQ should always be included in the regression analysis, while the 
concentration at tmax and any concentrations BLQ which occur after the last quantifiable data point 
>LLOQ should not be used.  
If AUCextra%>20%, the coefficient of correlation (Rsq adj) of λz is <0.8 or the observation period 
over which the regression line is estimated (span ratio) is less than 2-fold the resulting t1/2, the rate 
constants and all derived parameters (e.g. t1/2, AUC0-, CL etc.) will be listed, flagged and included 
in the parameter outputs descriptive statistics.  
The molecular weights of berzosertib and metabolite(s) to be used in the calculation of M/P and 
MRTR ratios are as follows:  
Analyte 
Molecular Weight 
M6620    
463.55 g/mol 
MSC2699092A (M11)       
464.79 g/mol 
The parameter AUC0-tlast or other common partial area may be used to determine M/P(AUC)  and 
MRTR AUC if AUC0-∞ or AUC cannot be reliably calculated for the majority of participants. 
16.1.4.2 
Estimation of Pharmacokinetic Parameters in Urine and 
Feces 
For samples such as urine or feces which are collected within a time range the nominal midpoint 
may be used for PK evaluation, in case where the actual sampling time is missing. Otherwise, there 
will be no further imputation of missing data. Where available, actual collection intervals will be 
used in the calculation of urine PK parameters. Urine concentrations which are BLQ will be set to 
zero. The following urine PK parameters will be calculated where appropriate: 
Symbol 
Definition 
Aet1-t2, urine 
Amount excreted in urine between times t1 (= start) and t2 (= end), calculated per 
collection interval and cumulative. 
Global Version ID: CCI


Berzosertib 
                                                                                    Human Mass Balance Study 
MS201923_0008                                                                                                                             Version 1.0 
 
 
 
 
C O N F I D E N T I A L 
I N F O R M A T I O N 
38/48 
 
 
 
 
Symbol 
Definition 
Aet1-t2, feces 
Amount excreted in feces between times t1 (= start) and t2 (= end), calculated per 
collection interval and cumulative. 
Aetotal 
Total (cumulative) amount radioactivity recovered in urine and feces over the entire 
collection period. 
CLR (berzosertib only) 
The renal clearance of study intervention. CLR= Ae0-t_urine/AUC0-t 
fe (%) (berzosertib only) 
Percent of dose excreted as an unchanged berzosertib in urine. 
fet1-t2, urine % 
Fraction of administered drug that is excreted in urine between times  
t1 (= start) and t2 (= end), calculated per collection interval and cumulative. 
fet1-t2, feces % 
Fraction of administered radioactivity that is excreted in feces between times 
t1 (= start) and t2 (= end), calculated per collection interval and cumulative. 
fetotal % 
Total (cumulative) fraction of administered radioactivity recovered in urine and feces 
over the entire collection period. 
16.1.5 
Statistical Analysis of PK Parameter Data  
PK and mass balance TLFs will be presented with the following subtitles: 
 
Period 1 – ADME: 
• Berzosertib in plasma and urine 
• Selected metabolites (see Section 16.1.4.1) in plasma 
• Total radioactivity in plasma, whole blood, urine, feces, total (urine + feces) 
• Metabolite profiling in plasma, urine and feces  
16.1.6 
Presentation of PK Concentration and PK Parameter Data – 
Period 1 ADME 
16.1.6.1 
Listings and Tables  
The following PK tables as also mentioned in section 18.1 will be produced (PK Analysis Set): 
• Descriptive statistics (presented together with individual values) of concentrations by analyte, 
matrix, and nominal timepoint  
• Descriptive statistics (presented together with individual values) of PK parameters by analyte, 
matrix, and nominal timepoint 
The following PK Listings as also mentioned in section 18.1 will be produced (Safety Analysis 
Set): 
Global Version ID: CCI


Berzosertib 
                                                                                    Human Mass Balance Study 
MS201923_0008                                                                                                                             Version 1.0 
 
 
 
 
C O N F I D E N T I A L 
I N F O R M A T I O N 
39/48 
 
 
 
 
• PK Sampling date, actual time, nominal time, deviation from time and concentration by 
participant, analyte, matrix sorted in chronological order. The listing will include the whole 
blood to plasma ratio of total radioactivity at each timepoint. Calculated as follows from the 
concentration in whole blood (Cwhole blood) and plasma (Cplasma): 
o 
Ratio = Cwhole blood / Cplasma 
• Individual PK parameters by analyte, matrix, and nominal timepoint 
• Start and end time and date of collection interval, urine volume/ feces weight, concentration, 
excreted amount by participant, analyte, matrix and group sorted in chronological order 
• Radioactivity parameters in Urine, Feces and total will be listed in addition to their total and 
Cumulative Recovery in Urine and Feces 
• Phoenix WinNonlin NCA Core Output 
16.1.6.2 
Graphical Summaries and Individual plots (PK Analysis Set)  
• Individual concentration versus time plots overlaying berzosertib and its metabolites in plasma; 
linear and semi-log; using the actual time points by participant; if any post-dose concentration 
is BLQ the line representing LLOQ may be added to the semi-log plots 
• Individual concentration versus time plots overlaying berzosertib (plasma), the sum of 
berzosertib and metabolites measured (total SUM of berzosertib and metabolite concentration 
(molecular weight adjusted) in plasma) and TRA in whole blood and plasma. Linear and semi-
log; using the actual time points by participant; if any post-dose concentration is BLQ the line 
representing LLOQ may be added to the semi-log plots.  
 
• Individual Total Radioactivity, Berzosertib and its Metabolite (s) Plasma Concentrations 
Versus Time Profiles (Linear and Semi Logarithmic Scale); using the actual time points by 
participant; if any post-dose concentration is BLQ the line representing LLOQ may be added 
to the semi-log plots.   
• Arithmetic mean plasma concentration-time profiles overlaying berzosertib and its metabolites 
on linear scale (±SD for arithmetic mean) and semi-logarithmic scale using scheduled 
(nominal) time points; if any post-dose concentration is BLQ the line representing LLOQ will 
be added to the semi-log plots. 
• Arithmetic mean plasma and whole blood concentration-time profiles overlaying berzosertib, 
the sum of berzosertib and metabolites measured (total plasma) and total radioactivity in 
plasma and whole blood. On linear scale (±SD for arithmetic mean) and semi-logarithmic 
Global Version ID: CCI


Berzosertib 
                                                                                    Human Mass Balance Study 
MS201923_0008                                                                                                                             Version 1.0 
 
 
 
 
C O N F I D E N T I A L 
I N F O R M A T I O N 
40/48 
 
 
 
 
scale. If any post-dose concentration is BLQ the line representing LLOQ may be added to the 
semi-log plots. 
• Arithmetic mean whole blood to plasma ratios versus time on linear scale. 
• Arithmetic Mean Profiles of Cumulative Total Radioactivity Excretion in Urine, Feces and 
Total Recovery (Linear Scale) 
• 
Individual Profiles of Cumulative Total Radioactivity Excretion in Urine, Feces and Total 
Recovery (Linear Scale) 
• 
Individual Radioactivity Excretion Rate Profiles, Including Excretion and Plasma Profiles. 
16.1.6.3 
Metabolite Profiling (Period 1) 
For the metabolite profiling, where the plasma samples from different time points are pooled using 
Hamilton pooling method and then analysed individually per subject or pooled over selected or all 
subjects or timepoints. Metabolite and 14C-berzosertib will be presented as % ROI over the 
sampling interval of the Hamilton pool, corresponding to the % of drug-related material in the 
analyzed pool.  
The results of the metabolite profiling excretion data in urine and feces will be listed. The % of 
dose per collection interval will be tabulated. 
16.2 
Further Other Endpoint(s)   
Not Applicable 
17 
References  
Not Applicable 
Global Version ID: CCI


Berzosertib 
                                                                                    Human Mass Balance Study 
MS201923_0008                                                                                                                             Version 1.0 
 
 
 
 
C O N F I D E N T I A L 
I N F O R M A T I O N 
41/48 
 
 
 
 
18 
Appendices  
18.1 
Appendix 1        List of Tables, Figures and Listings  
A list of tables, figures and listings are presented below. 
No.  
Tables/ Figures 
8.1 
Demographic and Baseline Data 
8.1.1 
Subject Disposition 
Table 8.1.1.1 
Subject Disposition Status 
Table 8.1.1.2 
Analysis Sets 
8.1.2 
Demographic Characteristics 
Table 8.1.21 
Demographic Characteristics 
8.1.3 
Other Baseline Characteristics 
Table 8.1.3.1 
Height, Weight, and Body Mass Index at Baseline 
8.1.4 
Treatment Compliance and Exposure 
Table 8.1.4.1 
Exposure Duration, Total Infusions, Cumulative Dose and Dose Intensity 
8.2 
Efficacy Data (Not Applicable) 
8.3 
Safety Data 
8.3.1 
Display of Adverse Events 
Table 8.3.1.1 
Overall Overview of Treatment Emergent Adverse Events (TEAEs) 
Table 8.3.1.2 
TEAE by Primary System Organ Class (SOC) and Preferred Term (PT) by 
Periods and Overall 
Table 8.3.1.3 
TEAEs by Trial Drug Relationship, SOC and PT by Periods and Overall 
Table 8.3.1.4 
TEAEs by Trial Drug Relationship, SOC and PT by Drugs for Period 2 
Table 8.3.1.5 
TEAE by Worst Severity Grade, SOC and PT by Periods and Overall 
Global Version ID: CCI


Berzosertib 
                                                                                    Human Mass Balance Study 
MS201923_0008                                                                                                                             Version 1.0 
 
 
 
 
C O N F I D E N T I A L 
I N F O R M A T I O N 
42/48 
 
 
 
 
Table 8.3.1.6 
Related TEAE by Worst Severity Grade, SOC and PT by Periods and Overall 
Table 8.3.1.7 
Related TEAE by Worst Severity Grade, SOC and PT by Drugs for Period 2 
8.3.2 
Deaths, Other Serious and Significant Adverse Events 
Table 8.3.2.1 
Listing of Deaths 
Table 8.3.2.2 
Listing of Serious TEAEs 
8.3.3 
Clinical Laboratory Evaluations 
Table 8.3.3.1 
Hematology – Summary Statistics over Time 
Table 8.3.3.2 
Blood chemistry – Summary Statistics over Time 
8.3.4 
Other Safety Evaluations 
Table 8.3.4.1 
Vital Signs Summary Statistics over Time 
Table 8.3.4.2 
ECG Results Summary Statistics over Time 
8.3.5 
Abnormal Laboratory Value Listing (Each Subject) 
Table 8.3.5.1 
Listing of Abnormal Hematology Values 
Table 8.3.5.2 
Listing Abnormal Blood Chemistry Values   
Table 8.3.5.3 
Listing Abnormal Urinalysis Values   
8.4 
Pharmacokinetic Data 
8.4.1 
Plasma and Whole Blood Concentrations Period 1 (ADME) 
Table 8.4.1.1 
Individual Values and Summary Statistics of Berzosertib and its Metabolites Plasma 
Concentrations  
Figure 8.4.1.2 
Arithmetic Mean Plasma Concentrations Versus Time Profiles of Berzosertib and its 
Metabolites, (Linear +/- SD and Semi-Logarithmic Scale) 
Figure 8.4.1.3 
Combined Individual Berzosertib Plasma Concentration-Time Profiles (Linear and 
Semi-Logarithmic Scale) 
Table 8.4.1.4 
Individual Values and Summary Statistics of Total Radioactivity in Plasma and Whole 
Blood Concentrations 
Global Version ID: CCI


Berzosertib 
                                                                                    Human Mass Balance Study 
MS201923_0008                                                                                                                             Version 1.0 
 
 
 
 
C O N F I D E N T I A L 
I N F O R M A T I O N 
43/48 
 
 
 
 
Figure 8.4.1.5 
Arithmetic Mean Concentration Versus Time Profiles of Berzosertib in Plasma and 
Total Radioactivity in Plasma and Whole Blood (Linear +/- SD and Semi-Logarithmic 
Scale) 
Figure 8.4.1.6 
Combined Individual Total Radioactivity Plasma and Whole Blood Concentrations 
Versus Time Profiles (Linear and Semi-Logarithmic Scale) 
Figure 8.4.1.7 
Individual Berzosertib in Plasma,Total Radioactivity in Plasma and Whole Blood 
Concentrations Versus Time Profiles (Linear and Semi-Logarithmic Scale) 
Figure 8.4.1.8 
Individual Total Radioactivity, Berzosertib and its Metabolites Plasma Concentrations 
Versus Time Profiles (Linear and Semi Logarithmic Scale) 
Figure 8.4.1.9 
Individual Berzosertib and its Metabolites Plasma Versus Time Profiles (Linear and 
Semi-Logarithmic Scale) 
Table 8.4.1.10 
Individual Values and Summary Statistics of Total Radioactivity Whole Blood/Plasma 
Ratios 
Figure 8.4.1.11 
Arithmetic Mean Whole Blood to Plasma Ratios Versus Time on Linear Scale  
8.4.2 
Plasma PK Parameters Period 1 (ADME) 
Table 8.4.2.1 
Individual Values and Summary Statistics of Berzosertib and Metabolite Plasma PK 
Parameters 
Table 8.4.2.2 
Individual Values and Summary Statistics of Total Radioactivity Plasma and Whole 
Blood PK Parameters 
8.4.3 
Excretion Data Period 1 (ADME) 
Table 8.4.3.1 
Individual Values and Summary Statistics of Total Radioactivity Excretion in Urine, 
Feces and Total Recovery by Collection Interval 
Table 8.4.3.2 
Individual Values and Summary Statistics of Berzosertib Excretion in Urine by 
Collection Interval 
Figure 8.4.3.3 
Arithmetic Mean Profiles of Cumulative Total Radioactivity Excretion in Urine, Feces 
and Total Recovery (Linear Scale) 
Figure 8.4.3.4 
Individual Profiles of Cumulative Total Radioactivity Excretion in Urine, Feces and 
Total Recovery (Linear Scale) 
Global Version ID: CCI


Berzosertib 
                                                                                    Human Mass Balance Study 
MS201923_0008                                                                                                                             Version 1.0 
 
 
 
 
C O N F I D E N T I A L 
I N F O R M A T I O N 
44/48 
 
 
 
 
Figure 8.4.3.5 
Individual Radioactivity Excretion Rate Profiles, Including Excretion and Plasma 
Profiles. 
8.4.4 
Excretion Parameters 
Table 8.4.4.1 
Individual Values and Summary Statistics of Excretion Parameters in Urine, Feces and 
Total Recovery 
8.5 
Metabolite Profiling Data Period 1 (ADME) 
8.5.1 
Plasma Concentrations 
Table 8.5.1.1 
Metabolites Plasma Percentage of Total Drug-related Material in Hamilton Pool 
8.5.2 
Excretion Data 
Table 8.5.2.1 
Metabolites Excretion in Urine and Feces by Pooled Collection Interval 
 
No. 
Listings 
9 
SUBJECT DATA LISTINGS 
9.1 
Study Disposition 
Listing 9.1.1 
Discontinued Subjects 
Listing 9.1.2 
Eligibility Determination - In-/Exclusion Criteria 
9.2 
Protocol Deviations 
Listing 9.2.1 
Protocol Deviations 
9.3 
Analysis Sets 
Listing 9.3.1 
Subjects Excluded from Any Analysis Set 
Listing 9.3.2 
Listing of Subjects Excluded from the Pharmacokinetic Analysis Set / Clinically 
Important Protocol Deviations 
9.4 
Demographic Data and Other Baseline Characteristics 
Global Version ID: CCI


Berzosertib 
                                                                                    Human Mass Balance Study 
MS201923_0008                                                                                                                             Version 1.0 
 
 
 
 
C O N F I D E N T I A L 
I N F O R M A T I O N 
45/48 
 
 
 
 
Listing 9.4.1 
Demographic Data 
Listing 9.4.2 
Medical History 
Listing 9.4.3 
Previous Medication 
Listing 9.4.4 
Concomitant Medication 
Listing 9.4.5 
Concomitant Procedures 
Listing 9.4.6 
Pregnancy, FSH and Estradiol Test 
Listing 9.4.7 
Disease History 
Listing 9.4.8 
Previous Anti-Cancer Therapy 
Listing 9.4.9 
Previous Anti-Cancer Radiotherapy 
Listing 9.4.10 
Previous Anti-Cancer Surgery 
9.5 
Compliance and/or Drug Concentration Data 
Listing 9.5.1 
Treatment Compliance and Exposure 
Listing 9.5.2 
Treatment Compliance and Exposure with Cumulative Dose and Dose Intensity 
Listing 9.5.3 
Individual PK Plasma and Whole Blood Concentrations, Sampling Time Deviations 
and Comments  
Listing 9.5.4 
Individual PK Urine and Feces Excretion Data, Including Volumes, Weights and 
Amount Excreted by Collection Interval 
Listing 9.5.5 
Individual Radioactivity total and Cumulative Recovery – Urine and Feces 
Listing 9.5.6 
Individual Radioactivity Parameters - Urine, Feces and Total 
Listing 9.5.7 
Metabolites Profiling 
Listing 9.5.8 
Metabolites Excretion 
Global Version ID: CCI


Berzosertib 
                                                                                    Human Mass Balance Study 
MS201923_0008                                                                                                                             Version 1.0 
 
 
 
 
C O N F I D E N T I A L 
I N F O R M A T I O N 
46/48 
 
 
 
 
Listing 9.5.9 
Free fraction (% unbound) of Berzosertib in plasma 
9.6 
Efficacy-Response Data 
Listing 9.6.1 
Tumor Response, Overall Response and Best Overall Response (RECIST v1.1)  
9.7 
Adverse Events Listings 
Listing 9.7.1 
Listing of TEAEs 
Listing 9.7.2 
Listing of IRRs 
Listing 9.7.3 
Listings of ISRs 
Listing 9.7.4 
Listing of Pre-treatment AEs 
Listing 9.7.5 
Listing of TEAEs Leading to Trial Treatment Discontinuation 
9.8 
Listing of Individual Laboratory Measurements by Subject 
Listing 9.8.1 
Listing of Hematology Values by Subject 
Listing 9.8.2 
Listing of Blood Chemistry Values by Subject 
Listing 9.8.3 
Listing of Urinalysis Values by Subject 
Listing 9.8.4 
Listing of Laboratory Comments 
9.9 
Other Observations Related to Safety 
Listing 9.9.1 
Listing of Vital Signs Values by Subject 
Listing 9.9.2 
Listing of 12-Lead ECG Results by Subject 
Listing 9.9.3 
Listing of 12-lead ECG Investigator’s Interpretation and Specification of 
Abnormalities by Subject 
Listing 9.9.4 
ECOG Performance Status 
 
Global Version ID: CCI


Berzosertib 
                                                                                    Human Mass Balance Study 
MS201923_0008                                                                                                                             Version 1.0 
 
 
 
 
C O N F I D E N T I A L 
I N F O R M A T I O N 
47/48 
 
 
 
 
18.2 
Appendix 2        Criteria for infusion related reactions (IRRS) 
and infusion site reactions (ISRs)  
 
Infusion related reactions 
Reactions - Considered when onset is during berzosertib and/or 
topotecan infusion or within 24 hours of infusion and resolution on 
the same day or the day after onset: 
• 
Infusion related reaction 
• 
Drug hypersensitivity 
• 
Anaphylactic reaction 
• 
Hypersensitivity 
• 
Type 1 hypersensitivity  
Signs and Symptoms - when onset is during berzosertib and/or 
topotecan infusion or within 24 hours of infusion and resolution on 
the same day or the day after onset 
• 
Erythema 
• 
Rash 
• 
Rash erythematous 
• 
Rash macular 
• 
Rash pruritic 
• 
Pruritus 
• 
Pruritus allergic 
• 
Flushing 
• 
Chills 
• 
Urticaria 
• 
Headache 
• 
Bronchospasm 
• 
Dyspnoea 
• 
Hypotension 
• 
Hypertension 
Infusion site reactions 
Infusion site reactions - if develop during infusion or within 24 
hours of Berzosertib administration with resolution on the same 
day or the day after onset. 
• 
Catheter site pain 
• 
Catheter site pruritus 
• 
Catheter site rash 
Global Version ID: CCI


Berzosertib 
                                                                                    Human Mass Balance Study 
MS201923_0008                                                                                                                             Version 1.0 
 
 
 
 
C O N F I D E N T I A L 
I N F O R M A T I O N 
48/48 
 
 
 
 
• 
Catheter site-related reaction 
• 
Infusion site discomfort 
• 
Infusion site erythema 
• 
Infusion site extravasation 
• 
Infusion site pruritus 
• 
Infusion site rash 
• 
Infusion site reaction 
• 
Injection site rash 
• 
Infusion site reaction 
 
Global Version ID: CCI